Multi-Drug Rapid Test Cassette

with/without Adulteration (Urine)

Package Insert

Instruction Sheet for testing of any combination of the following drugs: ACE/AMP/BAR/BZO/BUP/COC/THC/MTD/MET/MDMA/MOP/MQL/OPI/PCP/PPX/TCA/TML/ KET/OXY/COT/EDDP/FYL/K2/6-MAM/MDA/ETG/CLO/LSD/MPD/ZOL/MEP/MDPV/DIA/ZOP/ MCAT/7-ACL/CAF/CFYL/CAT/TRO/ALP/PGB/ZAL/MPRD/CNB/GAB/TZD/CAR/ABP/QTP/ FLX/UR-144/KRA/TLD/a-PVP/MES/PAP/CIT/FKET/OZP/RPD/TAP/NND/SCOP/MTZ/ALC Including Specimen Validity Tests (S.V.T.) for:

Oxidants/PCC, Specific Gravity, pH, Nitrite, Glutaraldehyde, Creatinine and Bleach

A rapid test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in human urine. For healthcare professionals including professionals at point of care sites. Immunoassay for in vitro diagnostic use only.

[INTENDED USE]

The Multi-Drug Rapid Test Cassette is a rapid chromatographic immunoassay for the qualitative detection of multiple drugs and drug metabolites in urine at the following cut-off concentrations: Calibratan

Test	Calibrator	Cut-off (ng/mL)
Acetaminophen (ACE)	Acetaminophen	5,000
Amphetamine (AMP)	d-Amphetamine	1,000/500/300
Barbiturates (BAR)	Secobarbital	300/200
Benzodiazepines (BZO)	Oxazepam	500/300/200/100
Buprenorphine (BUP)	Buprenorphine	10/5
Cocaine (COC)		300/200/150/100
Marijuana (THC)	11-nor-Δ ⁹ -THC-9 COOH	300/200/150/50/30/25/20
Methadone (MTD)	Methadone	300/200
Methamphetamine (MET)	d-Methamphetamine	1,000/500/300
Methylenedioxyme- thamphetamine(MDMA)	d,I-Methylenedioxymethamphetamine	
Morphine/Opiate (MOP/OPI)		300/200/100
Methaqualone (MQL)	Methaqualone	300
Meperidine (MPRD)	Normeperidine	100
Opiate (OPI)	Morphine	2,000/1,000
Phencyclidine (PCP)	Phencyclidine	50/25
Propoxyphene (PPX)	Propoxyphene	300
Tricyclic Antidepressants (TCA)	Nortriptyline	1,000/500/300
Tramadol (TML)	Cis-Tramadol	100/200/300/500
Ketamine (KET)	Ketamine	1,000/500/300/100
Oxycodone (OXY) Cotinine (COT)	Oxycodone Cotinine	300/100
2-ethylidene-1,5-dimethyl-	2-ethylidene-1,5-dimethyl-	500/300/200/100/50/10
3,3-diphenylpyrrolidine (EDDP)	3,3-diphenylpyrrolidine	300/100
Fentanyl (FYL)		300/200/100/20/10
Synthetic Marijuana (K2)	JWH-018、JWH-073	50/30/25
6-Monoacetylmorphine (6-MAM)		10
(±) 3,4-Methylenedioxy-	(+) 3 4 Mothylopodioxy	
Amphetamine (MDA)	Amphetamine	500
Ethyl- β-D-Glucuronide (ETG)	Ethyl- β -D-Glucuronide	1,000/500/300
Clonazepam (CLO)	Clonazepam	400/150
Lysergic Acid Diethylamide (LSD)	Lysergic Acid Diethylamide	10/20/50
Methylphenidate (MPD)	Methylphenidate	300/150
Methylphenidate (MPD)	Ritalin acid	1,000
Zolpidem (ZOL)	Zolpidem	50
Mephedrone (MEP)	Mephedrone	500/100
3, 4-methylenedioxy- pyrovalerone(MDPV)	3, 4-methylenedioxypyrovalerone	1,000/500/300
Diazepam (DIA)	Diazepam	300/200
Zopiclone (ZOP)		50
Methcathinone (MCAT)		500
7-Aminoclonazepam (7-ACL)	7-Aminoclonazepam	300/200/100
Carfentanyl (CFYL)		500/250
Cannabinol (CNB)	Cannabinol	500
Caffeine (CAF)	Caffeine	1,000
Cathine (CAT)	(+)-Norpseudoephedrine	150
Tropicamide (TRO)	Tropicamide	350
Alprazolam (ALP)	Alprazolam	100
Pregabaline (PGB)	Pregabaline	50,000/500
Gabapentin (GAB)		2,000
Zaleplon (ZAL)	Zaleplon	100
Carisoprodol (CAR)	Carisoprodol	2,000/1,000
AB-PINACA (ABP)	AB-PINACA	10
Quetiazepam (QTP)	Quetiazepam	1,000

Fluoxetine (FLX)	Fluoxetine	500
UR-144	UR-144 5-Pentanoic acid	25
Kratom (KRA)	Mitragynine	300
Tilidine (TLD)	Nortilidine	50
Trazodone (TZD)	Trazodone	200
Alpha-Pyrrolidinovalerophenone (α-PVP)	Alpha-Pyrrolidinovalerophenone	2,000/1,000/500/300
Mescaline (MES)	Mescaline	100/300
Papaverine (PAP)	Papaverine	500
Citalopram (CIT)	Citalopram	500
Fluoketamine (FKET)	Fluoketamine	1,000
Olanzapine (OZP)	Olanzapine	1,000
Risperidone (RPD)	Risperidone	150
Tapentadol (TAP)	Tapentadol	1,000
N,N-Dimethyltryptamine (NND)	N,N-Dimethyltryptamine	1,000
Scopolamine (SCOP)	Scopolamine	500
Mirtazapine (MTZ)	Desmethylmirtazapine	500

Test	Calibrator	Cut-off
Alcohol(ALC)	Alcohol	0.02%
Configurations of the	Julti-Drug Papid Test Cassette co	mo with any combination of the above

Configurations of the Multi-Drug Rapid Test Cassette come with any combination of the above listed drug analytes with or without S.V.T. This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

[SUMMARY]

The Multi-Drug Rapid Test Cassette is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes monoclonal antibodies to selectively detect elevated levels of specific drugs in urine.

Acetaminophen (ACE)

Acetaminophen is one of the most commonly used drugs, yet it is also an important cause of serious liver injury. Acetaminophen is the generic name of a drug found in many common brand name over-the-counter (OTC) products, such as Tylenol, and Prescription (Rx) products, such as Vicodin and Percocet. Acetaminophen is an important drug, and its effectiveness in relieving pain and fever is widely known. Unlike other commonly used drugs to reduce pain and fever (e.g., non steroidalant inflammatory drugs (NSAIDs), such as aspirin, ibuprofen, and naproxen), at recommended doses acetaminophen does not cause adverse effects, such as stomach discomfort and bleeding, and acetaminophen is considered safe when used according to the directions on its OTC or Rx labeling. However, taking more than the recommended amount can cause liver damage, ranging from abnormalities in liver function blood tests, to acute liver failure, and even death. Many cases of overdose are caused by patients inadvertently taking more than the recommended dose (i.e., 4 grams a day) of a particular product, or by taking more than one product containing acetaminophen (e.g., an OTC product and an Rx drug containing acetaminophen). The mechanism of liver injury is not related to acetaminophen itself, but to the production of a toxic metabolite. The toxic metabolite binds with liver proteins, which cause cellular injury. The ability of the liver to remove this metabolite before it binds to liver protein influences the extent of liver injury.

Amphetamine (AMP)

Amphetamine is a Schedule II controlled substance available by prescription (Dexedrine®) and is also available on the illicit market. Amphetamines are a class of potent sympathomimetic agents with therapeutic applications. They are chemically related to the human body's natural catecholamines: epinephrine and norepinephrine. Acute higher doses lead to enhanced stimulation of the central nervous system (CNS) and induce euphoria, alertness, reduced appetite, and a sense of increased energy and power. Cardiovascular responses to amphetamines include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia, hallucinations, and psychotic behavior. The effects of Amphetamines generally last 2-4 hours following use and the drug has a half-life of 4-24 hours in the body. About 30% of amphetamines are excreted in the urine in unchanged form, with the remainder as hydroxylated and deaminated derivatives.

Barbiturates (BAR)

Barbiturates are CNS depressants. They are used therapeutically as sedatives, hypnotics, and anticonvulsants barbiturates are almost always taken orally as capsules or tablets. The effects resemble those of intoxication with alcohol. Chronic use of barbiturates leads to tolerance and physical dependence.

Short-acting barbiturates taken at 400 mg/day for 2-3 months can produce a clinically significant degree of physical dependence. Withdrawal symptoms experienced during periods of drug abstinence can be severe enough to cause death.

Only a small amount (less than 5%) of most barbiturates are excreted unaltered in the urine. The approximate detection time limits for barbiturates are:

Short acting (e.g. Secobarbital)	100 mg PO (oral)	4.5 days
Long acting (e.g. Phenobarbital)	400 mg PO (oral)	7 days ²
Benzodiazepines (BZO)		

Benzodiazepines are medications that are frequently prescribed for the symptomatic treatment of anxiety and sleep disorders. They produce their effects via specific receptors involving a neurochemical called gamma aminobutyric acid (GABA). Because they are safer and more effective, benzodiazepines have replaced barbiturates in the treatment of both anxiety and insomnia. Benzodiazepines are also used as sedatives before some surgical and medical procedures, and for the treatment of seizure disorders and alcohol withdrawal

Risk of physical dependence increases if benzodiazepines are taken regularly (e.g., daily) for more than a few months, especially at higher than normal doses. Stopping abruptly can bring on such symptoms as trouble sleeping, gastrointestinal upset, feeling unwell, loss of appetite, sweating, trembling, weakness, anxiety and changes in perception.

Only trace amounts (less than 1%) of most benzodiazepines are excreted unaltered in the urine; most of the concentration in urine is conjugated drug. The detection period for benzodiazepines in urine is 3-7 days.

Buprenorphine (BUP)

Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is sold under the trade names Subutex™, Buprenex™, Temgesic™ and Suboxone™, which contain Buprenorphine HCI alone or in combination with Naloxone HCI. Therapeutically, Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or identical substance to the drug normally used. In substitution therapy, Buprenorphine is as effective as Methadone but demonstrates a lower level of physical dependence. Concentrations of free Buprenorphine and Norbuprenorphine in urine may be less than 1 ng/mL after therapeutic administration, but can range up to 20 ng/mL in abuse situations. The plasma half -life of Buprenorphine is 2-4 hours. While complete elimination of a single dose of the drug can take as long as 6 days, the window of detection for the parent drug in urine is thought to be approximately 3 days.

Substantial abuse of Buprenorphine has also been reported in many countries where various forms of the drug are available. The drug has been diverted from legitimate channels through theft, doctor shopping, and fraudulent prescriptions, and been abused via intravenous. sublingual, intranasal and inhalation routes.

Cocaine (COC)

Cocaine is a potent central nervous system stimulant and a local anesthetic. Initially, it brings about extreme energy and restlessness while gradually resulting in tremors, over-sensitivity and spasms. In large amounts, cocaine causes fever, unresponsiveness, difficulty in breathing and unconsciousness

Cocaine is often self-administered by nasal inhalation, intravenous injection and free-base smoking. It is excreted in the urine in a short time primarily as benzoylecgonine. Benzoylecgonine, a major metabolite of cocaine, has a longer biological half-life (5-8 hours) than cocaine (0.5-1.5 hours), and can generally be detected for 24-48 hours after cocaine exposure.⁴ Marijuana (THC)

THC (Δ^9 -tetrahydrocannabinol) is the primary active ingredient in cannabis (marijuana). When smoked or orally administered, THC produces euphoric effects. Users have impaired short-term memory and slowed learning. They may also experience transient episodes of confusion and anxiety. Long-term, relatively heavy use may be associated with behavioral disorders. The peak effect of marijuana administered by smoking occurs in 20-30 minutes and the duration is 90-120 minutes after one cigarette. Elevated levels of urinary metabolites are found within hours of exposure and remain detectable for 3-10 days after smoking. The main metabolite excreted in the urine is 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH).

Methadone (MTD)

Methadone is a narcotic analgesic prescribed for the management of moderate to severe pain and for the treatment of opiate dependence (heroin, Vicodin, Percocet, morphine). The pharmacology of oral methadone is very different from IV methadone. Oral methadone is partially stored in the liver for later use. IV methadone acts more like heroin. In most states you must go to a pain clinic or a methadone maintenance clinic to be prescribed methadone.

Methadone is a long acting pain reliever producing effects that last from twelve to forty-eight hours. Ideally, methadone frees the client from the pressures of obtaining illegal heroin, from the dangers of injection, and from the emotional roller coaster that most opiates produce. Methadone, if taken for long periods and at large doses, can lead to a very long withdrawal period. The withdrawals from methadone are more prolonged and troublesome than those provoked by heroin cessation, yet the substitution and phased removal of methadone is an acceptable method of detoxification for patients and therapists.

Methamphetamine (MFT)

Methamphetamine is an addictive stimulant drug that strongly activates certain systems in the brain. Methamphetamine is closely related chemically to Amphetamine, but the central nervous system effects of Methamphetamine are greater. Methamphetamine is made in illegal laboratories and has a high potential for abuse and dependence. The drug can be taken orally, injected, or inhaled. Acute higher doses lead to enhanced stimulation of the central nervous system and induce euphoria, alertness, reduced appetite, and a sense of increased energy and power. Cardiovascular responses to Methamphetamine include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia, hallucinations, psychotic behavior, and eventually, depression and exhaustion.

The effects of Methamphetamine generally last 2-4 hours and the drug have a half-life of 9-24 hours in the body. Methamphetamine is excreted in the urine primarily as Amphetamine, and oxidized and deaminated derivatives. However, 10-20% of Methamphetamine is excreted unchanged. Thus, the presence of the parent compound in the urine indicates Methamphetamine use. Methamphetamine is generally detectable in the urine for 3-5 days, depending on urine pH level

Methylenedioxymethamphetamine (MDMA)

Methylenedioxymethamphetamine (ecstasy) is a designer drug first synthesized in 1914 by a German drug company for the treatment of obesity.⁵ Those who take the drug frequently report adverse effects, such as increased muscle tension and sweating. MDMA is not clearly a stimulant, although it has, in common with amphetamine drugs, a capacity to increase blood pressure and heart rate. MDMA does produce some perceptual changes in the form of

increased sensitivity to light, difficulty in focusing, and blurred vision in some users. Its mechanism of action is thought to be via release of the neurotransmitter serotonin. MDMA may also release dopamine, although the general opinion is that this is a secondary effect of the drug (Nichols and Oberlender, 1990). The most pervasive effect of MDMA, occurring in virtually all people who took a reasonable dose of the drug, was to produce a clenching of the jaws.

Morphine/Opiate (MOP/OPI)

Opiate refers to any drug that is derived from the opium poppy, including the natural products, morphine and codeine, and the semi-synthetic drugs such as heroin. Opioid is more general, referring to any drug that acts on the opioid receptor.

Opioid analgesics comprise a large group of substances which control pain by depressing the CNS. Large doses of morphine can produce higher tolerance levels, physiological dependency in users, and may lead to substance abuse. Morphine is excreted unmetabolized, and is also the major metabolic product of codeine and heroin. Morphine is detectable in the urine for several days after an opiate dose.²

Methagualone (MQL)

Methaqualone (Quaalude, Sopor) is a quinazoline derivative that was first synthesized in 1951 and found clinically effective as a sedative and hypnotic in 1956.¹⁰ It soon gained popularity as a drug of abuse and in 1984 was removed from the US market due to extensive misuse. It is occasionally encountered in illicit form, and is also available in European countries in combination with diphenhydramine (Mandrax). Methaqualone is extensively metabolized *in vivo* principally by hydroxylation at every possible position on the molecule. At least 12 metabolites have been identified in the urine.

Meperidine (MPRD)

Meperidine (also known as Pethidine, Pethidin, Meperidol and Dolantin) a phenylpiperidine derivative, is a synthetic opioid analgesic. Many of its pharmacologic properties and indications are similar to those of morphine, Meperidine is preferred to morphine for obstetric use because its rapid onset of action and shorter duration usually permit greater flexibility in maternal analgesia, possibly with less effect on neonatal respiration. Like other opioid drugs, pethidine has the potential to cause physical dependence or addiction. It may be more likely to be abused than other prescription opioids, perhaps because of its rapid onset of action. When compared with oxycodone, hydromorphone, and placebo, pethidine was consistently associated with more euphoria, difficulty concentrating, confusion, and impaired psychomotor and cognitive performance when administered to healthy volunteers. The especially severe side effects unique to pethidine among opioids—serotonin syndrome, seizures, delirium, dysphoria, tremor—are primarily or entirely due to the action of its metabolite, norpethidine.

Phencyclidine (PCP)

Phencyclidine, also known as PCP or Angel Dust, is a hallucinogen that was first marketed as a surgical anesthetic in the 1950's. It was removed from the market because patients receiving it became delirious and experienced hallucinations.

PCP is used in powder, capsule, and tablet form. The powder is either snorted or smoked after mixing it with marijuana or vegetable matter. PCP is most commonly administered by inhalation but can be used intravenously, intra-nasally, and orally. After low doses, the user thinks and acts swiftly and experiences mood swings from euphoria to depression. Self-injurious behavior is one of the devastating effects of PCP.

PCP can be found in urine within 4 to 6 hours after use and will remain in urine for 7 to 14 days, depending on factors such as metabolic rate, user's age, weight, activity, and diet.⁶ PCP is excreted in the urine as an unchanged drug (4% to 19%) and conjugated metabolites (25% to 30%).⁶

Propoxyphene (PPX)

Propoxyphene (PPX) is a narcotic analgesic compound bearing structural similarity to methadone. As an analgesic, propoxyphene can be from 50-75% as potent as oral codeine. Darvocet™, one of the most common brand names for the drug, contains 50-100 mg of propoxyphene napsylate and 325-650 mg of acetaminophen. Peak plasma concentrations of propoxyphene are achieved from 1 to 2 hours post dose. In the case of overdose, propoxyphene blood concentrations can reach significantly higher levels.

In humans, propoxyphene is metabolized by N-demethylation to yield norpropoxyphene. Norpropoxyphene has a longer half-life (30 to 36 hours) than parent propoxyphene (6 to 12 hours). The accumulation of norpropoxyphene seen with repeated doses may be largely responsible for resultant toxicity.

Tricyclic Antidepressants (TCA)

TCA (Tricyclic Antidepressants) are commonly used for the treatment of depressive disorders. TCA overdoses can result in profound CNS depression, cardiotoxicity and anticholinergic effects. TCA overdose is the most common cause of death from prescription drugs. TCAs are taken orally or sometimes by injection. TCAs are metabolized in the liver. Both TCAs and their metabolites are excreted in urine mostly in the form of metabolites for up to ten days.

Tramadol (TML)

Tramadol (TML) is a quasi-narcotic analgesic used in the treatment of moderate to severe pain. It is a synthetic analog of codeine, but has a low binding affinity to the mu-opioid receptors. Large doses of tramadol can develop tolerance and physiological dependency and lead to its abuse. Tramadol is extensively metabolized after oral administration. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% is excreted as metabolites. The major pathways appear to be N- and O- demethylation, glucoronidation or sulfation in the liver. Ketamine (KET)

Ketamine is a dissociative anesthetic developed in 1963 to replace PCP (Phencyclidine). While Ketamine is still used in human anesthesia and veterinary medicine, it is becoming increasingly abused as a street drug. Ketamine is molecularly similar to PCP and thus creates similar effects including numbness, loss of coordination, sense of invulnerability, muscle rigidity, aggressive / violent behavior, slurred or blocked speech, exaggerated sense of strength, and a blank stare. There is depression of respiratory function but not of the central nervous system, and cardiovascular function is maintained. The effects of Ketamine generally last 4-6 hours following use. Ketamine is excreted in the urine as unchanged drug (2.3%) and metabolites (96.8%).¹⁰ Oxycodone (OXY)

Oxycodone is a semi-synthetic opioid with a structural similarity to codeine. The drug is manufactured by modifying thebaine, an alkaloid found in the opium popp. Oxycodone, like all opiate agonists, provides pain relief by acting on opioid receptors in the spinal cord, brain, and possibly directly in the affected tissues. Oxycodone is prescribed for the relief of moderate to high pain under the well-known pharmaceutical trade names of OxyContin[®], Tyla[®], Percodan[®] and Percocet[®]. While Tylox[®], Percodan[®] and Percocet[®] contain only small doses of oxycodone hydrochloride combined with other analgesics such as acetaminophen or aspirin, OxyContin consists solely of oxycodone hydrochloride in a time-release form. Oxycodone is known to metabolize by demethylation into oxymorphone and noroxycodone. In a 24-hour urine, 33-61% of a single, 5 mg oral dose is excreted with the primary constituents being unchanged drug (13-19%), conjugated drug (7-29%) and conjugated oxymorphone (13-14%). The detection for Oxycodone in urine is expected to be similar to that of other opioids such as morphine. **Cotinine (COT)**

Cotinine is the first-stage metabolite of nicotine, a toxic alkaloid that produces stimulation of the autonomic ganglia and central nervous system when in humans. Nicotine is a drug to which virtually every member of a tobacco-smoking society is exposed whether through direct contact or second-hand inhalation. In addition to tobacco, nicotine is also commercially available as the active ingredient in smoking replacement therapies such as nicotine gum, transdermal patches and nasal sprays.

In a 24-hour urine, approximately 5% of a nicotine dose is excreted as unchanged drug with 10% as cotinine and 35% as hydroxycotinine; the concentrations of other metabolites are believed to account for less than 5%. ¹⁰While cotinine is thought to be an inactive metabolite, it's elimination profile is more stable than that of nicotine which is largely urine pH dependent. As a result, cotinine is considered a good biological marker for determining nicotine use. The plasma half-life of nicotine is approximately 60 minutes following inhalation or parenteral administration.¹¹Nicotine and cotinine are rapidly eliminated by the kidney; the window of detection for cotinine in the at a cutoff level is expected to be up to 2-3 days after nicotine use. **2-ethylidene-1,5-dimethyl-3,3-diphenylbyrrolidine (EDDP)**

Methadone is an unusual drug in that its primary urinary metabolites (EDDP and EMDP) are cyclic in structure, making them very difficult to detect using immunoassays targeted to the native compound.¹⁰ Exacerbating this problem, there is a subsection of the population classified as "extensive metabolizers" of methadone. In these individuals, a urine specimen may not contain enough parent methadone to yield a positive drug screen even if the individual is in compliance with their methadone maintenance. EDDP represents a better urine marker for methadone maintenance than unmetabolized methadone.

Fentanyl (FYL)

Fentanyl, belongs to powerful narcotics analgesics, and is a µ special opiates receptor stimulant. Fentanyl is one of the varieties that been listed in management of United Nations "Single Convention of narcotic drug in 1961". Among the opiates agents that under international control, fentanyl is one of the most commonly used to cure moderate to severe pain¹. After continuous injection of fentanyl, the sufferer will have the performance of protracted opioid abstinence syndrome, such as ataxia and irritability etc.²³, which presents the addiction after taking fentanyl in a long time. Compared with drug addicts of ampletamine, drug addicts who take fentanyl mainly have got the possibility of higher infection rate of HIV, more dangerous injection behavior and more lifelong medication overdose ⁴.

Synthetic Marijuana (K2)

Synthetic Marijuana or K2 a psychoactive herbal and chemical product that, when consumed, mimics the effects of Marijuana. It is best known by the brand names K2 and Spice, both of which have largely become genericized trademarks used to refer to any synthetic Marijuana product. The studies suggest that synthetic marijuana intoxication is associated with acute psychosis, worsening of previously stable psychotic disorders, and also may have the ability to trigger a chronic (long-term) psychotic disorder among vulnerable individuals such as those with a family history of mental illness.

Elevated levels of urinary metabolites are found within hours of exposure and remain detectable for 72 hours after smoking (depending on usage/dosage). As of March 1, 2011, five cannabinoids, JWH -018, JWH- 073, CP- 47, JWH- 200and cannabicyclohexanol are now illegal in the US because these substances have the potential to be extremely harmful and, therefore, pose an imminent hazard to the public safety.

6-Monoacetylmorphine (6-MAM)

6-MonoacetyImorphine (6-MAM) or 6-acetyImorphine (6-AM) is one of three active metabolites of heroin (diacetyImorphine), the others being morphine and the much less active 3-monoacetyImorphine (3-MAM). 6-MAM is rapidly created from heroin in the body, and then is either metabolized into morphine or excreted in the urine. 6-MAM remains in the urine for no more than 24 hours. So a urine specimen must be collected soon after the last heroin use, but the presence of 6-MAM guarantees that heroin was in fact used as recently as within the last day. 6-MAM is naturally found in the brain, but in such small quantities that detection of this compound in urine virtually guarantees that heroin has recently been consumed.

(±) 3, 4-Methylenedioxyamphetamine (MDA)

3,4-Methylenedioxyamphetamine (MDA), also known as tenamfetamine (INN), or with the street name "Sally" or "Sass" or "Sass-a-frass", is a psychedelic and entactogenic drug of the phenethylamine and amphetamine chemical classes. It is mainly used as a recreational drug, an entheogen, and a tool in use to supplement various types of practices for transcendence, including in meditation, psychonautics, and as an agent in psychedelic psychotherapy. It was first synthesized by G. Mannish and W. Jacobson in 1910. There are about 20 different synthetic routes described in the literature for its preparation.

Ethyl- β-D-Glucuronide (ETG)

Ethyl Glucuronide (ETG) is a metabolite of ethyl alcohol which is formed in the body by glucuronidation following exposure to ethanol, such as by drinking alcoholic beverages. It is

used as a biomarker to test for ethanol use and to monitor alcohol abstinence in situations where drinking is prohibited, such as in the military, in professional monitoring programs(health professionals, attorneys, airline pilots in recovery from addictions), in schools, in liver transplant clinics, or in recovering alcoholic patients. ETG can be measured in urine up to approximately 80 hours after ethanol is ingested. ETG is a more accurate indicator of the recent exposure to alcohol than measuring for the presence of ethanol itself.

Clonazepam (CLO)

Clonazepam is a benzodiazepine drug having anxiolytic, anticonvulsant, muscle relaxant, amnestic, sedative, and hypnotic properties. Clonazepam has an intermediate onset of action, with a peak blood level occurring one to four hours after oral administration. Long-term effects of benzodiazepines include tolerance, benzodiazepine dependence, and benzodiazepine withdrawal syndrome, which occurs in one third of patients treated with clonazepam for longer than four weeks. Benzodiazepines such as clonazepam have a fast onset of action, high effectivity rate, and low toxicity in overdose; however, as with most medications, it may have drawbacks due to adverse or paradoxical effects. The detection period for the Benzodiazepines in the urine is 3-7 davs.

Lysergic Acid Diethylamide (LSD)

Lysergic acid diethylamide (LSD) is a white powder or a clear, colorless liquid. LSD is manufactured from lysergic acid which occurs naturally in the ergot fungus that grows on wheat and rye. It is a Schedule I controlled substance, available in liquid, powder, tablet (microdots), and capsule form. LSD is recreationally used as a hallucinogen for its ability to alter human perception and mood. LSD is primarily used by oral administration, but can be inhaled, injected, and transdermally applied. LSD is a non-selective 5-HT agonist, may exert its hallucinogenic effect by interacting with 5-HT 2Areceptors as a partial agonist and modulating the NMDA receptor-mediated sensory, perceptual, affective and cognitive processes. LSD mimics 5-HT at 5-HT 1A receptors, producing a marked slowing of the firing rate of serotonergic neurons. LSD has a plasma half-life of 2.5-4 hours. Metabolites of LSD include N-desmethyl-LSD, hydroxy-LSD, 2-oxo-LSD, and 2-oxo-3-hydroxy-LSD. These metabolites are all inactive. LSD use can typically be detected in urine for periods of 2-5 days.

Methylphenidate (MPD)

Methylphenidate (Ritalin) is a psychostimulant drug approved for treatment of ADHD or attention-deficit hyperactivity disorder, postural orthostatic tachycardia syndrome and narcolepsy. Methylphenidate primarily acts as a norepinephrine-dopamine reuptake inhibitor. Methylphenidate is most active at modulating levels of dopamine and to a lesser extent norepinephrine. Similar to cocaine, methylphenidate binds to and blocks dopamine transporters and norepinephrine transporters. Methylphenidate has both dopamine transporter and norepinephrine transporter binding affinity, with the dextromethylphenidate enantiomers displaying a prominent affinity for the norepinephrine transporter. Methylphenidate taken orally has a bioavaitability of 11-52% with a duration of action around 1-4 hours forinstant release, 3–8 hours for sustained release, and 8–12 hours for extended release (Concerta). The half-life of methylphenidate is 2-3 hours, depending on the individual. The peak plasma time is achieved at about 2 hours.

Zolpidem (ZOL)

Zolpidem (brand names Ambien, Ambien CR, Intermezzo, Stilnox, Stilnoct, Sublinox, Hypnogen, Zonadin, Sanval and Zolsana) is a prescription medication used for the treatment of insomnia and some brain disorders. It is a short-acting nonbenzodiazepine hypnotic of the imidazopyridine class¹ that potentiates GABA, an inhibitory neurotransmitter, by binding to GABAA receptors at the same location as benzodiazepines.² It works quickly, usually within 15 minutes, and has a short half-life of two to three hours.

Zolpidem may be detected in blood or plasma to confirm a diagnosis of poisoning in hospitalized patients, provide evidence in an impaired driving arrest, or to assist in a medico-legal death investigation. Blood or plasma Zolpidem concentrations are usually in a range of 30–300 µg/l in persons receiving the drug therapeutically, 100–700 µg/l in those arrested for impaired driving, and 1000–7000 µg/l in victims of acute over dosage. Analytical techniques, in general, involve gas or liquid chromatography.^{34,5}

Mephedrone (MEP)

Mephedrone, also known as 4-methylmethcathinone (4-MMC) or 4-methylephedrone is a synthetic stimulant drug of the amphetamine and cathinone classes. Slang names include drone¹², M-CAT¹³, White Magic¹⁴ and meow meow¹⁵. It is chemically similar to the cathinone compounds found in the khat plant of eastern Africa.

Mephedrone comes in the form of tablets or a powder, which users can swallow, snort or inject, producing similar effects to MDMA, amphetamines and cocaine. In addition to its stimulant effects, Mephedrone produces side effects, of which teeth grinding are the most common. A number of metabolites are possible, however the n-demethyl metabolite of Mephedrone will be 4-Methylcathinone. This metabolite appears to be nearly inactive as a Monoamine Oxydase Inhibitor. On further metabolism of this metabolite one of the possible metabolites is 4-Methylnorephedrine, caused by the reduction of the Keto. A dose of 150mg-250mg is the average, giving a duration of around 2 hours. The duration will lengthen in larger 250mg+ dosanes

3, 4-methylenedioxypyrovalerone (MDPV)

3, 4-methylenedioxypyrovalerone (MDPV) is a psychoactive recreational drug with stimulant properties which acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was first developed in the 1960s by a team at Boehringer Ingelheim. MDPV remained an obscure stimulant until around 2004 when it was reportedly sold as a designer drug. Products labeled as bath salts containing MDPV were previously sold as recreational drugs in gas stations and convenience stores in the United States, similar to the marketing for Spice and K2 as incense. MDPV is the 3,4-methylenedioxy ring-substituted analog of the compound pyrovalerone, developed in the 1960s, which has been used for the treatment of chronic taigue and as an anorectic, but caused problems of abuse and dependence. However, despite its structural

similarity, the effects of MDPV bear little resemblance to other methylenedioxy phenylalkylamine derivatives such as 3,4-methylenedioxy-N -methylamphetamine (MDMA), instead producing primarily stimulant effects with only mild entactogenic qualities.

MDPV undergoes CYP450 2D6, 2C19, 1A2, and COMT phase 1 metabolism (liver) into methylcatechol and pyrrolidine, which in turn are glucuronated (uridine 5'-diphospho-glucuronosyl-transferase) allowing it to be excreted by the kidneys, with only a small fraction of the metabolites being excreted into the stools. No free pyrrolidine will be detected in the urine.

Diazepam (DIA)

Diazepam is a medication of the benzodiazepine family that typically produces a calming effect. It has anticonvulsant properties. Diazepam has no effect on GABA levels and no effect on glutamate decarboxylase activity, but has a slight effect on gamma-amino butyric acid transaminase activity. Diazepam can be administered orally, intravenously intramuscularly (IM), or as a suppository. When administered orally, it is rapidly absorbed and has a fast onset of action. The onset of action is one to five minutes for IV administration and 15–30 minutes for IM administration. The duration of diazepam's peak pharmacological effects is 15 minutes to role hour for both routes of administration. The bioavailability after oral administration is 100% and 90% after rectal administration. Peak plasma levels occur between 30 and 90 minutes after roral administration, peak plasma levels occur after 10 to 45 minutes. Diazepam is highly protein-bound, with 96 to 99% of the absorbed drug being protein-bound. The distribution half-life of diazepam is 2 to 13 minutes. When diazepam is administered IM, absorption is slow, erratic, and incomplete.

Zopiclone (ZOP)

Zopiclone is a nonbenzodiazepine hypnotic agent used in the treatment of insomnia. It is a cyclopyrrolone, which increases the normal transmission of the neurotransmitter gamma-aminobutyric acid in the central nervous system, as benzodiazepines do, but in a different way. Zopidone is indicated for the short-term treatment of insomnia where sleep initiation or sleep maintenance are prominent symptoms. Long-term use is not recommended, as tolerance, dependence, and addiction can occur with prolonged use. Zopiclone is partly extensively metabolized in the liver to form an active N-demethylated derivative (N-desmethylzopiclone) and an inactive zopiclone-N-oxide.

In urine, the N-demethyl and N-oxide metabolites account for 30% of the initial dose. Between 7 and 10% of zopiclone is recovered from the urine, indicating extensive metabolism of the drug before excretion. The terminal elimination half-life of zopiclone ranges from 3.5 to 6.5 hours (5 hours on average).¹⁶ Time to peak plasma concentration is 1 - 2 h, the absorption rate constant is 1.3 h-1 and maximum plasma concentration after administration of 7.5 mg is 131ug/L.

Zopiclone may be measured in blood, plasma, or urine by chromatographic methods. Plasma concentrations are typically less than 100µg/l during therapeutic use, but frequently exceed 100µg/L in automotive vehicle operators arrested for impaired driving ability and may exceed 1000µg/L in acutely poisoned patients. Post mortem blood concentrations are usually in a range of 0.4-3.9 mg/L in victims of fatal acute overdose.^{17,18,19}

Methcathinone (MCAT)

Methcathinone, is a monoamine alkaloid and psychoactive stimulant, a substituted cathinone. Methcathinone is a highly addictive drug, primarily psychologically addicting and most of the signs of addiction to the drug are emotional or psychological. It has been popularized and continues to be sold under misleading names such as "bath salts", "plant fertilizers" or "research chemicals", but it is actually a powerful psycho-stimulant used as a recreational drug. Effects of this drug typically last from 4 to 6 hours. It is used as a recreational drug due to its potent stimulant and euphoric effects and is considered to be addictive, with both physical and psychological withdrawal occurring if its use is discontinued after prolonged or high-dosage administration.²⁰ It is usually sonted, but can be smoked, injected, or taken orally. Methcathinone is listed as a Schedule I controlled substances by the Convention on Psychotropic Substances and the United States' Controlled Substances And thas use in ot considered to be approved medical use. Methcathinone has very strong affinities for the dopamine transporter and the norepinephrine (noradrenaline) transporter. Its affinity for the servicin.

Effects of short term intoxication are similar to those produced by crack cocaine or methamphetamine: stimulation of heart rate and respiration; feeling of euphoria; loss of appetite; increased alertness; pupils may be dilated; body temperature may be slightly elevated. Acute intoxication at higher doses may also result in: insomnia, tremors and muscle twitching, fever, headaches, convulsions, irregular heart rate and respirations, anxiety, restlessness, paranoia, hallucinations and delusions.

7-aminoclonazepam (7-ACL)

7-aminoclonazepam is the major metabolite of clonazepam. Clonazepam sold under the brandname Klonopin among others, is a medication used to prevent and treat seizures, panic disorder, and for the movement disorder known as akathisia. It is a type of benzodiazepine. As a major metabolite, 7-aminoclonazepam may be used to monitor use of the parent drug, clonazepam. Clonazepam, marketed as Klonopin and Rivotril, is a long-acting benzodiazepine with anxiolytic, anticonvulsant, muscle relaxant, and hypnotic properties.

Carfentanyl (CFYL)

Carfentanyl is an analog of the synthetic opioid analgesic fentanyl. It is 10,000 times more potent than morphine, making it among the most potent commercially used opioids. Carfentanil was first synthesized in 1974. It is marketed under the trade name Wildnil as a general anaesthetic agent for large animals. Side effects of carfentanil are similar to those of fentanyl, which include itching, nausea and respiratory depression, which can be life-threatening. Carfentanil is classified as Schedule II under the Controlled Substances Act in the United States with a DEA ACSCN of 9743.

Tropicamide (TRO)

Tropicamide is an antimuscarinic drug usually prescribed as an ophthalmic solution to induce short-term mydriasis and cycloplegia. Tropicamide is currently abused (injected intravenously) as an inexpensive recreational deliriant drug.²²

Misuse of tropicamide typically occurs through IV injection; its effects last from 30 min to 6 h, and It is usually mixed with heroin, methadone, and other opioid drugs to potentiate the " rush" when injected intravenously.Medical effects of tropicamide misuse include slurred speech, persistent mydriasis, unconsciousness/unresponsiveness, hallucinations, kidney pain, dysphoria, "open eye dreams," hyperthermia, tremors, suicidal feelings, convulsions, psychomotor agitation, tachycardia and headache.

Caffeine (CAF)

Caffeine is a central nervous system (CNS) stimulant of the methylxanthine class. It is the world's most widely consumed psychoactive drug. It is found in the seeds, nuts, or leaves of a number of plants native to South America and East Asia and confers on them several survival and reproductive benefits.

Caffeine can produce a mild form of drug dependence - associated with withdrawal symptoms such as sleepiness, headache, and irritability - when an individual stops using caffeine after repeated daily intake.^{13.14.15} After intravenous administration of caffeine the urine level of the drug is approximately the same in each of the first 4 hourly specimens. Blood samples taken 10 and 70 minutes after injection of the drug were analyzed and showed 0.29 and 0.28 mg. per 100 cc. respectively. There are to be contrasted with the 1st hour urine which contained 0.73mg.per 100 cc., essentially 3 times that in the blood. After oral administration of caffeine to the horse the concentration of caffeine in the urine rose progressively during the first 3 hours, remained relatively constant through the 8th hours. At 48 hours, a urine specimen contained approximately 0.17mg. per 100 cc. of caffeine. In addition, flu-like symptoms, nausea/vomiting, and muscle pain/stiffness were judged likely to represent valid symptom categories. In experimental studies, the incidence of headache was 50% and the incidence of clinically significant distress or functional impairment was 13%. Typically, onset of symptoms occurred 12-24 h after abstinence, with peak intensity at 20-51 h, and for a duration of 2-9 days.¹⁵ 1% to 3% of caffeine is excreted unchanged in the urine. The rate of caffeine metabolism is variable, with a half-life of 4 to 6h.¹

Cathine (CAT)

Cathinone, also known as benzoylethanamine, or β -keto-amphetamine is a monoamine alkaloid found in the shrub Catha edulis (CAT) and is chemically similar to ephedrine, Cathinone, methCathinone and other amphetamines. It with amphetamine, ephedrine, methamphetamine and mephedrone belongs to excitatory amphetamines psychiatric drugs, has the strong central excitement and suppress appetite, has been widely applied in the depression, fatigue, obesity, gastric ulcer, etc. The earliest found in Arab tea, because of its structure and pharmacological activities are similar to amphetamines, so called "natural amphetamine.²² It has approximately 10-14% the potency of amphetamine.³³

S-(-)-Cathinone (S-(-)-alpha-aminopropiophenone) is the major active principle of khat leaves (Catha edulis), which are widely used in East Africa and the Arab peninsula as an amphetamine-like stimulant. After oral administration of synthesized cathinone (isomers, racemate), 22-52% was recovered in 24 h urine samples mainly as aminoalcohol metabolites. With GC/MS, HPLC and CD, the main metabolite of S-(-)-cathinone was identified as R/S-(-)-norspeudoephedrine. Both aminoalcohols are formed by a stereospecific keto reduction.²⁴ Use too much Cathinone can cause loss of appetite, anxiety, irritability, insomnia, illusion and panic attacks. Abusers have for a long time for the development of personality disorder and continuing the risk of myocardial infarction. The World Anti-Doping Agency's list of prohibited substances (used for the Olympic Games among other athletic events) bars cathine in concentrations of over 5 micrograms per milliliter in urine. Cathine is a Schedule III drug under the Convention on Psychotropic Substances.²⁵

Alprazolam (ALP)

Alprazolam, available under the trade name Xanax among others, is a short-acting anxiolytic of the benzodiazepine class. It is commonly used for the treatment of panic disorder, and anxiety disorders, such as generalized anxiety disorder (GAD) or social anxiety disorder (SAD).^{27,26} Alprazolam, like other benzodiazepines, binds to specific sites on the GABAA receptor. It pospesses anxiolytic, sedative, hypnotic, skeletal muscle relaxant, anticonvulsant, and amnestic properties.

A mean half-life of alprazolam of 16.3 hours has been observed in healthy elderly subjects (range: 9.0-26.9 hours, n=16) compared to 11.0 hours (range: 6.3-15.8 hours, n=16) in healthy adult subjects.

Alprazolam and its metabolites are excreted primarily in the urine. The pharmacokinetics of alprazolam and two of its major active metabolites (4-hydroxyalprazolam and α -hydroxyalprazolam) are linear, and concentrations are proportional up to the recommended maximum daily dose of 10 mg given once daily. Peak concentrations in the plasma occur in one to two hours following administration. Plasma levels are proportionate to the dose given; over the dose range of 0.5 to 3.0 mg, peak levels of 8.0 to 37ng/mL were observed.²⁹

Pregabalin (PGB)

Pregabalin, also known as β-isobutyl-γ-amino butyric acid (beta-isobutyl-GABA), is a medication used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder.³⁴Common side effects include: sleepiness, confusion, trouble with memory, poor coordination, dry mouth, problem with vision, and weight gain. Potentially serious side effects include angioedema, drug misuse, and an increased suicide risk.³⁵

Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. The Pregabalin is predominantly excreted unchanged in urine (≥ 98%). ³⁶ Pregabalin mean elimination half-life is 6.3 hours.³⁷ 50% would be expected to have negative urine specimens within 3 days and a total of 5 days would be needed to achieve negative urine specimens in the subject with the maximum urinary concentration measured.³⁸

Zaleplon (ZAL)

Zaleplon is a sedative-hypnotic, almost entirely used for the management/treatment of insomnia. It is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class.

Zaleplon has a pharmacological profile similar to benzodiazepines, characterized by an increase in slow wave deep sleep (SWDS) with rapid onset of hypnotic action. Zaleplon is a full agonist for the benzodiazepine d1 receptor located on the GABAA receptor complex in the body, with lower affinity for the d2 and d3 subsites. It selectively enhances the action of GABA similar to, but more selectively than benzodiazepines. Zaleplon, although not a benzodiazepine, maintains a very similar chemical structure nonetheless, known for inducing hypnotic effects by d1 subreceptor sites, anxiolytic and muscle relaxant effects via d2 and d3 subsites, with negligible anticonvulsant properties (via d5 subsite), as zaleplon action is modulated at benzodiazepine receptor sites. The elimination half-life of zaleplon is about 1–1.5 hours. The absorption rate of zaleplon is primarily metabolised by aldehyde oxidase, rand its half-life can be affected by substances which inhibit or induce aldehyde oxidase. Taken orally, zaleplon reaches full concentration in about one hour. It is extensively metabolised into 5-oxozaleplon (integ) with less than 1% of it excreted intact in urine.

Cannabinol (CNB)

Cannabinol (CNB) is a non-psychoactive cannabinoid found only in trace amounts in Cannabis,³⁹ and is mostly found in aged Cannabis.⁴⁰ Pharmacologically relevant quantities are formed as a metabolite of tetrahydrocannabinol (THC).⁴¹ CNB acts as a partial agonistat the CB1 receptors, but has a higher affinity to CB2 receptors; however, it has lower affinities relative to THC.^{42, 43} Degraded or oxidized cannabis products, such as low-quality baled cannabis and traditionally produced hashish, are high in CNB, but modern production processes minimize the formation of CNB.

Unlike other cannabinoids, CNB does not stem from cannabigerol (CBG). There is no clinical evidence that THC breaks down naturally into CNB once the THC has become decarboxylated and forms delta-9 THC. CNB is formed by decarboxylation of cannabinolic acid.

Gabapentin (GAB)

Gabapentin, sold under the brand name Neurontin among others, is a medication which is used to treat epilepsy (specifically partial seizures), neuropathic pain, hot flashes, and restless legs syndrome.^{44,45}

Common side effects of gabapentin include sleepiness and dizziness. Serious side effects include an increased risk of suicide, aggressive behavior, and drug reaction with eosinophilia and systemic symptoms. In 2009 the U.S. Food and Drug Administration issued a warning of an increased risk of suicidal thoughts and behaviors in patients taking some anticonvulsant drugs, including gabapentin,⁴⁶ modifying the packaging inserts to reflect this.⁴⁷

The oral bioavailability of gabapentin enacarbil (as gabapentin) is greater than or equal to 68%, across all doses assessed (up to 2,800 mg), with a mean of approximately 75%. ^{48,49} Gabapentin undergoes little or no metabolism $^{50.61}$ The T-max of the instant-release (IR) formulation of gabapentin enacarbil (as active gabapentin) is about 2.1 to 2.6 hours across all doses (350–2,800 mg) with single administration and 1.6 to 1.9 hours across all doses (350–2,100 mg) with repeated administration.⁵²

Trazodone is a triazolopyridine derivative which is used to treat major depressive disorder. It possesses antidepressant, and also some anxiolytic and hypnotic activity.

Trazodone (TZD)

The primary use of trazodone is the treatment of major depression. Data from open and double-blind trials suggest the antidepressant efficacy of trazodone is comparable to that of amitriptyline, doxepin, and mianserin. Also, trazodone showed anxiolytic properties, low cardiotoxicity, and relatively mild side effects.⁵³ The half-life of trazodone in the initial phase is about 3–6 h and the half-life in the terminal phase is about 5–9 h. TZD is extensively metabolized with only about 1% of the dose excreted unchanged in urine after 24 hr.⁵³ Around 70 to 75% of 14C-labelled trazodone was found to be excreted in the urine within 72 hours.⁵⁴ Carisoprodo (CAR)

Carisoprodol, marketed under the brand name Soma among others, is a medication used for musculoskeletal pain. Use is only approved for up to three weeks. Effects generally begin within half an hour and last for up to six hours. It is taken by mouth.

Common side effects include headache, dizziness, and sleepiness. Serious side effect may include addiction, allergic reactions, and seizures. In people with a sulfa allergy certain formulations may result in problems. Safety during pregnancy and breastfeeding is not clear. Meprobamate and other muscle-relaxing drugs often were subjects of misuse in the 1950s and 60s.Overdose cases were reported as early as 1957, and have been reported on several accasions since then.

Carisoprodol is metabolized by the liver and excreted by the kidneys so this drug must be used with caution with patients that have impaired hepatic or renal function. Because of potential for more severe side effects, this drug is on the list to avoid for elderly people.

AB-PINACA (ABP)

AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012. It was originally developed by Pfizer in 2009 as an analgesic medication. AB-PINACA acts as a potent agonist for the CB1 receptor (Ki = 2.87 nM, EC50 = 1.2 nM) and CB2 receptor (Ki = 0.88 nM, EC50 = 2.5 nM) and fully substitutes for $\Delta9$ -THC in rat discrimination studies, while being 1.5x more potent.

Quetiapine (QTP)

Quetiapine, sold under the trade name Seroquel among others, is an atypical antipsychotic used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. It is also used as a sleep aid due to its sedating effect, but this use is not recommended. It is taken by mouth.

Common side effects include sleepiness, constipation, weight gain, and dry mouth. Other side effects include low blood pressure with standing, seizures, a prolonged erection, high blood

sugar, tardive dyskinesia, and neuroleptic malignant syndrome. In older people with dementia, its use increases the risk of death Use in the later part of pregnancy may result in a movement disorder in the baby for some time after birth. Quetiapine is believed to work by blocking a number of receptors including serotonin and dopamine.

Fluoxetine (FLX)

Fluoxetine, also known by trade names Prozac and Sarafem, among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used for the treatment of major depressive disorder, obsessive-compulsive disorder(OCD), bulimia nervosa, panic disorder and premenstrual dysphoric disorder. It may decrease the risk of suicide in those over the age of 65. It has also been used to treat premature ejaculation.Fluoxetine is taken by mouth.

Common side effects include trouble sleeping, sexual dysfunction, loss of appetite, dry mouth, rash and abnormal dreams. Serious side effects include serotonin syndrome, mania, seizures, an increased risk of suicidal behavior in people under 25 years old and an increased risk of bleeding. If stopped suddenly, a withdrawal syndromemay occur with anxiety, dizzinessand changes in sensation. It is unclear if it is safe in pregnancy. If already on the medication, it may be reasonable to continue during breastfeeding. Its mechanism of action is not entirely clear but believed to be related to increasing serotonin activity in the brain.

UR-144

UR-144 is a synthetic cannabinoid receptor agonist (SCRA) and has affinity for CB1 and CB2 receptors. It has a high selectivity for the CB2-receptors.

UR-144 is a psychoactive substance and has effects similar to delta-9-tetrahydrocannabinol (THC), though slightly less potent than THC. UR-144 has been detected in herbal products marketed under a variety of names.

In mice, UR-144 is moderately potent in reducing in a time- and dose-dependent manner the locomotor activity (ID50-value 7.8 mg/kg), induces an anti-nociceptive effect, and decreases rectal temperature and ring immobility with potencies several-fold greater than THC. In mice, UR-144 substituted for THC in a THC discrimination study (ED50-value 7.1 to 7.4 µmol/kg intra-peritoneal), an effect antagonized by rimonabant.

Kratom (KRA)

Mitragynine (MG) and its major metabolites 7-hydroxymitragynine (7-OH-MG) are two of the major components of the plant extract Kratom, which is a tree planted in Southeast Asia. Kratom has long been used by opioid-dependent individuals as an alternative to their unavailable opioid of choice and chronic pain medication, as a stealth-to-urine drug screening opiate substitute while in opioid recovery treatment and recreationally, alone or as a booster. In this study, a direct infusion method was utilized and electrospray ionization triple quadrupole mass spectrometer was used as the detector for data acquisition. Pharmacokinetic study was conducted to investigate the effect of mitragynine and 7-hydroxymitragynine and major fragments of both compounds were proposed.

Tilidine (TLD)

Tilidine, or tilidate (brand names: Tilidin, Valoron and Valtran) is a synthetic opioid painkiller, used mainly in Germany, Switzerland, South Africa and Belgium for treatment of moderate to severe pain, both acute and chronic. Its onset of pain relief after oral administration is about 10– 15 minutes and peak relief from pain occurs about 25–50 minutes after oral administration.

It usually comes in its hydrochloride hemihydrate salt form; in this form it is highly soluble in water, ethanol and dichloromethane and appears as a white/almost white crystalline powder. Its storage is restricted by its sensitivity to degradation by light and oxygen, hence necessitating its storage in amber bottles and at temperatures below 30 degrees Celsius, respectively.

Tilidine is a prodrug from which the active metabolite nortilidine is formed by demethylation. The pharmacokinetics of tilidine (T), nortilidine (NT) and bisnortilidine (BNT) were studied in nine healthy subjects following single intravenous (10 min infusion) and roal 50 mg T-HCI dose as well as following multiple 50 mg T-HCI oral doses. Systemic availability of the parent substance was 6% and of the active metabolite NT 99%. The terminal half-life of NT was 3.3 h following single oral administration and 10 lowing intravenous administration and 3.6 h following multiple dosing. Following intravenous infusion, concentrations of unchanged substance were found which were 30 times higher than following oral administration. BNT was eliminated with half-lives of 5 h after oral administration and 6.9 h after intravenous administration and less than 0.1% of the dose following oral administration. Approximately 3% were recovered in urine as NT and 5% as BNT following both routes of dministration.

Alpha-Pyrrolidinovalerophenone (α-PVP)

alpha-Pyrrolidinovalerophenone (also known as α-PVP, A-PVP, alpha-PVP, and Flakka) is a synthetic stimulant substance of the cathinone and pyrrolidine chemical classes 1α-PVP may be quantified in blood, plasma or urine to confirm a diagnosis of poisoning in hospitalized patients or to provide evidence in a medicolegal death investigation.2 It generally comes in the form of either a crystalline powder or crystallized shards which users can ingest to produce powerful but short-lived euphoric stimulant effects which are comparable to those of methamphetamine and cocaine when insufflated or vaporized. α-PVP has been reported to be the cause, or a significant contributory cause of death in suicides and overdoses caused by combinations of drugs.3, 4 It has also been linked to at least one death where it was combined with pentedrone and caused heart failure.

Mescaline (MES)

Mescaline (MES) is a derivative of phenethylamine. It is a strong hallucinogen. Can cause hallucinations, self-distortion and mind splitting, leading to depression and pupil dilation, tachycardia, excessive limbs, tremors, nausea, vomiting, and long-term use can lead to organ damage. Hallucinations can last for seven, eight or even 12 hours. The main hazard of using Mescaline is mental disorder. If users experience transient psychosis, they can also engage in violent attacks, suicide, self-harm and other behaviors.

Papaverine (PAP)

Papaverine (latin papaverine,"popy") is an opiu alkaloid antispasmodic drug, used primarily in the

treatment of visceral spasm and vasospasm(especially those involving the intestines,heart, or brain),and occasionally in the treatment of eretile dysfunction. It is used in the treatment of acute mesenteric ischemia. While it is found in the opium popy,papaverine differs in both structure and pharmacological action from the analgesic (morphine-related)opium alkaloids(opiates). Papaverine is found as a contaminantin some hroin and can be used by forensic laboratories in heroin profiling to identify its source. The metabolites can aslo be found in the urine of herin

users, allowing street heroin to be distinguished from pharmaceutical.

Papaverine (4-(3', 4'-dimethoxybenzyl)-6, 7-dimethoxy-quinoline, Mw 339), as one of benzyl isoquinoline alkaloids, was used clinically as a bronchodilator to relaxes various smooth muscles, smooth musculature of the larger blood vessels, especially coronary, systemic peripheral and pulmonary arteries to increase cerebral blood flow. By the *in vitro* metabolice experiment, there were five metabolites in liver microsomal incubation solution and two metabolites in intestinal flora incubation solution.

Citalopram (CIT)

Citalopram, an antidepressant of the selective serotonin reuptake inhibitor (SSRI) type, is only available as a racemic drug. Its metabolism occurs, partially, by N-demethylation to demethylcitalopram (DCIT) and didemethylcitalopram (DDCIT), but also by deamination to a propionic acid derivative (CIT-PROP) and by N-oxidation to CIT-N-oxide (NO-CIT). CIT has equal affinity for 5-HTT and dopamine transporters. Studies have shown that compared with healthy subjects, the binding potential of thalamus and brainstem binding area in patients with depression who take 20-60 mg citalopram every day is reduced by 50%.

It is supplied as the free base in 20 mg tablets oral administration; daily oral dose for adults usually range from 20-60 mg. The common adverse reactions were nausea, dry mouth and drowsiness. The rare adverse reactions were agitation, income and anxiety. The oral bioavailability of citalopram is about 80%.15% of citalopram is excreted by kidney, and 12%-23% of citalopram in daily dose is excreted in original form from urine.

Fluoketamine (FKET)

F-Ketamine is generally used as the replacement of ketamine with hallucinogenic properties. When abused, people are immersed in anesthesia situation with distorting perceptions of sight and sound and feeling out of control. Currently, there is limited research and using regulation of F-Ketamine. Therefore, a large number of people abuse F-Ketamine instead of ketamine. But nowadays, the detection of F-Ketamine is restricted to high performance liquid chromatography (HPLC), gas chromatograph-mass spectrometer (GC-MS), thin layer chromatography (TLC), etc. which require not only expensive equipment but professional analysis. At the same time, high purity of test material and complex operation are necessary as well. Therefore, it is a tendency that the test methods of FKET become fast and convenient.

Olanzapine (OZP)

Olanzapine is an atypical antipsychotic drug which antagonizes several neutrotransmitter receptors including dopamine and 5-HT receptors. It is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent and approved to be marketed in the US in 1996. However, there are known pharmacological actions, extrapyramidal and anticholinergic effects when drug in overdose, including somnolence, mydriasis, blurred vision, respiratory depression, and hypotension. Olanzapine is mainly eliminated through metabolism and hence, only 7% of the eliminated drug can be found as the unchanged form. It is mainly excreted in the urine which represents around 53% of th e excreted dose followed by the feces that represent about 30%.

Risperidone (RPD)

Risperidone is a benzisoxazole derivative with serotonergic and dopaminergic receptor antagonist properties. The drug has been used clinically since 1990 as an antipsychotic agent. It is supplied as the free base in 0.25-6 mg tablets and a 1 mg/mL solution for oral administration; daily oral dose for adults usually range from 2-6 mg. Adverse reactions include dizziness, somnolence, nausea, orthostatic hypotension, anxiety, headache and extrapyramidal symptoms. A single labeled oral risperidone dose is eliminated in urine (70%) and feces (14%) over a one week period.

Tapentadol (TAP)

Tapentadol is used to help relieve moderate to severe short-term pain such as pain from an injury or after surgery. It belongs to a class of drugs known as opioid analgesics. It works in the brain to change how the body feels and responds to pain. Tapentadol is mainly metabolized in the liver and is excreted by the kidneys in urine as well as in feces. The major pathway of metabolism is conjugation with glucuronic acid to produce glucuronides; tapentadol-O-glucuronide is the major metabolite. For monitoring the intake regularly, Tapentadol is tested in human urine.

N,N-Dimethyltryptamine (NND)

N, N-Dimethyltryptamine is a powerful and illegal hallucinogenic drug. While there is an open debate on whether or not N, N-Dimethyltryptamine is addictive, this drug poses dangerous physical and psychological effects for frequent users. Additionally, individuals who frequently abuse N, N-Dimethyltryptamine often develop a dependence on the drug, proving the dangers of N, N-Dimethyltryptamine abuse.

N, N-Dimethyltryptamine produces a high referred to as a psychedelic trip. When smoked, a N, N-Dimethyltryptamine trip usually begins instantly and lasts less than an hour. However, when drunk in the form of Ayahuasca tea, hallucinations begin after about 30 minutes and may last from 4-6 hours. Some users report experiencing mild, lingering hallucinogenic effects for several days after consuming or smoking N, N-Dimethyltryptamine. On a physiological level, N, N-Dimethyltryptamine causes an array of adverse side effects.

Scopolamine (SCOP)

Scopolamine is a tertiary amine antifungal drug often used in sedative anesthesia, cough and asthma.It is mainly derived from the Solanaceae plants Tianxian, mandola and so on. The drug has highly toxic and hallucinogenic effects and is used as a crime, even called the devil's breath. Therapeutically, Scopolamine is used as a substitution treatment for Patients allergic to atropine. In alternative therapy, Scopolamine is as effective as atropine, and even more potent. The plasma half-life of Scopolamine is 1-3 hours. Mirtazapine (MTZ)

Desmethylmirtazapine is a norepinephrine and specific serotonin antidepressant, which can act on central presynaptic d2 receptor antagonist and enhance adrenergic nerve conduction. The drug has been used clinically since 1990s as an antidepressants. The effective dose for adults is usually 15-45 mg/d. Adverse reactions include increased appetite, weight gain, sedationdizziness, somnolence, nausea, orthostatic hypotension, and mania. A single labeled oral Desmethylmirtazapine dose is eliminated in urine (85%) and feces (15%) over a one week period.

Alcohol (ALC)

Alcohol intoxication can lead to loss of alertness, coma, death and birth defects. Determination of ethyl alcohol in blood, saliva and urine is commonly used for measuring legal impairment, alcohol poisoning, etc. The BAC (Blood Alcohol Content) at which a person becomes impaired is variable. The United States Department of Transportation (DOT) has established a BAC of 0.02% (0.02g/dL) as the cut-off level at which an individual is considered positive for the presence of alcohol.

The Multi-Drug Rapid Test yields a positive result when the concentration of Alcohol in urine exceeds 0.02%.

WHAT IS ADULTERATION

Adulteration is the tampering of a urine specimen with the intention of altering the test results. The use of adulterants can cause false negative results in drug tests by either interfering with the screening test and/or destroying the drugs present in the urine. Dilution may also be employed in an attempt to produce false negative drug test results.

One of the best ways to test for adulteration or dilution is to determine certain urinary characteristics such as pH, specific gravity and creatinine and to detect the presence of oxidants/PCC, nitrites or glutaraldehyde in urine.

Oxidants/PCC (Pyridiniumchlorochromate) tests for the presence of oxidizing agents such as bleach and hydrogen peroxide. Pyridiniumchlorochromate (sold under the brand name Urine Luck) is a commonly used adulterant.8 Normal human urine should not contain oxidants of PCC. Specific gravity tests for sample dilution. The normal range is from 1.003 to 1.030. Values outside this range may be the result of specimen dilution or adulteration.

pH tests for the presence of acidic or alkaline adulterants in urine. Normal pH levels should be in the range of 4.0 to 9.0. Values outside of this range may indicate the sample has been altered. Nitrite tests for commonly used commercial adulterants such as Klear and Whizzies. They work by oxidizing the major cannabinoid metabolite THC-COOH.9 Normal urine should contain no trace of nitrite. Positive results generally indicate the presence of an adulterant.

Glutaraldehyde tests for the presence of an aldehyde. Adulterants such as Urin Aid and Clear Choice contain glutaraldehyde which may cause false negative results by disrupting the enzyme used in some immunoassay tests.⁹ Glutaraldehyde is not normally found in urine; therefore, detection of glutaraldehyde in a urine specimen is generally an indicator of adulteration.

Creatinine is a waste product of creatine; an amino-acid contained in muscle tissue and found in urine.² A person may attempt to foil a test by drinking excessive amounts of water or diuretics such as herbal teas to "flush" the system. Creatinine and specific gravity are two ways to check for dilution and flushing, which are the most common mechanisms used in an attempt to circumvent drug testing. Low Creatinine and specific gravity levels may indicate dilute urine. The absence of Creatinine (<5 mg/dl) is indicative of a specime not consistent with human urine.

Bleach tests for the presence of bleach bleach refers to a number of chemicals which remove color, whiten or disinfect, often by oxidation, Bleaches are used as household chemicals to whiten clothes and remove stains and as disinfectants. Normal human urine should not contain bleach

[PRINCIPLE (FOR DOA TESTS EXCLUDING ALCOHOL)]

During testing, a urine specimen migrates upward by capillary action. A drug, if present in the urine specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test region of the specific drug dipstick. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test region.

A drug-positive urine specimen will not generate a colored line in the specific test region of the dipstick because of drug competition, while a drug-negative urine specimen will generate a line in the test region because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

[PRINCIPLE (FOR ALCOHOL)]

The urine Alcohol Rapid Test Cassette consists of a plastic strip with a reaction pad attached at the tip. On contact with alcohol, the reaction pad will change colors depending on the concentration of alcohol present. This is based on the high specificity of alcohol oxidase for ethyl alcohol in the presence of peroxidase and enzyme substrate such as TMB.

[REAGENTS(FOR DOA TESTS EXCLUDING ALCOHOL)]

Each test line contains anti-drug mouse monoclonal antibody and corresponding drug-protein conjugates. The control line contains goat anti-rabbit IgG polyclonal antibodies and rabbit IgG. [REAGENTS (FOR ALCOHOL)]

Tetramethylbenzidine, Alcohol Oxidase, Peroxidase

CONTRACTOR INTO		
Adulteration Pad	Reactive indicator	Buffers and non-reactive ingredients
Creatinine	0.04%	99.96%
Nitrite	0.07%	99.93%
Bleach	0.39%	99.61%
Glutaraldehyde	0.02%	99.98%
рH	0.06%	99.94%

Specific Gravity 0.25%	99.75%
Oxidants / PCC 0.36%	99.64%

[PRECAUTIONS]

For healthcare professionals including professionals at point of care sites.

 Immunoassay for in vitro diagnostic use only. The Test should remain in the sealed pouch until use

· All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent

The used test should be discarded according to local regulations.

STORAGE AND STABILITY

Store as packaged in the sealed pouch at 2-30°C. The test is stable through the expiration date printed on the sealed pouch. The Test must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date

[SPECIMEN COLLECTION AND PREPARATION]

Urine Assay

The urine specimen should be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged. filtered, or allowed to settle to obtain a clear specimen for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed well before testing. When testing cards with S.V.T. or Alcohol storage of urine specimens should not exceed 2 hours at room temperature or 4 hours refrigerated prior to testing.

[MATERIALS]

Timer

Materials Provided


 Test Cassettes Package Insert Droppers Adulteration Color Chart (when applicable)

Materials Required But Not Provided

[DIRECTIONS FOR USE]

Allow the test and urine specimen to reach room temperature (15-30°C) prior to testing.

- 1. Bring the pouch to room temperature before opening it. Remove the test cassette from the sealed pouch and use it within one hour.
- 2. Place the test cassette on a clean and level surface. Hold the dropper vertically and transfer 3 full drops of urine (approx. 75 uL) to the specimen well (S) of the test cassette, and then start the timer. Avoid trapping air bubbles in the specimen well (S). See the illustration below.
- 3. Read the adulteration strips and Alcohol strip between 3-5 minutes according to color chart provided separately/on foil pouch. Refer to your Drug Free Policy for guidelines on adulterated specimens. We recommend not to interpret the drug test results and either retest the urine or collect another specimen in case of any positive result for any adulteration test.
- 4. The drug strip result should be read at 5 minutes. Do not interpret the result after 10 minutes



[INTERPRETATION OF RESULTS]

(Please refer to the illustration above)

NEGATIVE:* A colored line appears in the control region (C) and colored line appears in the test region (T). This negative result means that the concentrations in the urine sample are below the designated cut-off levels for a particular drug tested.

*NOTE: The shade of the colored lines(s) in the test region (T) may vary. The result should be considered negative whenever there is even a faint line.

POSITIVE: A colored line appears in the control region (C) and no line appears in the test region (T). The positive result means that the drug concentration in the urine sample is greater than the designated cut-off for a specific drug.

INVALID: No line appears in the control region (C). Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Read the directions again and repeat the test with a new test. If the result is still invalid, contact your manufacturer. **[INTERPRETATION OF RESULTS (S.V.T/ ADULTERATION)**]

(Please refer to the color chart)

Semi-Quantitative results are obtained by visually comparing the reacted color blocks on the strip to the printed color blocks on the color chart. No instrumentation is required.

[INTERPRETATION OF RESULTS (ALCOHOL STRIP)]

Negative: Almost no color change by comparing with the background. The negative result indicates that the urine alcohol level is less than 0.02%.

Positive: A distinct color developed all over the pad. The positive result indicates that the urine alcohol concentration is 0.02% or higher.

Invalid: The test should be considered invalid If only the edge of the reactive pad turned color that might be ascribed to insufficient sampling. The subject should be re-tested. Besides, if the color pad has a blue color before applying urine sample, do not use the test.

QUALITY CONTROL

A procedural control is included in the test. A line appearing in the control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit. However, it is recommended that positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify proper test performance.

[LIMITATIONS]

- 1. The Multi-Drug Rapid Test Cassette provides only a gualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography /mass spectrometry (GC/MS) is the preferred confirmatory method.^{1,}
- 2. There is a possibility that technical or procedural errors, as well as interfering substances in the urine specimen may cause erroneous results.
- 3. Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
- 4. A positive result does not indicate level or intoxication, administration route or concentration in urine.
- 5. A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.
- 6. This test does not distinguish between drugs of abuse and certain medications.
- 7. A positive test result may be obtained from certain foods or food supplements. Alcohol in the atmosphere, such as spray from perfumes, deodorizers, glass cleaners etc. can affect the Alcohol Rapid Tests, Therefore, adequate measures should be taken to avoid undue interference from such atmospheric agents in the testing area.
- 8. The test is only for detection of presence/ absence of alcohol in the urine, which may result from habitual drinking or medications and does not discriminate the two.

[S.V.T/ ADULTERATION LIMITATIONS]

1. The adulteration tests included with the product are meant to aid in the determination of abnormal specimens. While comprehensive, these tests are not meant to be an "all-inclusive" representation of possible adulterants.

2. Oxidants/PCC: Normal human urine should not contain oxidants or PCC. The presence of high levels of antioxidants in the specimen, such as ascorbic acid, may result in false negative results for the oxidants/PCC pad.

- 3. Specific Gravity: Elevated levels of protein in urine may cause abnormally high specific gravity values.
- 4. Nitrite: Nitrite is not a normal component of human urine. However, nitrite found in urine may indicate urinary tract infections or bacterial infections. Nitrite levels of > 20 mg/dL may produce false positive glutaraldehvde results.
- 5. Glutaraldehyde: is not normally found in urine. However certain metabolic abnormalities such as ketoacidosis (fasting, uncontrolled diabetes or high protein diets) may interfere with the test results
- 6. Creatinine: Normal Creatinine levels are between 20 and 350 mg/dL. Under rare conditions, certain kidney diseases may show dilute urine.
- 7. Bleach: Normal human urine should not contain bleach. The presence of high levels of bleach in the specimen may result in false negative results for the bleach pad.
- 8 nH Normal PH levels are between 4.0 and 9.0 [PERFORMANCE CHARACTERISTICS]

Accuracy A side-by-side comparison was conducted using the Multi-Drug Rapid Test and commercially

available drug rapid tests. Testing was performed on approximately hundred specimens per
drug type previously collected from subjects presenting for Drug Screen Testing. Presumptive
positive results were confirmed by GC/MS.

Met	hod	GC/N		% agreement with GC/MS	
Multi-Drug	Rapid Test	Positive	Negative	% agreement with GC/MS	
ACE	Positive	29	1	93.5%	
5,000	Negative	2	68	98.6%	
AMP	Positive	103	3	98.1%	
1,000	Negative	2	142	97.9%	
AMP	Positive	110	2	99.1%	
500	Negative	1	137	98.6%	
AMP	Positive	116	2	99.1%	
300	Negative	1	131	98.5%	
BAR	Positive	98	2	96.1%	
300	Negative	4	146	98.6%	
BAR	Positive	101	3	95.3%	
200	Negative	5	141	97.9%	
BZO	Positive	112	3	98.2%	
500	Negative	2	133	97.8%	
BZO	Positive	121	1	98.4%	
300	Negative	2	126	99.2%	

Meth		GC/M		% agreement with GC/MS
Multi-Drug		Positive 127	Negative 2	-
BZO	Positive	127	120	99.2% 98.4%
200	Negative	100		
BZO	Positive	128	3	99.2%
100	Negative	1	118	97.5%
BUP	Positive	105	0	99.1%
10	Negative	1	144	>99.9%
BUP	Positive	105	0	99.1%
5	Negative	1	144	>99.9%
COC	Positive	111	3	98.2%
300	Negative	2	134	97.8%
COC	Positive	40	0	>99.9%
200	Negative	0	60	>99.9%
COC	Positive	116	4	98.3%
150	Negative	2	128	97.0%
COC	Positive	117	4	99.2%
100	Negative	1	128	97.0%
THC	Positive	85	3	95.5%
300	Negative	4	158	98.1%
THC	Positive	85	4	93.4%
200	Negative	6	155	97.5%
THC	Positive	86	4	94.5%
150	Negative	5	155	97.5%
		92	3	
THC	Positive			97.9%
50	Negative	2	153	98.1%
THC	Positive	94	3	97.9%
30	Negative	2	151	98.1%
THC	Positive	95	4	96.9%
25	Negative	3	148	97.4%
THC	Positive	92	1	94.8%
20	Negative	5	152	99.3%
MTD	Positive	89	2	98.9%
300	Negative	1	158	98.8%
MTD	Positive	91	2	98.7%
200	Negative	1	156	98.7%
MET	Positive	76	5	96.2%
1,000	Negative	3	166	97.1%
MET	Positive	83	5	97.6%
500	Negative	2	160	97.0%
MET	Positive	88	4	97.8%
300	Negative	2	156	97.5%
MDMA	Positive	99	1	98.0%
1,000	Negative	2	148	99.3%
MDMA	Positive	102	1	98.1%
500		2	145	99.3%
	Negative		145	
MDMA	Positive	103		98.1%
300	Negative	2	144	99.3%
MOP/OPI	Positive	95	7	95.0%
300	Negative	5	143	95.3%
MOP/OPI	Positive	95	6	95.0%
200	Negative	5	144	96.0%
MOP/OPI	Positive	98	5	97.0%
100	Negative	3	144	96.6%
MPRD	Positive	19	3	95.0%
100	Negative	1	49	94.2%
MQL	Positive	79	11	89.8%
300	Negative	9	151	93.2%
OPI	Positive	117	8	96.7%
2,000	Negative	4	121	93.8%
OPI	Positive	116	8	95.9%
1,000	Negative	5	121	93.8%
PCP	Positive	84	5	92.3%
50	Negative	7	154	96.9%
PCP	Positive	85	5	92.4%
25	Negative	7	153	96.8%
PPX	Positive	97	9	96.0%
300	Negative	4	140	94.0%
TCA	Positive	91	13	94.8%
1,000	Negative	5	141	91.6%
TCA	Positive	93	12	94.9%
500	Negative	5	140	92.1%
TCA	Positive	94	12	94.9%
ICA				
300	Negative	5	139	92.1%

GC/MS

% agreement with CC/MS

Method

Mot	hod	GC/M	\$	
	Rapid Test	Positive	Negative	% agreement with GC/MS
100	Negative	11	145	92.4%
TML	Positive	82	6	88.2%
200	Negative	11	151	96.2%
TML	Positive	81	6	88.0%
300	Negative	11	152	96.2%
TML	Positive	26	2	92.9%
500	Negative	2	101	98.1%
KET	Positive	77	3	97.5%
1,000	Negative	2	168	98.2%
KET	Positive	81	3	97.6%
500	Negative	2	164	98.2%
KET	Positive	89	4	96.7%
300 KET	Negative Positive	3 97	154 4	97.5% 96.0%
100	Negative	97 4	145	97.3%
OXY	Positive	83	145	96.5%
300	Negative	3	163	99.4%
OXY	Positive	84	1	97.7%
100	Negative	2	163	99.4%
COT	Positive	88	4	97.7%
300	Negative	2	156	97.5%
COT	Positive	88	4	96.7%
200	Negative	3	155	97.5%
COT	Positive	93	3	97.9%
100	Negative	2	152	98.1%
COT	Positive	67	5	95.7%
500	Negative	3	123	96.1%
COT	Positive	89	4	96.7%
50	Negative	3	154	97.5%
COT	Positive	90	3	97.8%
10 EDDP	Negative	2	155	98.1%
300	Positive	92 2	1 155	97.9% 99.4%
EDDP	Negative Positive	95	5	99.4%
100	Negative	3	147	96.7%
FYL	Positive	32	2	97.0%
300	Negative	1	185	98.9%
FYL	Positive	79	1	97.5%
200	Negative	2	168	99.4%
FYL	Positive	79	1	98.8%
100	Negative	1	169	99.4%
FYL	Positive	79	1	98.8%
20	Negative	1	169	99.4%
FYL	Positive	80	1	98.8%
10	Negative	1	168	99.4%
K2-50	Positive	78	3	97.5%
	Negative	2	167	98.2%
K2-30	Positive	82	2	97.6%
-	Negative	2	164	98.8%
K2-25	Positive Negative	82	3 163	97.6% 98.2%
6-MAM	Positive	2 42		
6-MAM 10	Negative	42	2 105	97.7% 98.1%
MDA	Positive	103	3	98.1%
500	Negative	2	142	97.9%
ETG	Positive	79	142	98.8%
300	Negative	1	169	99.4%
ETG	Positive	83	109	97.6%
500	Negative	2	164	99.4%
ETG	Positive	81	1	95.3%
1,000	Negative	4	164	99.4%
CLO	Positive	101	1	97.1%
400	Negative	3	145	99.3%
CLO	Positive	103	2	99.0%
150	Negative	1	144	98.6%
LSD	Positive	33	1	94.3%
10	Negative	2	65	98.5%
LSD	Positive	33	1	94.3%
20	Negative	2	64	98.5%
LSD	Positive	32	1	94.1%
50	Negative	2	65	98.5%
MPD 200	Positive	35	1	94.6%
300	Negative	2	62	98.4%

	thod Rapid Test	GC/M Positive	S Negative	% agreement with GC/M
				01.0%
MPD 150	Positive Negative	<u>34</u> 3	1 62	91.9% 98.4%
150				
MPD	Positive	35	1	94.6%
1,000	Negative	2	62	98.4%
ZOL	Positive	20	2	90.9%
50	Negative	2	66	97.1%
MEP	Positive	19	2	95.2%
500	Negative	2	64	98.5%
MEP	Positive	19	2	90.5%
100	Negative	2	64	97.0%
MDPV	Positive	28	1	93.3%
1,000	Negative	2	69	98.6%
MDPV	Positive	27	1	93.1%
500	Negative	2	59	98.3%
MDPV	Positive	30	2	93.8%
300	Negative	2	68	97.1%
DIA	Positive	121	1	98.4%
300	Negative	2	126	99.2%
DIA	Positive	121	1	98.4%
200	Negative	2	126	99.2%
ZOP	Positive	19	2	86.4%
50	Negative	3	69	97.2%
MCAT	Positive	20	4	90.9%
500	Negative	2	76	95.0%
7-ACL	Positive	32	1	94.1%
300	Negative	2	43	97.7%
7-ACL	Positive	35	1	94.6%
200	Negative	2	40	97.6%
7-ACL	Positive	36	1	94.7%
100	Negative	2	39	97.5%
CFYL	Positive	36	1	94.7%
500	Negative	2	72	98.6%
			1	
CFYL	Positive	36 2	72	94.7% 98.6%
250	Negative			
CAF	Positive	21	3	91.3%
1,000	Negative	2	66	95.7%
CAT	Positive	19	2	90.5%
150	Negative	2	73	97.3%
TRO	Positive	23	2	92.0%
350	Negative	2	64	97.0%
ALP	Positive	20	2	90.9%
100	Negative	2	74	97.4%
PGB	Positive	20	2	90.9%
50,000	Negative	2	73	97.3%
PGB	Positive	20	2	95.2%
500	Negative	1	52	96.3%
ZAL	Positive	20	1	95.2%
100	Negative	1	38	97.4%
CNB	Positive	23	1	95.8%
500	Negative	1	40	97.6%
GAB	Positive	24	1	92.3%
2,000	Negative	2	65	98.5%
TZD	Positive	26	3	92.9%
200	Negative	2	73	96.1%
CAR	Positive	36	1	97.3%
2,000	Negative	1	57	98.3%
CAR	Positive	18	1	90.0%
1,000	Negative	2	51	98.1%
ABP	Positive	23	2	92.0%
АВР 10	Negative	23	68	97.1%
		34		
QTP 1 000	Positive		1	97.1%
1,000	Negative	1	59	98.3%
FLX	Positive	33	2	97.1%
500	Negative	1	57	96.6%
UR-144	Positive	34	1	97.1%
25	Negative	1	62	98.4%
KAR	Positive	22	1	95.7%
300	Negative	1	59	98.3%
TLD	Positive	36	1	97.3%
50	Negative	1	57	98.3%
α-PVP	Positive	33	2	86.8%

	Method			Desitiv	GC/MS		tirra	%	agreem	ent with	GC/MS
Multi-Di α-PVP	rug Rap	Positive		Positiv 35	e	-	gative 2	•	- (92.1%	
1,000	_	Negative		3			50			96.8%	
α-PVP		Positive		34			3			91.9%	
500		Negative		3		6	60		ç	95.2%	
α-PVP		Positive		35			3			92.1%	
300		Negative		3			59			95.2%	
MES		Positive		23			1 40			95.8%	
100 MES		Negative Positive		1 23			40 1			97.6% 95.8%	
300		Negative		1			40			97.6%	
PAP		Positive		31			1			96.8%	
500	_	Negative		1			49			98.0%	
CIT		Positive		28			3			93.3%	
500		Negative		2		6	63			95.5%	
FKET		Positive		29			2			96.7%	
1,000	_	Negative		1			64			97.0%	
RPD 150		Positive Negative		28			3 63			93.3% 95.5%	
TAP		Positive		34			1			94.4%	
1,000		Negative		2			55			98.2%	
NND		Positive		29			2			96.7%	
1,000		Negative		1		6	64		ç	97.0%	
SCOP		Positive		29			1			93.5%	
500		Negative		2			68			98.6%	
MTZ		Positive		28			3			93.3%	
500 OZP		Negative		2			65 1			95.6%	
1,000		Positive Negative	_	23			40			95.8% 97.6%	
1,000		riegative		1	1		10			7.070	
			% Agr	eement v	vith Cor	nmerci	ial Ki	it			
	ACE	AMP	BAR		BUP	COO		COC	THC	THC	MPD
	5,000	1,000/	300/		0 10/5	300		200/	200/	300/20/	150/30
		500/ 300	200	/200/ 100		100	5	150	150/50/ 25	30	/1,000
Positive	*							*		*	*
Agreement	*	>99.9%	>99.99	% >99.9%	>99.9%	6 >99.9	9%	*	>99.9%	*	*
Vegative	*	× 00 00/	× 00.00	% >99.9%	× 00 00		20/	*	>99.9%	*	*
Agreement											
Fotal Results	*	>99.9%	>99.99	% >99.9%	>99.9%	6 >99.9	9%	*	>99.9%	*	*
	7 10	MTD	NALT			MO			MOL		
	7-ACL		MET					NOP/	MQL	MEP	LSD
	300/20	MTD 0300/200	1,000	/ 1,000/	MDMA 300	OP	1	OPI		MEP 500/100	20/50
Positive		0300/200	0 1,000 500/30)/ 1,000/ 00 500	300	OP 300/1	'I 00		300		
Agreement	300/20	0300/200	0 1,000 500/30	/ 1,000/	300	OP	'I 00	OPI		500/100	20/50 10
Agreement Negative	300/20	0300/200 >99.9%	1,000 500/30 >99.9)/ 1,000/ 00 500	300	OP 300/1	1 00 9%	OPI	300	500/100	20/50 10
Agreement Negative Agreement	300/20 /100 * *	0300/200 >99.9% >99.9%	1,000 500/30 >99.9' >99.9'	0/ 1,000/ 500 % >99.9% % >99.9%	300 * *	OP 300/1 >99.9 >99.9	9%	OPI 200 *	300 >99.9% >99.9%	500/100 * *	20/50 10 *
Agreement Negative Agreement	300/20 /100 *	0300/200 >99.9% >99.9%	1,000 500/30 >99.9	0/ 1,000/ 500 % >99.9% % >99.9%	300 * *	OP 300/1 >99.9	9%	OPI 200 *	300 >99.9%	500/100 *	20/50 10 *
Agreement Negative Agreement	300/20 /100 * *	0300/200 >99.9% >99.9% >99.9%	1,000 500/30 >99.9' >99.9' >99.9'	// 1,000/ 00 500 % >99.9% % >99.9% % >99.9%	300	OP 300/1 >99.9 >99.9 >99.9	1 100 9% 9%	OPI 200 * *	300 >99.9% >99.9% >99.9%	500/100 * * *	20/50 10 * *
Agreement Negative Agreement	300/20 /100 * * *	0300/200 >99.9% >99.9% >99.9% TCA	1,000 500/30 >99.9 >99.9 >99.9 >99.9	// 1,000/ 500 % >99.9% % >99.9% % >99.9%	300 * * * * COT	OP 300/1 >99.9 >99.9 >99.9	1 100 2% 2% 2% 2%	OPI 200 * * * PCP	300 >99.9% >99.9% >99.9% PCP	500/100 * * DIA	20/50 10 * * *
Agreement Negative Agreement	300/20 /100 * *	0300/200 >99.9% >99.9% >99.9%	0 1,000 500/30 >99.9° >99.9° >99.9° >99.9° >99.9°	// 1,000/ 500 % >99.9% % >99.9% % >99.9% % >99.9% KET 1,000/	300 * * * * * * * * * * * * *	OP 300/1 >99.9 >99.9 >99.9 >99.9 >99.9	PI PI PI PI PI PI PI PI PI PI	OPI 200 * *	300 >99.9% >99.9% >99.9%	500/100 * * DIA 300/	20/50 10 * * MDP\ 1,000
Agreement Negative Agreement	300/20 /100 * * *	0300/200 >99.9% >99.9% >99.9% TCA 1,000/	0 1,000 500/30 >99.9° >99.9° >99.9° >99.9° >99.9°	// 1,000/ 500 // >99.9% // >99.9% // >99.9% // >99.9% // >99.9% // >99.9% // >99.9% // >99.9% // >99.9% // >99.9%	300 * * * COT 300/20 0/100, 500/50	OP 300/1 >99.9 >99.9 >99.9 >99.9 >99.9 >99.9 >99.9 >99.9 >99.9 >99.9 >99.9	PI PI PI PI PI PI PI PI PI PI	OPI 200 * * * PCP	300 >99.9% >99.9% >99.9% PCP	500/100 * * DIA 300/	20/50 10 * * MDP\ 1,000
Agreement Vegative Agreement Fotal Results	300/20 /100 * * *	300/200 >99.9% >99.9% >99.9% TCA 1,000/ 500/30	1,000 500/30 >99.90 >99.90 >99.90 >99.90 >99.90 TML 200/1 0 0/300 500	// 1,000/ 500 // >99.9% // >99.9% // >99.9% // >99.9% // >99.9% // >99.9% // >99.9% // >99.9% // >99.9% // >99.9%	300 * * * COT 300/20 0 0/100. 500/50 10	OP 300/1 >99.9 >99.9 >99.9 >99.9 >99.9 2,00 / 1,00	PI PI PI PI PI PI PI PI PI PI	OPI 200 * * * * * * * * * *	300 >99.9% >99.9% >99.9% PCP	500/100 * * DIA 300/ 200	20/50 10 * * * MDP\ 1,000 500/30
Agreement Negative Agreement Fotal Results	300/20 /100 * * *	300/200 >99.9% >99.9% >99.9% TCA 1,000/ 500/30	1,000 500/30 >99.9 >99.9 >99.9 >99.9 >99.9 TML 200/1 0 0/300	// 1,000/ 500 // >99.9% // >99.9% // >99.9% // >99.9% // >99.9% // >99.9% // >99.9% // >99.9% // >99.9% // >99.9%	300 * * COT 300/20 0/100, 500/50 10	OP 300/1 >99.9 >99.9 >99.9 >99.9 >99.9 >99.9 >99.9 >99.9 >99.9 >99.9 >99.9	PI PI PI PI PI PI PI PI PI PI	OPI 200 * * * PCP	300 >99.9% >99.9% >99.9% PCP	500/100 * * DIA 300/ 200	20/50 10 * * MDP\ 1,000
Positive Agreement Agreement Total Results Positive Agreement Negative	300/20 /100 * * * PPX 300 >99.9'	300/200 >99.9% >99.9% >99.9% TCA 1,000/ 500/30	1,000 500/30 >99.9' >99.9' >99.9' >99.9' >99.9' TML 200/1 0 0/300 500 *	// 1,000/ 00 500 % >99.9% % >99.9% % >99.9% % >99.9% KET 1,000/ 0/ 500/30 /100 >99.9%	300 * * COT 300/20 0 /100 500/50 10 6 *	OP 300/1 >99.9 >99.9 >99.9 >99.9 >99.9 2,00 / 1,00	PI PI PI PI PI PI PI PI PI PI	OPI 200 * * * * * * * * * *	300 >99.9% >99.9% >99.9% PCP 25 >99.9%	500/100 * * DIA 300/ 200 *	20/50 10 * * * MDP\ 1,000 500/30
Agreement Negative Agreement Fotal Results Positive	300/20 /100 * * * PPX 300	300/200 >99.9% >99.9% >99.9% TCA 1,000/ 500/30	1,000 500/30 >99.90 >99.90 >99.90 >99.90 >99.90 TML 200/1 0 0/300 500	// 1,000/ 500 % >99.9% % >99.9% % >99.9% % >99.9% % >99.9% % >99.9% % >90.9% % >0.0% 1,000/ 500/30 /100	300 * * COT 300/20 0 /100 500/50 10 6 *	OP 300/1 >99.9 >99.9 >99.9 >99.9 >99.9 2,00 / 1,00	PI PI PI PI PI PI PI PI PI PI	OPI 200 * * * * * * * * * *	300 >99.9% >99.9% >99.9% PCP 25	500/100 * * DIA 300/ 200 *	20/50 10 * * * MDP\ 1,000 500/30
Agreement Agreement Fotal Results Positive Agreement Agreement	300/20 /100 * * * * 300 >99.9' >99.9'	0300/200 >99.9% >99.9% >99.9% TCA 1,000/ 500/30 % * % *	1,000 500/30 >99.9' >99.9' >99.9' >99.9' >99.9' TML 200/1 0 0/300 500	// 1,000/ 00 500 % >99.9% % >99.9% % >99.9% % >99.9% KET 1,000/ 0/ 500/30 /100 >99.9%	300 * * COT 300/20 0/100, 500/50 10 6 *	OP 300/1 >99.9 >99.9 >99.9 >99.9 >99.9 2,00 / 1,00	PI PI PI PI PI PI PI PI PI PI	OPI 200 * * * * * * * * * *	300 >99.9% >99.9% >99.9% PCP 25 >99.9%	500/100 * * DIA 300/ 200 * *	20/50 10 * * * MDP\ 1,000 500/30
Agreement Agreement Fotal Results Positive Agreement Agreement	300/20 /100 * * * PPX 300 >99.9' >99.9'	0300/200 >99.9% >99.9% >99.9% >99.9% TCA 1,000/ 500/30 % * % * % *	1,000 500/30 >99.99 >99.99 >99.99 TML 200/1 0 0/300 500 * *	// 1,000/ 0 500 % >99.9% % >99.9% % >99.9% % >99.9% 500/30 /100 >99.9% >99.9% >99.9%	300 * * * COT 300/2(0 0/100,0 500/5(0 10 6 * 6 *	OP 300/1 >99.9 >99.9 >99.9 >99.9 2,00 1,00 / / / / / / / / /	PI 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00	OPI 200 * * * PCP 50 * *	300 >99.9% >99.9% >99.9% >99.9% >99.9% >99.9%	500/100 * DIA 300/ 200 * *	20/50 10 * * * * 1,000 500/30 * *
Agreement Agreement Total Results Positive Agreement Agreement	300/20 /100 * * * PPX 300 >99.9' >99.9' >99.9'	0300/200 >99.9% >99.9% >99.9% TCA 1,000/ 500/30 % * % * % *	1,000 500/30 >99.9' >99.9' >99.9' TML 200/1 0 0/300 500 * * *	// 1,000/ 0 500 % >99.9% % >99.9% % >99.9% % >99.9% For KET 0 1,000 /100 >99.9% >99.9% >99.9% >99.9% X2-50/[6-	300 * * COT 300/20 0/100, 500/50 10 6 * 6 * MAM N	OP 300/1 >99.9 >99.9 >99.9 >99.9 1,00 / / / / / / / / / / /	P1 00 9% 9% P2 00/ 00 ETG	OPI 200 * * * * 50 * * * *	300 >99.9% >99.9% PCP 25 >99.9% >99.9% >99.9% > ZOL	500/100 * * DIA 300/ 200 * * * ZOP	20/50 10 * * * MDP\ 1,000 500/30 * * * *
Agreement Agreement Fotal Results Positive Agreement Agreement	300/20 /100 * * * PPX 300 >99.9' >99.9' >99.9' >99.9'	300/200 >99.9% >99.9% >99.9% >99.9% TCA 1,000/ 500/30 % * % * EDDP 300/	1,000 500/30 >99.9' >99.9' >99.9' 200/1 200/1 0 0/300 500 * * * *	// 1,000/ 0 500 % >99.9% % >99.9% % >99.9% % >99.9% For KET 0 1,000 /100 >99.9% >99.9% >99.9% >99.9% X2-50/[6-	300 * * COT 300/20 0/100, 500/50 10 6 * 6 * MAM N	OP 300/1 >99.9 >99.9 >99.9 >99.9 2,00 / 1,00 / / / * *	P1 00 9% 9% 9% 9% 9% 00/ 00 ETG ,000/	OPI 200 * * * * PCP 50 * * * * * * * * * * * * * * * * * * *	300 >99.9% >99.9% >99.9% 25 >99.9% >99.9% >99.9% >99.9% 20L 50	500/100 * DIA 300/ 200 * *	20/50 10 * * * * 1,000 500/30 * *
Agreement Agreement Fotal Results Positive Agreement Agreement	300/20 /100 * * * PPX 300 >99.9' >99.9' >99.9'	300/200 >99.9% >99.9% >99.9% >99.9% TCA 1,000/ 500/30 % * % * EDDP 300/	1,000 500/30 999.9' 999.9' 999.9' TML 200/1 0 0/300 500 * * * * * 300/20 0/100/	// 1,000/ 0 500 % >99.9% % >99.9% % >99.9% % >99.9% For KET 0 1,000 /100 >99.9% >99.9% >99.9% >99.9% X2-50/[6-	300 * * COT 300/20 0/100, 500/50 10 6 * 6 * MAM N	OP 300/1 >99.5 >99.5 >99.5 >99.5 >99.5 >0 2,000 1,000 * * *	P1 00 9% 9% P2 00/ 00 ETG	OPI 200 * * * * 50 * * * *	300 >99.9% >99.9% >99.9% 25 >99.9% >99.9% >99.9% >99.9% 20L 50	500/100 * * DIA 300/ 200 * * * ZOP	20/50 10 * * * MDP\ 1,000 500/30 * * * *
Agreement Negative Agreement Total Results Positive Agreement Fotal Results	300/20 /100 * * * PPX 300 >99.9' >99.9' >99.9' OXY 300/ 100	300/200 >99.9% >99.9% >99.9% TCA 1,000/ 500/30 % * % * % * % * * * * * * * * * *	>1,000 500/3C >99.9' >99.9' >99.9' TML 200/11 0 0/30(500 * * * FYL 300/20 0/100/ 20/10	// 1,000/ 500 // >99.9% // >99.9% // >99.9% // >99.9% // S00/30 // 100 >99.9% >99.9% >99.9% >99.9% >99.9% >99.9% >99.9%	300 * * COT 300/2(0 0/100 500/5(10 6 * * * MAM M 10 5	OP 300/1 >99.9 >99.9 >99.9 >99.9 >99.9 >0 2,000 1,000 1,000 1,1 2	ETG ,000/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 0	OPI 200 * * * * * * * * * * * * *	300 >99.9% >99.9% >99.9% >99.9% >99.9% >99.9% >99.9% >50 ZOL 50	500/100	20/50 10 * * * MDP\ 1,000 500/3C * * * * MCAT
Agreement Agreement Total Results Positive Agreement Otal Results Total Results	300/20 /100 * * * PPX 300 >99.9' >99.9' >99.9' >99.9'	300/200 >99.9% >99.9% >99.9% >99.9% TCA 1,000/ 500/30 % * % * EDDP 300/	1,000 500/30 999.9' 999.9' 999.9' TML 200/1 0 0/300 500 * * * * * *	// 1,000/ 0 500 % >99.9% % >99.9% % >99.9% % >99.9% For KET 0 1,000 /100 >99.9% >99.9% >99.9% >99.9% X2-50/[6-	300 * * COT 300/20 0/100, 500/50 10 6 * 6 * MAM N	OP 300/1 >99.5 >99.5 >99.5 >99.5 >99.5 >0 2,000 1,000 * * *	ETG ,000/	OPI 200 * * * * PCP 50 * * * * * * * * * * * * * * * * * * *	300 >99.9% >99.9% >99.9% 25 >99.9% >99.9% >99.9% >99.9% 20L 50	500/100 * * DIA 300/ 200 * * * ZOP	20/50 10 * * * * 1,000 500/30 * * *
Agreement Agreement Fotal Results Positive Agreement Fotal Results Positive Agreement Fotal Results Positive Agreement Negative Positive Agreement Negative	300/20 /100 * * * PPX 300 >99.9' >99.9' >99.9' OXY 300/ 100	300/200 >99.9% >99.9% >99.9% TCA 1,000/ 500/30 % * % * % * % * * * * * * * * * *	>1,000 500/3C >99.9' >99.9' >99.9' TML 200/11 0 0/30(500 * * * FYL 300/20 0/100/ 20/10	// 1,000/ 500 // >99.9% // >99.9% // >99.9% // >99.9% // S00/30 // 100 >99.9% >99.9% >99.9% >99.9% >99.9% >99.9% >99.9%	300 * * COT 300/2(0 0/100 500/5(10 6 * * * MAM M 10 5	OP 300/1 >99.9 >99.9 >99.9 >99.9 >99.9 >0 2,000 1,000 1,000 1,1 2	ETG ,000/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 0	OPI 200 * * * * * * * * * * * * *	300 >99.9% >99.9% >99.9% >99.9% >99.9% >99.9% >99.9% >50 ZOL 50	500/100	20/50 10 * * * MDP\ 1,000 500/3C * * * * MCAT
Agreement Agreement Total Results Positive Agreement Vegative Agreement Total Results Positive Agreement Negative Agreement	300/20 /100 * * PPX 300 >99.9' >99.9' 300/ 100 *	300/200 >99.9% >99.9% >99.9% TCA 1,000/ 500/30 % * % * % * % * % * % * * * * *	>99.9' >99.9' >99.9' 200/10' 200/10' 200/10' 500 500 500 500 500 500 500 500 500 5	// 1,000/ 500 % >99.9% % >99.9% % >99.9% % >99.9% % >99.9% 7 KET 1,000/ 500/30 /100 >99.9% >99.9% >99.9% >99.9% \$99.9%	300 * * COT 300/20 0/100, 500/50 10 6 * MAM M MAM M *	OP 300/1 >99.5 >99.5 >99.5 >99.5 >99.5 >99.5 >99.5 (/ 1,00 // 1,00 // 1,00 1 ; ; *	ETG ,000/ 500/ 500/ 500/ 500/ 300 *	OPI 200 * * * * * * * * * * * * * * * * * *	300 >99.9% >99.9% >99.9% >99.9% >99.9% >99.9% >99.9% 7 ZOL 7 50	500/100	20/50 10 * * MDPP 1,000 500/30 * * * * MCAT 500 *
Agreement Agreement Total Results Positive Agreement Regative Agreement Total Results	300/20 /100 * * PPX 300 >99.9' >99.9' 300/ 100 *	300/200 >99.9% >99.9% >99.9% TCA 1,000/ 500/30 % * % * % * % * % * % * * * * *	>99.9' >99.9' >99.9' 200/10' 200/10' 200/10' 500 500 500 500 500 500 500 500 500 5	// 1,000/ 500 % >99.9% % >99.9% % >99.9% % >99.9% % >99.9% 7 KET 1,000/ 500/30 /100 >99.9% >99.9% >99.9% >99.9% \$99.9%	300 * * COT 300/20 0/100, 500/50 10 6 * MAM M MAM M *	OP 300/1/ >99.5 >99.5 >99.5 2007 1,007 1,007 1,007 1,007 1,5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	* 100 100 100 100 100 100 100 10	OPI 200 * * * * * * * * * * * * * * * * * *	300 >99.9% >99.9% >99.9% >99.9% >99.9% >99.9% >99.9% 7 ZOL 7 50	500/100	20/50 10 * * MDPP 1,000 500/30 * * * MCAT 500 *
Agreement Agreement Total Results Positive Agreement Total Results Positive Agreement Negative Agreement Negative Agreement	300/20 /100 * * * * * * * * * * * * * * * * * *	300/200 >99.9% >99.9% >99.9% TCA 1,000/ 500/30 % * 300/ 100 * * *	>99.9 >99.9 >99.9 >99.9 TML 200/10 500 0/300 500 0/300 500 0/100/ 20/10 * *	// 1,000/ 500 % >99.9% % >99.9% % >99.9% % >99.9% % >99.9% % >99.9% 100 /100 >99.9% >99.9% >99.9% >99.9% >99.9% × 100 * *	300	OP 300/1 >99.5 >99.5 >99.5 2,000 / 1,00 / 1,00 / 1,00 / 1 // * * *	*	OPI 200 * * * * * * * * * * * * * * * * * *	300 >99.9% >99.9% >99.9% >99.9% >99.9% >99.9% 2 2 2 2 2 2 2 2 2 2 2 2 2	500/100	20/50 10 * * MDPN 1,000 500/30 * * * MCAT 500 *
Agreement Agreement Total Results Positive Agreement Total Results Positive Agreement Negative Agreement Negative Agreement	300/20 /100 * * PPX 300 >99.9' >99.9' 300/ 100 *	300/200 >99.9% >99.9% >99.9% TCA 1,000/ 500/30 % * % * * * * * * * * * * * * * * * * * * *	> 1,000 500/30 >99.9' >99.9' TMLL 200710 500 0 0/300 500 0 0/300 500 500 500 500 500 500 500	<pre>// 1,000/ 500 % >99.9% % >99.9% % >99.9% % >99.9% % >99.9% // 500/30 // 100 // 500/30 // 100 // 100 // 200/30 // 100 // 100 // 200/30 // 200/</pre>	300 * * COT 300/20 0/100, 500/50 10 6 * MAM M MAM M *	OP 300/1/ >99.5 >99.5 >99.5 2007 1,007 1,007 1,007 1,007 1,5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Pl Pl Pl Pl DO/ DO/ DO/ DO/ DO/ DO/ ETG ,000/ 3000 * * *	OPI 200 * * * * * * * * * * * * * * * * * *	300 >99.9% >99.9% >99.9% >99.9% >99.9% >99.9% >99.9% 7 ZOL 7 50	500/100	20/50 10 * * * MDP\ 1,000 500/3C * * * * * * * * * * * * *

Agreement										
Negative Agreement	*	*	*	*	*	*	*	*	*	*
Total Results	*	*	*	*	*	*	*	*	*	*

	CAR 2,000/ 1,000	MPRD 100	QTP 1,000	FLX 500	UR-144 25	KRA 300	TLD 50	α-PVP 2,000/ 1,000/ 500/ 300	MES 100/ 300	ZAL 100
Positive Agreement	*	*	*	*	*	*	*	*	*	*
Negative Agreement	*	*	*	*	*	*	*	*	*	*
Total Results	*	*	*	*	*	*	*	*	*	*

	CIT	FKET	RPD	TAP	NND	SCOP	MTZ	OZP	PAP
	500	1,000	150	1,000	1,000	500	500	1,000	500
Positive	*	*	*	*	*	*	*	*	*
Agreement									
Negative	*	*	*	*	*	*	*	*	*
Agreement									
Total Results	*	*	*	*	*	*	*	*	*

*Note: Based on GC/MS data instead of Commercial Kit.

Precision

A study was conducted at three hospitals by laypersons using three different lots of product to demonstrate the within run, between run and between operator precision. An identical test of coded specimens, containing drugs at concentrations of \pm 50% and \pm 25% cut-off level, was labeled, blinded and tested at each site. The results are given below: ACETAMINOPHEN (ACE 5,000)

Amphetamine	n per	Sit	e A	Sit	eВ	Sit	еC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
2,500	10	10	0	10	0	10	0
3,750	10	9	1	9	1	8	2
6,250	10	1	9	1	9	1	9
7,500	10	0	10	0	10	0	10

AMPHETAMINE (AMP 1,000)

Amphetamine	n per	Sit	e A	Sit	eВ	Sit	еC	
conc. (ng/mL)	site	-	+	-	+	-	+	
0	10	10	0	10	0	10	0	Ì
500	10	10	0	10	0	10	0	
750	10	9	1	8	2	9	1	Ì
1,250	10	1	9	2	8	2	8	
1.500	10	0	10	0	10	0	10	Ĩ

AMPHETAMINE (AMP 500)

Site C + 0 0 0 0 1 1 8 8 10
0 0 0 0 1 8
0 0
1
8
10
Site C
+
0 0
0 C
2
8
10
Site C
+
0 0
0 0
1
- 0

	375	10	2	8	1	9	2	8
	450	10	0	10	0	10	0	10
BAR	BITURATES (BAR 200)							
	Secobarbital	n per	Sit	e A	Sit	eВ	Site	еC
	conc. (ng/mL)	site	-	+	-	+	-	+

Secobarbital	n per			Site	eВ	Site C		
conc. (ng/mL)	site	•	+	-	+	-	+	
0	10	10	0	10	0	10	0	
100	10	10	0	10	0	10	0	

150							
	10	9	1	9	1	9	1
250	10	1	9	1	9	1	9
300	10	0	10	0	10	0	10
BENZODIAZEPINES (BZO 500) Oxazepam	n per	Sit	e A	Sit	B	Site	
conc. (ng/mL)	site	-	+		+	- 310	+
0	10	10	0	10	0	10	0
250	10	10	Ő	10	Ő	10	0
375	10	8	2	9	1	8	2
625	10	1	9	2	8	1	9
750	10	0	10	0	10	0	10
SENZODIAZEPINES (BZO 300)							
Oxazepam	n per	Site	e A	Sit		Site	
conc. (ng/mL)	site	-	+	-	+	-	+
0 150	10 10	10 10	0	10 10	0	10 10	0
225	10	9	1	9	1	9	1
375	10	1	9	1	9	1	9
450	10	0	10	0	10	0	10
BENZODIAZEPINES (BZO 200)							
Oxazepam	n per	Site	еA	Sit	эB	Site	ЭC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
100	10	10	0	10	0	10	0
150	10	9	1	8	2	9	1
250	10	1	9	1	9	2	8
300	10	0	10	0	10	0	10
ENZODIAZEPINES (BZO 100)							
Oxazepam	n per	Sit	e A	Sit	эB	Site	эC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
50	10	10	0	10	0	10	0
75	10	9	1	8	2	7	3
125	10	1	9	1	9	2	8
150	10	0	10	0	10	0	10
SUPRENORPHINE (BUP 10)	.0	Ű		Ũ		Ű	
Buprenorphine	n per	Sit	еA	Sit	эB	Site	эC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
5	10	10	0	10	0	10	0
7.5	10	9	1	9	1	8	2
12.5	10	1	9	1	9	1	9
15	10	0	10	0	10	0	10
UPRENORPHINE (BUP 5)	10	0	10	0	10	0	10
Buprenorphine	T						
		Site	eΑ	Sit	эв	Site	ъC
	n per site	Site		Site		Site	
conc. (ng/mL)	n per site 10		e A + 0		ев + 0		e C + 0
conc. (ng/mL)	site	-	+	-	+	-	+
conc. (ng/mL)	site 10	- 10	+ 0	- 10	+ 0	- 10	+ 0
conc. (ng/mL) 0 2.5	site 10 10	- 10 10	+ 0 0	- 10 10	+ 0 0	- 10 10	+ 0 0
conc. (ng/mL) 0 2.5 3.75 6.25 7.5	site 10 10 10	- 10 10 9	+ 0 0 1	- 10 10 9	+ 0 0 1	- 10 10 8	+ 0 0 2
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 OCAINE (COC 300)	site 10 10 10 10 10	- 10 10 9 1 0	+ 0 1 9 10	- 10 10 9 1 0	+ 0 1 9 10	- 10 10 8 1 0	+ 0 2 9 10
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 COCAINE (COC 300) Benzoylecgonine	site 10 10 10 10 10 10	- 10 10 9 1 0	+ 0 0 1 9	- 10 10 9 1	+ 0 1 9 10	- 10 10 8 1	+ 0 2 9 10
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL)	site 10 10 10 10 10 10 10	- 10 10 9 1 0 Site	+ 0 1 9 10 e A +	- 10 10 9 1 0 Situ	+ 0 1 9 10 • B +	- 10 10 8 1 0 Site	+ 0 2 9 10 • C +
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0	site 10 10 10 10 10 10 10 10 10	- 10 10 9 1 0 Site - 10	+ 0 1 9 10 e A + 0	- 10 9 1 0 Site - 10	+ 0 1 9 10 ÷ B + 0	- 10 10 8 1 0 Site - 10	+ 0 2 9 10 € C + 0
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150	site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 9 1 0 Site - 10 10	+ 0 1 9 10 e A + 0 0	- 10 10 9 1 0 Situ - 10 10	+ 0 1 9 10 • B + 0 0	- 10 10 8 1 0 Site - 10 10	+ 0 2 9 10 € C + 0 0
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225	site 10	- 10 9 1 0 Site - 10 10 9	+ 0 1 9 10 e A + 0 0 1	- 10 9 1 0 Site - 10 10 9	+ 0 1 9 10 • B + 0 0 1	- 10 10 8 1 0 Site - 10 10 9	+ 0 2 9 10 € C + 0 0 1
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 OCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375	site 10 10 10 10 10 10 10 10 10 10	- 10 9 1 0 Sitt - 10 10 9 1	+ 0 1 9 10 e A + 0 0 1 9	- 10 9 1 0 Site - 10 10 9 1	+ 0 1 9 10 0 8 8 + 0 0 1 9	- 10 10 8 1 0 Site - 10 10 9 1	+ 0 2 9 10 ÷ C + 0 0 1 9
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 OCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375 450	site 10	- 10 9 1 0 Site - 10 10 9	+ 0 1 9 10 e A + 0 0 1	- 10 9 1 0 Site - 10 10 9	+ 0 1 9 10 • B + 0 0 1	- 10 10 8 1 0 Site - 10 10 9	+ 0 2 9 10 € C + 0 0 1
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 OCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375 450 OCAINE (COC 200)	site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 9 1 0 Situ - 10 10 9 1 0	+ 0 1 9 10 e A + 0 0 1 9 10	- 10 10 9 1 0 Situ - 10 10 9 1 0	+ 0 1 9 10 0 8 + 0 0 1 9 10	- 10 10 8 1 0 Site - 10 10 9 1 0	+ 0 2 9 10 € C + 0 0 1 9 9 10
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375 450 COCAINE (COC 200) Benzoylecgonine	site 10 10 10 10 10 10 10 10 10 10	- 10 9 1 0 Situ - 10 10 9 1 0	+ 0 1 9 10 e A + 0 0 1 9 10 e A	- 10 9 1 0 Site - 10 10 9 1	+ 0 1 9 10 € B + 0 0 1 9 10 € B	- 10 10 8 1 0 Site - 10 10 9 1	+ 0 2 9 9 10 € C + 0 0 1 9 9 10
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 conc. (ng/mL) 0 150 225 375 450 Conc. (ng/mL) 0 150 225 375 450 Benzoylecgonine conc. (ng/mL)	site 10 10 10 10 10 10 10 10 10 10	- 10 9 1 0 Sitt 10 10 9 1 0 0 Sitt	+ 0 1 9 10 e A + 0 0 1 9 10 e A +	- 10 9 1 0 Site - 10 9 1 0 Site - - Site - - - - - - - - - - - - -	+ 0 1 9 10 + 0 1 9 10 0 1 9 10	- 10 10 8 1 0 Site - 10 10 9 1 0 Site - - - - - - - - - - - - -	+ 0 2 9 9 10 2 9 9 10 0 0 1 10 10 10 0 € C + 10 0 10 10 10 10 10 10 10 10 10 10 10 1
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 conc. (ng/mL) 0 150 225 375 450 conc. (ng/mL) 0 0 0 0 0 0 0 0 0 0 0 0 0	site 10 10 10 10 10 10 10 10 10 10	- 10 9 1 0 5 itt - 10 10 9 1 0 5 itt - 10	+ 0 1 9 10 e A + 0 10 9 10 10 e A + 0 10	- 10 9 1 0 Situ - 10 10 9 1 0 0 Situ - 10	+ 0 1 9 10 * B + 0 0 1 9 10 * 9 10	- 10 8 1 0 Sitte - 10 10 9 1 0 Sitte - 10	$ \begin{array}{c} + \\ 0 \\ 0 \\ 2 \\ 9 \\ 9 \\ 10 \\ \hline + \\ 0 \\ 10 \\ \hline + \\ 0 \\ \hline + \\ - \\ - \\ + \\ + \\ - \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ +$
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375 450 COCAINE (COC 200) Benzoylecgonine conc. (ng/mL) 0 100	site 10	- 10 9 1 0 Site - 10 10 9 1 0 Site - 10 10 0 Site - 10 10 10 9 1 10 9 10 10 10 10 10 10 10 10 10 10	+ 0 1 9 10 e A + 0 0 10 9 10 0 10 e A + 0 0 0	- 10 9 1 0 5 it - 10 10 9 1 0 5 it - 10 10 10	+ 0 1 9 10 0 + 0 0 1 9 10 0 10 0 0 10 0 0 0 0 0	- 10 10 8 - - 10 - - - - - - - - - - - - -	$ \begin{array}{c} + \\ 0 \\ 2 \\ 9 \\ 9 \\ 10 \\ \hline 0 \\ \hline 0 \\ 10 \\ \hline 0 \\ \hline \hline 0 \\ \hline 0 \\ \hline 0 \\ \hline 0 \\ \hline \hline 0 \\ \hline 0 \\ \hline \hline 0 \\ \hline 0 \\ \hline \hline \hline \hline 0 \\ \hline \hline \hline \hline \hline 0 \\ \hline \hline$
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 COC AINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375 450 COC AINE (COC 200) Benzoylecgonine conc. (ng/mL) 0 100 150	site 10	- 10 9 1 0 Sitt - 10 10 9 1 0 Sitt - 10 10 9 1 0 9 1 0 9 1 0 9 1 0 9 1 1 1 1 1 1 1 1 1 1 1 1 1	+ 0 1 9 9 10 e A + 0 1 9 10 10 e A + 0 0 1	- 10 9 1 0 Situ - 10 10 9 1 0 Situ - 10 10 9 1 0 9 1 0 9 1 0 9 1 0 9 1 1 0 9 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1	+ 0 1 9 10 • • • • • • • • • • • • • • • • • •	- 10 10 8 - 10 10 10 9 1 0 Sitte - 10 10 9 1 0 9 1 0	+ 0 2 9 9 10 2 0 + 0 0 1 0 0 10 0 0 0 10 0 0 0 10 0 0 10 0 0 0 10 0 0 0 10 0 0 0 10 0 0 0 0 10 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 6000 Benzoylecgonine conc. (ng/mL) 0 150 225 375 450 Benzoylecgonine conc. (ng/mL) 0 150 225 375 450 COCAINE (COC 200) Benzoylecgonine conc. (ng/mL) 0 100 150 250	site 10	- 10 9 1 0 Sitt - 10 10 9 1 0 Sitt - 10 10 9 1 0 10 10 9 1 0 10 10 9 1 10 9 10 10 10 10 10 10 10 10 10 10	+ 0 1 9 10 e A + 0 0 1 9 10 e A + 0 0 1 9 10	- 10 9 1 0 Sitt - 10 10 9 1 0 Sitt - 10 9 1 0 10 9 1 0 10 10 9 1 0 10 10 9 1 10 10 10 10 10 10 10 10 10	+ 0 1 9 10 € B + 0 0 1 9 10 0 0 1 0 0 1 9 9	- 10 10 8 1 0 Sitte - 10 10 9 1 0 Sitte - 10 10 9 1 0 - - 10 10 9 1 0 - - - - - - - - - - - - -	+ 0 2 9 9 10 • • • • • • • • • • • • • • • • • •
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375 450 COCAINE (COC 200) Benzoylecgonine conc. (ng/mL) 0 100 150 250 300	site 10	- 10 9 1 0 Sitt - 10 10 9 1 0 Sitt - 10 10 9 1 0 9 1 0 9 1 0 9 1 0 9 1 1 1 1 1 1 1 1 1 1 1 1 1	+ 0 1 9 9 10 e A + 0 1 9 10 10 e A + 0 0 1	- 10 9 1 0 Situ - 10 10 9 1 0 Situ - 10 10 9 1 0 9 1 0 9 1 0 9 1 0 9 1 1 0 9 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1	+ 0 1 9 10 • • • • • • • • • • • • • • • • • •	- 10 10 8 - 10 10 10 9 1 0 Sitte - 10 10 9 1 0 9 1 0	+ 0 2 9 9 10 2 0 + 0 0 1 0 0 10 0 0 0 10 0 0 0 10 0 0 10 0 0 0 10 0 0 0 10 0 0 0 10 0 0 0 0 10 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375 COCAINE (COC 200) Benzoylecgonine conc. (ng/mL) 0 150 225 450 COCAINE (COC 200) Benzoylecgonine conc. (ng/mL) 0 100 150 250 300 COCAINE (COC 150)	site 10	- 10 10 9 1 0 - 10 10 9 1 0 Sitt - 10 10 9 1 0 - 10 0 - 10 10 9 1 0 - - - - - - - - - - - - -	+ 0 0 9 10 e A + 0 0 1 9 10 e A + 0 0 10 e A 10 9 10	- 10 10 9 1 0 Sitt - 10 10 9 1 0 Sitt - 10 10 9 1 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0	+ 0 0 1 9 10 0 10 10 10 9 9 10 0 1 9 9 10 0 1 1 9 9 10	- 10 10 8 1 0 Site - 10 10 9 1 0 Site - 10 10 9 1 0 0 - - 10 10 0 - - - - - - - - - - - - -	+ 0 2 9 9 10 + 0 0 1 1 9 10 0 0 1 0 0 1 1 9 9 10
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 COC AINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375 450 COC AINE (COC 200) Benzoylecgonine conc. (ng/mL) 0 150 225 375 450 COC AINE (COC 200) Benzoylecgonine conc. (ng/mL) 0 100 150 250 300 COC AINE (COC 150) Benzoylecgonine	site 10	- 10 9 1 0 Sitt - 10 10 9 1 0 Sitt - 10 10 9 1 0 10 10 9 1 0 10 10 9 1 10 9 10 10 10 10 10 10 10 10 10 10	+ 0 0 1 9 10 e A + 0 0 1 1 9 10 e A + 0 0 0 1 1 9 10 0 0 1 1 9 0 10 0 0 0 1 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	- 10 9 1 0 Sitt - 10 10 9 1 0 Sitt - 10 9 1 0 10 9 1 0 10 10 9 1 0 10 10 9 10 10 10 10 10 10 10 10 10 10	+ 0 0 1 9 10 € B + 0 0 1 1 0 9 10 1 0 0 1 1 9 9 10 0 0 1 1 9 9 10 0 0 1 9 9 8	- 10 10 8 1 0 Sitte - 10 10 9 1 0 Sitte - 10 10 9 1 0 - - 10 10 9 1 0 - - - - - - - - - - - - -	+ 0 2 9 9 10 2 0 0 10 10 9 9 10 0 0 1 9 9 10 0 0 1 10 0 0 0
conc. (ng/mL) 0 2.5 3.75 6.25 7.5 COCAINE (COC 300) Benzoylecgonine conc. (ng/mL) 0 150 225 375 COCAINE (COC 200) Benzoylecgonine conc. (ng/mL) 0 150 225 375 450 COCAINE (COC 200) Benzoylecgonine conc. (ng/mL) 0 100 150 250 300 COCAINE (COC 150)	site 10	- 10 10 9 1 0 5 10 10 9 1 0 5 10 10 9 1 0 5 11 0 5 1 10 10 9 1 10 10 10 9 11 10 10 10 10 10 10 10 10 10	+ 0 0 9 10 e A + 0 0 1 9 10 e A + 0 0 10 e A 10 9 10	- 10 10 9 1 0 - 10 10 9 1 0 - Sitt - 10 10 9 1 0 - Sitt - - - - - - - - - - - - -	+ 0 0 1 9 10 0 10 - 9 9 10 - 9 9 10 - 9 9 10 - 1 9 10 - 1 9 10 - 1 9 10 - 10 -	- 10 10 8 1 0 Sitte - 10 9 1 0 Sitte - 10 9 1 0 Sitte - Sitte - - - - - - - - - - - - -	+ 0 2 9 9 10 + 0 0 1 1 9 10 0 0 1 0 0 1 1 9 9 10

112.5	10	9	1	9	1	9	1
187.5	10	2	8	2	8	2	8
225	10	0	10	0	10	0	10
COCAINE (COC 100)							
Benzoylecgonine	n per	Site			еB	Site	
conc. (ng/mL)	site	-	+	-	+	-	+
0 50	10 10	10 10	0	10 10	0	10 10	0
75	10	9	1	9	1	9	1
125	10	2	8	2	8	2	8
150	10	0	10	0	10	0	10
MARIJUANA (THC300)							
11-nor-∆ ⁹ -THC-9 COOH	n per	Site		Sit	eВ	Site	
conc. (ng/mL)	site	-	+	-	+	-	+
0 150	10 10	10 10	0	10 10	0	10 10	0
225	10	8	2	9	0	9	1
375	10	2	2	3	7	3	9
450	10	0	10	0	10	0	10
MARIJUANA (THC 200)	10	0	10	0	10	0	10
11-nor-∆ ⁹ -THC-9 COOH	n per	Site	эA	Sit	eВ	Site	эC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
100	10	10	0	10	0	10	0
150	10	9	1	9	1	9	1
250	10	2	8	1	9	1	9
300	10	0	10	0	10	0	10
MARIJUANA (THC 150)							
11-nor-∆ ⁹ -THC-9 COOH	n per	Site			еB	Site	
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
75	10	10	0	10	0	10	0
112.5 187.5	10 10	9 2	1	9 1	9	9 1	1 9
225	10	2	10	0	9 10	0	10
MARIJUANA (THC 50)	10	0	10	0	10	0	10
11-nor- Δ^9 -THC-9 COOH	n per	Site	эA	Sit	eВ	Site	эC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
25	10	10	0	10	0	10	0
37.5	10	9	1	8	2	9	1
62.5	10	1	9	1	9	2	8
75	10	0	10	0	10	0	10
MARIJUANA (THC 30)		,	N:4 - A		2:4- D		214-0
11-nor-∆ ⁹ -THC-9 COOH conc. (ng/mL)	n per site	-	Site A	-	Site B	+	Site C
0	10		+				-
		10	0	10	0		0
15	-	10 10	0	10 10	0	10	0
15 22.5	10 10 10	10 10 9	0 0 1	10 10 9	0 0 1		0 0 1
	10	10	0	10	0	10 10	0
22.5 37.5 45	10 10	10 9	0	10 9	0	10 10 9	0
22.5 37.5 45 MARIJUANA (THC 25)	10 10 10 10	10 9 2 0	0 1 8 10	10 9 2 0	0 1 8 10	10 10 9 1 0	0 1 9 10
22.5 37.5 45 MARIJUANA (THC 25) 11-nor-∆ ⁹ -THC-9 COOH	10 10 10 10 n per	10 9 2	0 1 8 10 e A	10 9 2 0	0 1 8 10 e B	10 10 9 1	0 1 9 10 e C
22.5 37.5 45 MARIJUANA (THC 25) 11-nor-Δ ⁹ -THC-9 COOH conc. (ng/mL)	10 10 10 10 n per site	10 9 2 0 Site	0 1 8 10 e A +	10 9 2 0 Site	0 1 8 10 e B +	10 10 9 1 0 Site	0 1 9 10 e C +
22.5 37.5 45 MARIJUANA (THC 25) 11-nor-3 ⁰ -THC-9 COOH conc. (ng/mL) 0	10 10 10 10 n per site 10	10 9 2 0 Site -	0 1 8 10 e A + 0	10 9 2 0 Site -	0 1 8 10 e B + 0	10 10 9 1 0 Site - 10	0 1 9 10 e C + 0
22.5 37.5 45 MARIJUANA (THC 25) 11-nor-A ⁵ -THC-9 COOH conc. (ng/mL) 0 12.5	10 10 10 10 n per site 10 10	10 9 2 0 Site - 10 10	0 1 8 10 e A + 0 0	10 9 2 0 Site - 10 10	0 1 8 10 e B + 0 0	10 10 9 1 0 Site - 10 10	0 1 9 10 ÷ C + 0 0
22.5 37.5 45 MARIJUANA (THC 25) 11-nor-A ⁹ -THC-9 COOH conc. (ng/mL) 0 12.5 18.75	10 10 10 10 10 site 10 10 10	10 9 2 0 Site - 10 10 8	0 1 8 10 e A + 0 0 2	10 9 2 0 Situ - 10 10 8	0 1 8 10 e B + 0 0 2	10 10 9 1 0 Site - 10 10 8	0 1 9 10 • C + 0 0 2
22.5 37.5 45 MARIJUANA (THC 25) 11-nor-∆ ⁹ -THC-9 COOH conc. (ng/mL) 0 12.5 18.75 31.25	10 10 10 10 10 site 10 10 10 10	10 9 2 0 Site - 10 10 8 1	0 1 8 10 • A + 0 0 2 9	10 9 2 0 Situ - 10 10 8 1	0 1 8 10 • B + 0 0 2 9	10 10 9 1 0 Site - 10 10 8 2	0 1 9 10 10 • C + 0 0 2 8
$\begin{array}{r} 22.5 \\ 37.5 \\ 45 \\ \hline \mbox{Marijuana (THC 25)} \\ \hline 11-nor-\Delta^3-THC-9 COOH \\ conc. (ng/mL) \\ 0 \\ 12.5 \\ 18.75 \\ 31.25 \\ 37.5 \\ \hline \end{array}$	10 10 10 10 10 site 10 10 10	10 9 2 0 Site - 10 10 8	0 1 8 10 e A + 0 0 2	10 9 2 0 Situ - 10 10 8	0 1 8 10 e B + 0 0 2	10 10 9 1 0 Site - 10 10 8	0 1 9 10 • C + 0 0 2
22.5 37.5 45 MARIJUANA (THC 25) 11-nor-A ³⁻ THC-9 COOH conc. (ng/mL) 0 12.5 18.75 31.25 37.5 MARIJUANA (THC 20)	10 10 10 10 10 10 10 10 10 10	10 9 2 0 Site - 10 10 8 1	0 1 8 10 e A + 0 0 2 9 10	10 9 2 0 10 10 8 1 0	0 1 8 10 • B + 0 0 2 9	10 10 9 1 0 Site - 10 10 8 2	0 1 9 10 ÷ C + 0 0 2 8 10
22.5 37.5 45 MARIJUANA (THC 25) 11-nor-Å ³ -THC-9 COOH conc. (ng/mL) 0 12.5 18.75 31.25 37.5	10 10 10 10 10 site 10 10 10 10	10 9 2 0 10 10 8 1 0	0 1 8 10 e A + 0 0 2 9 10	10 9 2 0 10 10 8 1 0	0 1 8 10 e B + 0 0 2 9 10	10 10 9 1 0 Site - 10 10 8 2 0	0 1 9 10 ÷ C + 0 0 2 8 10
22.5 37.5 45 MARIJUANA (THC 25) 11-nor-Δ ⁹ -THC-9 COOH conc. (ng/mL) 0 12.5 18.75 31.25 37.5 MARIJUANA (THC 20) 11-nor-Δ ⁹ -THC-9 COOH	10 10 10 10 10 10 10 10 10 10 10 10	10 9 2 0 5 10 10 8 1 0 Sitt	0 1 8 10 • A + 0 0 2 9 10 • A	10 9 2 0 5 10 10 8 1 0 Site	0 1 8 10 • B + 0 0 2 9 10 • B	10 10 9 1 0 Sitte - 10 10 8 2 0 Sitte	0 1 9 10 • C + 0 0 2 8 10 • C
22.5 37.5 45 MARIJUANA (THC 25) 11-nor-Δ ⁹ -THC-9 COOH conc. (ng/mL) 0 12.5 18.75 31.25 37.5 MARIJUANA (THC 20) 11-nor-Δ ⁹ -THC-9 COOH conc. (ng/mL)	10 10 10 10 10 10 10 10 10 10 10 10 10	10 9 2 0 10 10 8 1 0 Site -	0 1 8 10 • A + 0 0 2 9 10 • A +	10 9 2 0 5 10 10 8 1 0 5 1 0 5 1 0 5	0 1 8 10 • B + 0 0 2 9 10 • B +	10 10 9 1 0 Site - 10 10 8 2 0 Site -	0 1 9 10 + 0 0 2 8 10 2 8 10
22.5 37.5 45 MARIJUANA (THC 25) 11-nor-Δ ⁹ -THC-9 COOH conc. (ng/mL) 0 12.5 18.75 31.25 37.5 MARIJUANA (THC 20) 11-nor-Δ ⁹ -THC-9 COOH conc. (ng/mL) 0	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 9 2 0 5 10 10 8 1 0 5 10 5 10	0 1 8 10 • A + 0 0 2 9 10 • A + 0 0 2 9 10 • A	10 9 2 0 5 10 10 8 1 0 5 10 5 10	0 1 8 10 e B + 0 0 2 9 10 2 9 10 e B + 0	10 10 9 1 0 Site - 10 10 8 2 0 Site - 10	0 1 9 10 ÷ C + 0 2 8 10 ÷ C + 0 2 8 10 ÷ C + 0 0 2 8 10 · ·
$\begin{array}{c} 22.5\\ 37.5\\ 45\\ \hline \\ \text{MARIJUANA (THC 25)}\\ \hline \\ 11-\text{nor-} \Delta^9\text{-THC-9 COOH}\\ conc. (ng/mL)\\ 0\\ 12.5\\ 18.75\\ 31.25\\ 37.5\\ \hline \\ \text{MARIJUANA (THC 20)}\\ \hline \\ 11-\text{nor-} \Delta^9\text{-THC-9 COOH}\\ conc. (ng/mL)\\ 0\\ 10\\ 15\\ 25\\ \hline \end{array}$	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 9 2 0 10 10 10 8 1 0 Sitt - 10 10 10 8 1	0 1 8 10 • A + 0 0 2 9 10 • A + 0 0 2 9 10 • A + 0 0 2 9 10 • A • A • 0 0 2 9 10 • 0 • 0 • 0 • 0 • 0 • 0 • 0 •	10 9 2 0 10 10 8 1 0 5 it - 10 10 8 1	0 1 8 10 • B + 0 0 2 9 10 • B + 0 0 2 9 10 • B + 0 0 2 9 10 • B • C • C • C • C • C • C • C • C	10 10 9 1 0 5 10 10 8 2 0 5 10 5 10 10 10 8 2 2	0 1 9 10 0 2 8 10 0 2 8 10 0 2 8 10 0 2 8 10 2 8 10 2 8 10 10 10 10 10 10 10 10 10 10
$\begin{array}{c} 22.5 \\ 37.5 \\ 45 \\ \hline \mbox{Marijuana (THC 25)} \\ \hline 11-nor-\Delta^3-THC-9 COOH \\ conc. (ng/mL) \\ 0 \\ 12.5 \\ 18.75 \\ 31.25 \\ 37.5 \\ \hline \mbox{Marijuana (THC 20)} \\ \hline 11-nor-\Delta^9-THC-9 COOH \\ conc. (ng/mL) \\ 0 \\ 10 \\ 15 \\ 25 \\ 30 \\ \end{array}$	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 9 2 0 10 10 8 1 0 5 itt - 10 10 8 8	0 1 8 10 e A + 0 0 2 9 10 e A + 0 0 2 9 10 2 0 2 0 2 0 2 0 2 0 2 0 2 0 2 0 0 2 0 0 2 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0	10 9 2 0 10 10 8 1 0 5 itt - 10 10 8 8	0 1 8 10 e B + 0 0 2 9 10 e B + 0 0 2 9 10 2 0 2 0 2 0 2 0 2 0 2 0 2 0 2 0 2 0 2 0 2 0 2 0 2 0 2 0 2 0 0 2 0 0 2 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 0 2 0 0 0 2 0 0 0 2 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0	10 10 9 1 0 5 10 10 8 2 0 5 5 10 10 10 8 8	0 1 9 10 e C + 0 0 2 8 10 e C + 0 0 2 8 10 e C + 0 0 2 8 10 - - - - - - - - - - - - -
$\begin{array}{c} 22.5\\ 37.5\\ 45\\ \hline \\ \text{MARIJUANA (THC 25)}\\ \hline \\ 11-\text{nor-} \Delta^{2}\text{-THC-9 COOH}\\ \hline \\ conc. (ng/mL)\\ 0\\ \hline \\ 12.5\\ 18.75\\ 31.25\\ 37.5\\ \hline \\ \text{MARIJUANA (THC 20)}\\ \hline \\ 11-\text{nor-} \Delta^{9}\text{-THC-9 COOH}\\ \hline \\ conc. (ng/mL)\\ \hline \\ 0\\ 10\\ \hline \\ 10\\ 15\\ 25\\ 30\\ \hline \\ \text{METHADONE (MTD 300)}\\ \end{array}$	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 9 2 0 10 10 8 1 0 5 itt - 10 10 8 10 10 8 10 0	0 1 8 10 9 4 - - - - - - - - - - - - -	10 9 2 0 10 10 10 8 1 0 5 10 10 10 8 1 0 0	0 1 8 10 e B + 0 0 2 9 10 e B + 0 0 2 9 10 2 9 10 10 10 10 10 10 10 10 10 10	10 10 9 1 0 5 10 10 10 8 2 0 5 10 10 8 5 10 10 8 2 0	0 1 9 10 € C + 0 0 2 8 10 € C + 0 0 2 8 10 € C + 0 0 2 8 10 10 10 10 10 10 10 10 10 10
22.5 37.5 45 MARIJUANA (THC 25) 11-nor-A ⁹ -THC-9 COOH conc. (ng/mL) 0 12.5 18.75 31.25 37.5 MARIJUANA (THC 20) 11-nor-A ⁹ -THC-9 COOH conc. (ng/mL) 0 10 15 25 30 METHADONE (MTD 300) Methadone	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 9 2 0 10 10 8 1 0 5 itt 0 0 5 itt	0 1 8 10 9 10 2 9 10 2 9 10 2 9 10 2 9 10 2 9 10 2 9 10 2 9 10 2 9 10 2 9 10 10 2 9 10 10 2 9 10 10 2 9 10 10 10 10 10 10 10 10 10 10	10 9 2 0 10 10 8 1 0 5 10 10 10 8 1 0 0 5 itt	0 1 8 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 0 2 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0	10 10 9 1 0 5 10 10 10 8 2 0 5 10 10 10 8 2 0 5 10 5 10 5 10 10 10 10 5 10 5 10 10 10 10 10 10 10 10 10 10 10 10 10	0 1 9 10 9 C + 0 0 2 8 10 - - - - - - - - - - - - -
22.5 37.5 45 MARIJUANA (THC 25) 11-nor-∆ ⁹ -THC-9 COOH conc. (ng/mL) 0 12.5 18.75 31.25 37.5 MARIJUANA (THC 20) 11-nor-∆ ⁹ -THC-9 COOH conc. (ng/mL) 0 11-nor-∆ ⁹ -THC-9 COOH conc. (ng/mL) 0 15 25 30 METHADONE (MTD 300) Methadone conc. (ng/mL)	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 9 2 0 10 10 10 8 1 0 10 10 10 8 1 0 5 itt - - - - - - - - - - - - - - - - - -	0 1 8 10 8 4 + 0 0 2 9 10 8 4 + 0 0 2 9 10 8 4 + 0 0 2 9 10 10 8 4 + 10 10 10 10 10 10 10 10 10 10	10 9 2 0 10 10 8 1 10 10 8 1 10 10 8 1 10 8 5 11 0 5 11 0 5 11 10 10 8 11 0 10 10 10 8 11 10 10 10 10 10 10 10 10 10 10 10 10	0 1 8 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 10 0 2 9 10 0 2 10 0 2 10 0 2 10 0 10 0 2 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 1	10 10 9 1 0 10 10 10 8 2 0 5 itte - 10 10 10 10 8 2 0 5 itte - - - - - - - - - - - - - - - - - -	0 1 9 10 3 C + 0 0 2 8 10 3 C + 0 0 2 8 10 3 C + 10 0 2 8 10 - - - - - - - - - - - - -
$\begin{array}{c} 22.5 \\ 37.5 \\ 45 \\ \end{array} \\ \begin{array}{c} \text{MARIJUANA (THC 25)} \\ \hline 11 \text{-nor} \ \Delta^3 \text{-THC-9 COOH} \\ \hline conc. (ng/mL) \\ 0 \\ \hline 12.5 \\ 18.75 \\ \hline 31.25 \\ 37.5 \\ \end{array} \\ \begin{array}{c} \text{MARIJUANA (THC 20)} \\ \hline 11 \text{-nor} \ \Delta^3 \text{-THC-9 COOH} \\ \hline conc. (ng/mL) \\ \hline 0 \\ \hline 10 \\ 15 \\ 25 \\ \hline 30 \\ \end{array} \\ \begin{array}{c} \text{METHADONE (MTD 300)} \\ \hline \text{Methadone} \\ \hline conc. (ng/mL) \\ \hline 0 \\ \end{array} \\ \end{array}$	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 9 2 0 10 10 10 8 1 0 5 10 10 8 1 0 5 10 10 10	0 1 8 10 0 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 0 2 9 10 0 0 0 2 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0	10 9 2 0 10 10 10 8 1 10 10 10 0 8 8 1 0 0 5 10 10 10 10 10 10 10 10 10 10 10 10 10	0 1 8 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 0 2 9 10 0 0 0 2 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0	10 10 9 1 0 Sitter 2 0 Sitter 2 0 Sitter 2 0 Sitter 10 10 8 8 2 0 Sitter 2 0 10 10 10 10 9 1 10 10 10 9 9 1 10 9 9 11 0 9 9 11 0 9 11 0 9 11 10 9 10 10 9 10 10 9 10 10 10 10 10 10 10 10 10 10 10 10 10	0 1 9 10 9 C + 0 0 2 8 10 9 C + 0 0 2 8 10 0 2 8 10 0 2 8 10 0 2 8 10 0 0 2 8 10 0 0 0 0 0 0 0 0 0 0 0 0 0
$\begin{tabular}{ c c c c c } \hline & 22.5 & & & 37.5 & & & & & & & & & & & & & & & & & & &$	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 9 2 0 10 10 10 8 1 0 5 8 1 0 0 10 10 10 8 1 0 0 5 8 1 0 0 10 10 10	0 1 8 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 0 2 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0	10 9 2 0 10 10 10 8 1 0 5 10 10 10 8 8 1 0 0 5 10 10 10 10	0 1 8 10 0 2 9 10 0 2 9 10 0 2 9 10 0 0 2 9 10 0 0 0 2 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0	10 10 9 1 0 5itte - - 10 10 8 8 2 0 0 5itte - - 10 10 10 8 8 2 0 0 10 10 10	0 1 9 10 • C + 0 0 2 8 10 • • C + 0 0 0 - - - - - - - - - - - - -
$\begin{array}{c} 22.5 \\ 37.5 \\ 45 \\ \end{array} \\ \begin{array}{c} \text{MARIJUANA (THC 25)} \\ \hline 11 \text{-nor} \ \Delta^3 \text{-THC-9 COOH} \\ \hline conc. (ng/mL) \\ 0 \\ \hline 12.5 \\ 18.75 \\ \hline 31.25 \\ 37.5 \\ \end{array} \\ \begin{array}{c} \text{MARIJUANA (THC 20)} \\ \hline 11 \text{-nor} \ \Delta^3 \text{-THC-9 COOH} \\ \hline conc. (ng/mL) \\ \hline 0 \\ \hline 10 \\ 15 \\ 25 \\ \hline 30 \\ \end{array} \\ \begin{array}{c} \text{METHADONE (MTD 300)} \\ \hline \text{Methadone} \\ \hline conc. (ng/mL) \\ \hline 0 \\ \end{array} \\ \end{array}$	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 9 2 0 10 10 10 8 1 0 5 10 10 8 1 0 5 10 10 10	0 1 8 10 0 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 0 2 9 10 0 0 0 2 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0	10 9 2 0 10 10 10 8 1 10 10 10 0 8 8 1 0 0 5 10 10 10 10 10 10 10 10 10 10 10 10 10	0 1 8 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 0 2 9 10 0 0 0 2 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0	10 10 9 1 0 Sitter 2 0 Sitter 2 0 Sitter 2 0 Sitter 10 10 8 8 2 0 Sitter 2 0 10 10 10 10 9 1 10 10 10 9 9 1 10 9 9 11 0 9 9 11 0 9 11 0 9 11 10 9 10 10 9 10 10 9 10 10 10 10 10 10 10 10 10 10 10 10 10	0 1 9 10 9 C + 0 0 2 8 10 9 C + 0 0 2 8 10 9 C + 10 0 2 8 10 0 2 8 10 0 0 2 8 10 0 0 0 0 0 0 0 0 0 0 0 0 0

450	1	0	0)	10		0	10		0	10
METHADONE (MTD 200)				Cite	^	1	0:44		-	0:44	
Methadone		per		Site	: A	_	Site		_	Site	
conc. (ng/mL)		ite	-		+	_	-	+	_	-	+
0		0	10		0		10	0	_	10	0
100		0	10	_	0	_	10	0	_	10	0
150	_	0	8	_	2	_	8	2	_	8	2
250	_	0	1		9	_	1	9	_	2	8
300	1	0	0)	10		0	10		0	10
IETHAMPHETAMINE (MET1,000)											
Methamphetamine		per		Site			Site		_	Site	
conc. (ng/mL)		ite	-		+		-	+	_	-	+
0		0	1		0		10	0	_	10	0
500		0	1	-	0	_	10	0	_	10	0
750		0	9	_	1	_	9	1	_	9	1
1,250		0	1		9	-	2	8	_	1	9
1,500	1	0	C)	10		0	10		0	10
IETHAMPHETAMINE (MET 500)				Cite		T	0:44	. D		Cite	
Methamphetamine		per		Site		_	Site		_	Site	
conc. (ng/mL)		ite	-		+		-	+	_	-	+
0		0	1	_	0		10	0		10	0
250		0	1	_	0		10	0		10	0
375		0	ç	_	1		9	1		9	1
625		0	1		9		1	9		1	9
750	1	0	C)	10		0	10		0	10
IETHAMPHETAMINE (MET 300)											
Methamphetamine	n	per		Site	A		Site	Β		Site	еС
conc. (ng/mL)		ite		· [+		-	+		-	+
0	1	0	1	0	0		10	0	Ι	10	0
150	1	0	1	0	0		10	0	T	10	0
225	1	0	ç)	1		9	1		9	1
375	1	0	1		9		1	9		1	9
450	1	0	C)	10		0	10		0	10
IETHYLENEDIOXYMETHAMPHET	ГАМІ	NE (N	IDN	IA 1	. 000)) Ec	stasy	/			
Methylenedioxymethamphetar		np			Site			Site B		Sit	еC
conc. (ng/mL)		sit		-	-	+	-		+	-	+
0		10	n	1	0	0	10		0	10	0
500		10	-	1		0	10	_	0	10	0
750		10				1	9	_	1	8	2
1,250		1()	1	1	9	1		9	1	9
1,500		10	0	()	10	0	1	0	0	10
IET HYLENEDIOXYMETHAMPHET	ΓAMI	NE (N	1DN	IA 5	00) I	Ecsta	asy				
Methylenedioxymethamphetar	nine	np	er		Site	А	5	Site B		Sit	еC
conc. (ng/mL)		sit	e	-		+	-	-	+	-	+
0		1(0	1	0	0	10		0	10	0
250		1(0	1	0	0	10		0	10	0
375		1(0	8		2	9	_	1	9	1
625		10		1	_	9	1	_	9	1	9
750		10		(10	0		0	0	10
IETHYLENEDIOXYMETHAMPHET	ГАМІ					Ecsta			-	. <u> </u>	
Methylenedioxymethamphetar		np			Site			Site B		Sit	еC
conc. (ng/mL)		sit		-		+	-	-	+	-	+
0		1(0	0	10		0	10	0
150		10		-	0	0	10	_	0	10	0
225		10		8	-	2	9	_	1	7	3
375		10		2	_	2	9		9	1	9
450		10		4	_		0	_	9	0	9
HORPHINE (MOP/OPI 300)		10	J	, C	,	10	0	1	0	0	
			. 1		Nite .	•	6			0.14	- C
Morphine		n pe	r -	3	site /		3	ite B		51	eC
conc. (ng/mL)		site		-	_	+	-	+		-	+
0		10		10		0	10	0		10	0
150		10		10		0	10	0		10	0
225		10		9		1	9	1		9	1
		10		1		9	1	9		1	9
375		10		0		10	0	1	0	0	10
450		_									
450 IORPHINE (MOP/OPI 200)			- [5	Site /	4	S	ite B		Sit	еC
450		n pe			_	+	-	4		-	+
450 IORPHINE (MOP/OPI 200)		n per site	<u> </u>	-			_				
450 IORPHINE (MOP/OPI 200) Morphine				- 10	+	0	10	0)	10	0
450 MORPHINE (MOP/OPI 200) Morphine conc. (ng/mL) 0		site 10			_	0	10	(-
450 IORPHINE (MOP/OPI 200) Morphine conc. (ng/mL) 0 100		site 10 10		10	_	0 0	10 10	0)	10	0
450 IORPHINE (MOP/OPI 200) Morphine conc. (ng/mL) 0 100 150		site 10 10 10		10 7	_	0 0 3	10 10 9	(()	10 9	0
450 IORPHINE (MOP/OPI 200) Morphine conc. (ng/mL) 0 100		site 10 10		10		0 0	10 10	0) }	10	0 0 1 9

	Morphine	n per	Site	eΑ	Site	eВ	Sit	еC
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	50	10	10	0	10	0	10	0
	75	10	9	1	9	1	9	1
	125	10	1	9	1	9	1	9
	150	10	0	10	0	10	0	10
MET	HAQUALONE (MQL 300)							

Methaqualone	n per	Site	еA	Site	е В	Sit	еC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	9	1	9	1	9	1
375	10	1	9	1	9	1	9
450	10	0	10	0	10	0	10

MORPHINE/OPIATE (OPI 2,000)

	Morphine	n per	Site	e A	Sit	eВ	Sit	еC
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	1,000	10	10	0	10	0	10	0
	1,500	10	9	1	9	1	9	1
	2,500	10	1	9	1	9	1	9
	3,000	10	0	10	0	10	0	10
MOR	PHINE/OPIATE (OPI 1,000)							

MORPHINE/OPIATE (OPI 1,000

Morphine	n per	Site	eА	Site	eВ	Sit	еC	1
conc. (ng/mL)	site	-	+	-	+	-	+	1
0	10	10	0	10	0	10	0	1
500	10	10	0	10	0	10	0	l.
750	10	8	2	9	1	9	1	l.
1,250	10	1	9	2	8	1	9	
1 500	10	0	10	0	10	0	10	

MEPERIDINE (MPRD 100)

Normeperidine	n per	Site	eΑ	Site	еB	Sit	еC
conc. (ng/mL)	site	1	+	1	+	-	+
0	10	10	0	10	0	10	0
50	10	10	0	10	0	10	0
75	10	8	2	9	1	9	1
125	10	2	8	3	7	1	9
150	10	0	10	0	10	0	10

PHENCYCLIDINE (PCP 50)

Phencyclidine	n per	Site	εA	Site	е В	Site	эC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
25	10	10	0	10	0	10	0
37.5	10	8	2	9	1	9	1
62.5	10	1	9	1	9	1	9
75	10	0	10	0	10	0	10

PHENCYCLIDINE (PCP 25)

Phencyclidine	n per	Site	e A	Site	e B	Sit	еC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
12.5	10	10	0	10	0	10	0
18.75	10	8	2	9	1	9	1
31.25	10	1	9	1	9	1	9
37.5	10	0	10	0	10	0	10

PROPOXYPHENE (PPX 300)

Propoxyphene	n per	Site	еA	Site	eВ	Sit	еC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	8	2	9	1	9	1
375	10	1	9	1	9	1	9
450	10	0	10	0	10	0	10

TRICYCLIC ANTIDEPRESSANTS (TCA 1,000)

Nortriptyline	n per	Site	еA	Site	eВ	Sit	еC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
500	10	10	0	10	0	10	0
750	10	9	1	8	2	8	2
1,250	10	1	9	1	9	1	9
1,500	10	0	10	0	10	0	10

TRICTCLIC ANTIDEPRESSANTS (TO	A 500)						
Nortriptyline	n per	Sit	e A	Site	е В	Sit	еC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
			2		1		2
375	10	8		9		8	
625	10	2	8	1	9	1	9
750	10	0	10	0	10	0	10
RICYCLIC ANTIDEPRESSANTS (TO	CA 300)	-		-		-	
Nortriptyline	n per	Sit	e A	Site	eВ	Sit	еC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	8	2	9	1	8	2
375	10	2	8	1	9	1	9
450	10	0	10	0	10	0	10
RAMADOL (TML 100)							
	n per	Sit	e A	Site	е В	Sit	e C
Tramadol conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
50	10	10	0	10	0	10	0
75	10	7	3	9	1	8	2
125	10	2	8	9	9	1	9
		2	8	0	9 10	0	
	10	U	10	U	10	U	10
RAMADOL (TML 200)		0	• ^	0	• D	0.	
Tramadol conc. (ng/mL)	n per		e A		e B	Sit	e C
	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
100	10	10	0	10	0	10	0
150	10	9	1	9	1	8	2
250	10	1	9	1	9	2	8
300	10	0	10	0	10	0	10
RAMADOL (TML 300)							
Transa dal anna (natarl)	n per	Sit	еA	Site	eВ	Sit	еC
Tramadol conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	Ő	10	0
225	10	9	1	9	1	8	2
375	10	1	9	1	9	2	8
450	10	0	10	0	10	0	10
RAMADOL (TML 500)	10	0	10	0	10	0	10
RAMADOL (THE 500)	1	0.1		0.1	- D	0.1	
Tramadol conc. (ng/mL)	n per	Sit	e A	Site	eВ	Sit	e C
(•)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	8	2	9	1	8	2
625	10	1	9	1	9	2	8
750	10	0	10	0	10	0	10
KETAMINE (KET 1, 000)							
	n per	Sit	e A	Site	е В	Sit	еC
Ketamine conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
500	10	10	0	10	0	10	0
750	10	9	1	8	2	9	1
1,250	10	1	9	1	9	2	8
1,500	10	0	10	0	10	0	10
KETAMINE (KET 500)	10	U	10		10	U	10
	n	0:4	e A	0:4	eВ	0:4	e C
Ketamine conc. (ng/mL)	n per	SI		SIL		SIL	
	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	9	1	9	1	8	2
625	10	1	9	1	9	2	8
750	10	0	10	0	10	0	10
KETAMINE (KET 300)		Ŭ		, v		Ň	
	n per	Qi+	e A	Qi+	eВ	Qi+	еC
Ketamine conc. (ng/mL)							
,	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	9	1	9	1	9	1
375	10	1	9	1	9	1	9
450	10	0	10	0	10	0	10
KETAMINE (KET 100)							
	n per	Sit	eΑ	Site	e B	Sit	e C

TRICYCLIC ANTIDEPRESSANTS (TCA 500)

Site C

- +

Site B

- +

10 10 0 10 0 10 0

Site A

- +

n per

site

Ketamine conc. (ng/mL)

10 10 10 10 10 10 10 10 10 10 10 10 10 1	- 10 10 9 1 0 Sitt - 10 10 9 1 0 Sitt - 10 10 10 10 10 10 10 10 10 10	0 1 9 10 e A + 0 0 1 9 9 10 e A + 0 0 1 9 9 10 e A + 10 e A + + - - - - - - - - - - - - -	- 10 9 1 0 Sit - - 10 9 1 0	0 1 9 10 e B + 0 0 1 9 10 e B + 0 10 e B 10 e B 10 10 e B 10 10 e B 10 10 e B 10 10 10 e B 10 10 10 10 10 10 10 10 10 10	10 9 2 0 5itte - 10 10 9 1 0 5itte - 10 10 9 1 0	+ 0 1 9 10
10 10	1 0 Sitt - 10 10 9 1 0 Sitt - 10 10 9 1 0 Sitt - 10 10 10 10 9 1 10 10 10 10 10 10 10 10 10	9 10 • A + 0 0 1 9 10 • A + 0 0 0 1 1 9 10 • A + 0 0 0 1 1 9 • A +	1 0 5itt - 10 10 9 1 0 5itt - 10 10 9 10 0 5itt 5itt	9 10 e B + 0 1 9 10 e B + 0 0 0 1 9 10	2 0 10 10 9 1 0 Sitte - 10 10 10 9 1 0	8 10 e C + 0 0 1 9 10 e C + 0 0 1 9
10 n per site 10	0 Sitt - - - - - - - - - - - - -	10 e A + 0 1 9 9 10 e A + 0 0 10 e A + 10 e A + 10 e A + 0 0 10 e A + 0 0 10 e A + 10 e A + 0 0 10 e A + 10 0 0 0 10 0 0 0 0 10 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 Sitt - 10 10 9 1 0 Sitt - 10 10 9 9 1 0 Sitt	10 e B + 0 0 1 9 10 e B + 0 0 1 9 10	0 Site - 10 10 9 1 0 Site - 10 10 9 1 0	10 e C + 0 10 9 10 e C + 0 0 10 9 9 10 9 9 10
n per site 10 10 10 10 10 10 10 10 10 10 10 10 10	Sitt 	e A + 0 1 9 10 e A + 0 0 1 9 10 e A +	Sit - 10 10 9 1 0 Sit - 10 10 9 1 0 Sit 5 Sit 5 Sit 5 Sit 5 Sit 5 Sit 5 Sit 5 Sit 5 Sit 5 Sit 5 Sit 5 Sit 5 Sit 5 Sit 5 Sit Sit Sit Sit Sit Sit Sit Sit	e B + 0 1 9 10 e B + 0 0 1 9 10	Site - 10 10 9 1 0 Site - 10 10 9 9 1 0	e C + 0 0 1 9 10 e C + 0 0 1 9
site 10 10 10 10 10 10 10 10 10 10	- 10 10 9 1 0 Sitt - 10 10 9 1 0 Sitt - 10 10 10 10 10 10 10 10 10 10	+ 0 1 9 10 e A + 0 0 1 9 10 e A +	- 10 10 9 1 0	+ 0 1 9 10 e B + 0 0 1 9 10	- 10 9 1 0	+ 0 1 9 10 e C + 0 0 1 9
site 10 10 10 10 10 10 10 10 10 10	- 10 10 9 1 0 Sitt - 10 10 9 1 0 Sitt - 10 10 10 10 10 10 10 10 10 10	+ 0 1 9 10 e A + 0 0 1 9 10 e A +	- 10 10 9 1 0	+ 0 1 9 10 e B + 0 0 1 9 10	- 10 9 1 0	+ 0 1 9 10 e C + 0 0 1 9
10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 10 9 1 0 Sitt - - 0 5 10 0 5 10 10 10 10	0 0 1 9 10 e A + 0 0 1 9 10 e A + + 0 0 + 10 + + 0 0 + + + + + + + + + + + + +	10 10 9 1 0 Sitt - - 10 10 9 1 0 Sitt	0 0 1 9 10 e B + 0 0 1 9 10	10 10 9 1 0 Sitte - 10 10 9 1 0	0 0 1 9 10 e C + 0 0 1 9
10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 9 1 0 5it - - 10 10 9 9 1 0 0 5it - 10 10	0 1 9 10 e A + 0 0 1 9 10 e A +	10 9 1 0 Sitt - 10 10 9 1 0 Sitt	0 1 9 10 e B + 0 0 1 9 10	10 9 1 0 Site - 10 10 9 1 0	0 1 9 10 e C + 0 0 1 9
10 10 10 10 10 10 10 10 10 10 10 10 10 1	9 1 0 - 10 10 9 1 0 Sitt - 10 10	1 9 10 e A + 0 0 1 9 10 e A +	9 1 0 Sitt - 10 10 9 1 0 Sitt	1 9 10 e B + 0 0 1 9 10	9 1 0 - 10 10 9 1 0	1 9 10 e C + 0 0 1 9
10 10 10 10 10 10 10 10 10 10 10 10 10 1	1 0 - 10 10 9 1 0 Sitt - 10 10	9 10 e A + 0 0 1 9 10 e A +	1 0 5it - 10 10 9 1 0 Sit	9 10 e B + 0 0 1 9 10	1 0 - 10 10 9 1 0	9 10 e C + 0 0 1 9
10 n per site 10 10 10 10 10 10 10 10 10 10	0 Sitt - 10 10 9 1 0 Sitt - 10 10	10 e A + 0 0 1 9 10 e A +	0 	10 e B + 0 0 1 9 10	0 - 10 9 1 0	10 e C + 0 0 1 9
n per site 10 10 10 10 10 10 10 10 10 10 10	Sit - 10 10 9 1 0 Sit - 10 10	e A + 0 1 9 10 e A +	Sit - 10 10 9 1 0 Sit	e B + 0 0 1 9 10	Site - 10 10 9 1 0	e C + 0 1 9
site 10 10 10 10 10 10 10 10 10 10	- 10 9 1 0 Sit - 10 10	+ 0 1 9 10 e A +	- 10 10 9 1 0 Sit	+ 0 1 9 10	- 10 10 9 1 0	+ 0 0 1 9
site 10 10 10 10 10 10 10 10 10 10	- 10 9 1 0 Sit - 10 10	+ 0 1 9 10 e A +	- 10 10 9 1 0 Sit	+ 0 1 9 10	- 10 10 9 1 0	+ 0 0 1 9
10 10 10 10 10 10 10 10 10 10 10	10 10 9 1 0 Sit - 10 10	0 0 1 9 10 e A +	10 10 9 1 0 Sit	0 0 1 9 10	10 10 9 1 0	0 0 1 9
10 10 10 10 10 site 10 10 10 10	10 9 1 0 Sitt - 10 10	0 1 9 10 e A +	10 9 1 0 Sit	0 1 9 10	10 9 1 0	0 1 9
10 10 10 n per site 10 10 10 10	9 1 0 Sit - 10 10	1 9 10 e A +	9 1 0 Sit	1 9 10	9 1 0	1 9
10 10 n per site 10 10 10 10	1 0 - 10 10	9 10 e A +	1 0 Sit	9 10	1 0	9
10 n per site 10 10 10 10	0 - 10 10	10 e A +	0 Sit	10	0	
site 10 10 10 10 10	- 10 10	+		e B		
site 10 10 10 10 10	- 10 10	+		е В		
site 10 10 10 10 10	10 10		-		Site	e C
10 10 10	10	0		+	-	+
10 10		5	10	0	10	0
10		0	10	0	10	0
	9	1	9	1	9	1
10	1	9	1	9	2	8
	0	10	0	10	0	10
- T .	0	~ ^	0	• D	0	
n per	Sit	eΑ	Sit	e B	Site	
site	-	+	-	+	-	+
						0
						0
						1
				-	_	10
10	U	10	0	10	0	10
n ner	Sit	eΑ	Sit	e B	Site	e C
	-					+
						0
						0
10	9	1	9	1	9	1
10	1	9	1	9	1	9
10	0	10	0	10	0	10
			-			
n per	Sit	e A	Sit	еВ	Site	эC
	-		-	+	-	+
10						0
						0
		•			-	1
						9 10
10		10	U	10	U	10
n ner	Sit	e A	Sit	e B	Site	e C
	-		-		-	+
			10		10	0
		0		0	10	0
10	9	1	9	1	9	1
10	1	9	1	9	1	9
10	0	10	0	10	0	10
-	-		-			
n per	Sit	eΑ	Sit	eВ	Site	еC
site	-	+	-	+	- 1	+
		0		0		0
				-		0
						1
	-					9
					U	10
					0:1	- C
						+
						0
						0
						9
1.0	0	10			0	
	10 10	10 10 9 10 1 10 9 10 1 10 0 n per site Site - 10 10 10 10 </td <td>10 10 0 10 9 1 10 1 9 10 0 10 10 0 10 n per site - + 10 10 0 10 10 0 10 10 0 10 10 0 10 10 10 10 1 9 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 0 10</td> <td>$\begin{array}{c ccccccccccccccccccccccccccccccccccc$</td> <td>10 10 0 10 0 10 9 1 9 1 9 1 10 1 9 1 9 1 9 1 10 0 10 0 10 0 10 0 n per site - + - + + + 10 10 0 10 0 10 0 10 10 1 9 1 9 1 10 10 0 10 0 10 0 10 10 10 0 10 0 10 10 10 0 10 0 10 0 10 10 10 0 10 0 10 10 10 0 10 0 10 0 10 10 0 10 0 10 0 <</td> <td>$\begin{array}{c ccccccccccccccccccccccccccccccccccc$</td>	10 10 0 10 9 1 10 1 9 10 0 10 10 0 10 n per site - + 10 10 0 10 10 0 10 10 0 10 10 0 10 10 10 10 1 9 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 10 0 10 0 10	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	10 10 0 10 0 10 9 1 9 1 9 1 10 1 9 1 9 1 9 1 10 0 10 0 10 0 10 0 n per site - + - + + + 10 10 0 10 0 10 0 10 10 1 9 1 9 1 10 10 0 10 0 10 0 10 10 10 0 10 0 10 10 10 0 10 0 10 0 10 10 10 0 10 0 10 10 10 0 10 0 10 0 10 10 0 10 0 10 0 <	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

2-ETHYLIDENE-1,5-DIMETHYL-3,3-D							
EDDP conc. (ng/mL)	n per		e A	Site			e C
,	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
50	10	10	0	10	0	10	0
75	10	9	1	9	1	9	1
125	10	1	9	1	9	1	9
150 ENTANYL (FYL 300)	10	0	10	0	10	0	10
ENTANTE (FTE 300)		0:4	• •	0.14	- D	0:4	
FYL conc. (ng/mL)	n per	Site		Site		SIte	e C
	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	7	3	9	1	9	1
375	10	1	9	1	9	1	9
450	10	0	10	0	10	0	10
ENTANYL (FYL 200)							
FYL conc. (ng/mL)	n per	Site	eА	Site	эB	Site	еC
TTE cone. (Ig/IIIE)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
100	10	10	0	10	0	10	0
150	10	9	1	9	1	9	1
250	10	1	9	1	9	1	9
300	10	0	10	0	10	0	10
ENTANYL (FYL 100)							
	n per	Site	еA	Site	эB	Site	еC
FYL conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
50	10	10	0	10	0	10	0
75	10	9	1	9	1	9	1
125	10	1	9	1	9	1	9
150	10	0	10	0	10	0	10
ENTANYL (FYL 20)							
	n per	Site	eА	Site	эB	Site	еC
FYL conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
10	10	10	0	10	0	10	Ő
15	10	9	1	9	1	9	1
25	10	1	9	1	9	1	9
30	10	0	10	0	10	0	10
ENTANYL (FYL10)							
	n per	Site	еA	Site	эB	Site	еC
FYL conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
5	10	10	0	10	0	10	0
7.5	10	9	1	9	1	9	1
12.5	10	1	9	1	9	1	9
12.5	10	0	9 10	0	9 10	0	9 10
SYNTHETIC MARIJUANA (K2-50)	10	U	10	U	10	U	10
	n per	Sit	eΑ	Site	e B	Site	еC
K2 conc. (ng/mL)	site	-	+	-	+	-	+
<u>^</u>			e -		r -		
	10	10	Λ	10	Λ	10	
0	10	10	0	10	0	10	0
25	10	10	0	10	0	10	0
25 37.5	10 10	10 8	0	10 8	0	10 9	0 0 1
25 37.5 62.5	10 10 10	10 8 1	0 2 9	10 8 2	0 2 8	10 9 2	0 0 1 8
25 37.5 62.5 75	10 10	10 8	0	10 8	0	10 9	0 0 1 8
25 37.5 62.5 75	10 10 10 10	10 8 1 0	0 2 9 10	10 8 2 0	0 2 8 10	10 9 2 0	0 0 1 8 10
25 37.5 62.5	10 10 10 10 10	10 8 1	0 2 9 10 e A	10 8 2	0 2 8 10	10 9 2	0 0 1 8 10 e C
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL)	10 10 10 10 10 n per site	10 8 1 0 Site	0 2 9 10 e A +	10 8 2 0 Site	0 2 8 10 = B +	10 9 2 0 Site	0 0 1 8 10 e C +
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0	10 10 10 10 10 n per site 10	10 8 1 0 Site -	0 2 9 10 e A + 0	10 8 2 0 Site -	0 2 8 10 e B + 0	10 9 2 0 Site -	0 0 1 8 10 e C +
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0 15	10 10 10 10 10 10 n per site 10 10	10 8 1 0 Site - 10 10	0 2 9 10 e A + 0 0	10 8 2 0 Site - 10 10	0 2 8 10 • B + 0 0	10 9 2 0 Site	0 0 1 8 10 e C + 0 0
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0	10 10 10 10 10 n per site 10	10 8 1 0 Site -	0 2 9 10 e A + 0	10 8 2 0 Site -	0 2 8 10 e B + 0	10 9 2 0 Site -	0 0 1 8 10 e C +
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0 15	10 10 10 10 10 10 n per site 10 10	10 8 1 0 Site - 10 10	0 2 9 10 e A + 0 0	10 8 2 0 Site - 10 10	0 2 8 10 • B + 0 0	10 9 2 0 Site - 10 10	0 0 1 8 10 e C + 0 0
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0 15 22.5	10 10 10 10 10 10 10 10 10	10 8 1 0 Site - 10 10 8	0 2 9 10 • A + 0 0 2	10 8 2 0 Site - 10 10 9	0 2 8 10 • B + 0 0 1	10 9 2 0 Site - 10 10 9	0 0 1 8 10 e C + 0 0 1 9
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0 15 22.5 37.5 45	10 10 10 10 10 n per site 10 10 10	10 8 1 0 Situ - 10 10 8 1	0 2 9 10 e A + 0 0 2 9	10 8 2 0 Site - 10 10 9 1	0 2 8 10 • B + 0 0 1 9	10 9 2 0 Site - 10 10 9 1	0 0 1 8 10 e C + 0 0 1 9
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0 15 22.5 37.5 45 SYNTHETIC MARIJUANA (K2-25)	10 10 10 10 10 10 10 10 10 10	10 8 1 0 Situ - 10 10 8 1	0 2 9 10 + 0 2 9 9 9 10	10 8 2 0 Site - 10 10 9 1	0 2 8 10 • B + 0 0 0 1 9 10	10 9 2 0 Sitte - 10 10 9 9 1 0	0 0 1 8 10 e C + 0 0 1 9
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0 15 22.5 37.5 45	10 10 10 10 10 10 10 10 10 10 10 10	10 8 1 0 Situ - 10 10 8 1 0	0 2 9 10 + 0 2 9 9 9 10	10 8 2 0 Sitte - 10 10 9 9 1 0	0 2 8 10 € B + 0 0 1 9 10 € B	10 9 2 0 Sitte - 10 10 9 9 1 0	0 0 1 8 10 e C + 0 0 1 10 e C
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0 15 22.5 37.5 45 SYNTHETIC MARIJUANA (K2-25) K2 conc. (ng/mL)	10 10 10 10 10 10 10 10 10 10 10 10	10 8 1 0 Situ - 10 10 8 1 0 Situ -	0 2 9 10 e A + 0 0 2 9 10 2 9 10	10 8 2 0	0 2 8 10 2 8 10 2 8 10 10 9 10 10 € B +	10 9 2 0 5ite 10 10 9 9 1 0 5ite -	0 0 1 8 10 e C + 0 0 1 1 9 10 e C +
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0 15 22.5 37.5 45 SYNTHETIC MARIJUANA (K2-25) K2 conc. (ng/mL) 0	10 10 10 10 10 10 10 10 10 10 10 10 10	10 8 1 0 - 10 10 8 1 0 Situ - 10	0 2 9 10 + 0 2 9 10 2 9 10 • • • • •	10 8 2 0 - 10 10 9 1 0 Sitte - 10	0 2 8 10 + 0 1 9 10 2 8 + 0 10 9 10	10 9 2 0 - 10 10 9 1 0 Sitte - 10	0 0 1 8 10 e C + 0 10 e C + 0 10 e C + 0 10 e C + 0 0 10 e C + 0 0 0 0 0 0 0 0 0 0 0 0 0
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0 15 22.5 37.5 45 SYNTHETIC MARIJUANA (K2-25) K2 conc. (ng/mL) 0 12.5	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 8 1 0 Site 10 10 8 1 0 Site - 10 10	0 2 9 10 + 0 2 9 10 2 9 10 * + 0 0	10 8 2 0 - 10 10 9 1 0 Sitte - - 10 10	0 2 8 10 + 0 0 1 9 10 2 8 + 0 0 0	10 9 2 0 - 10 10 9 1 0 Sitte - - 10 10	0 0 1 8 10 + 0 0 1 1 9 9 10 0 0 0 0 0
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0 15 22.5 37.5 45 SYNTHETIC MARIJUANA (K2-25) K2 conc. (ng/mL) 0 12.5 18.75	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 8 1 0 - 10 10 10 8 1 0 - - 10 10 7	0 2 9 10 • A + 0 0 2 9 9 10 • A + 0 0 2 9 10 • A • + 0 0 3	10 8 2 0 10 10 10 9 1 1 0 5 itt - 10 10 8	0 2 8 10 + 0 0 1 9 10 10 € B + 0 0 2	10 9 2 0 10 10 10 9 1 1 0 5 itt 0 9 1 1 0 8	0 0 1 8 10 + 0 0 1 1 9 9 10 0 1 0 0 2
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0 15 22.5 37.5 45 SYNTHETIC MARIJUANA (K2-25) K2 conc. (ng/mL) 0 12.5 18.75 31.25	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 8 1 0 3 10 10 10 8 1 0 3 3 10 10 10 7 1	0 2 9 10 e A + 0 0 2 9 10 2 9 10 e A + 0 0 2 9 10 0 3 9	10 8 2 0 10 10 9 1 0 5 itt 0 9 1 0 0 10 10 8 1	0 2 8 10 + 0 0 1 9 10 10 € B + 0 0 2 9	10 9 2 0 10 10 10 9 1 1 0 5 itt 0 9 1 1 0 0 8 2	0 0 1 8 10 + 0 0 1 1 9 9 10 0 1 0 0 2 8
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0 15 22.5 37.5 45 SYNTHETIC MARIJUANA (K2-25) K2 conc. (ng/mL) 0 12.5 18.75 31.25 37.5	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 8 1 0 - 10 10 10 8 1 0 - - 10 10 7	$ \begin{array}{c} 0 \\ 2 \\ 9 \\ 10 \\ e \\ A \\ + \\ 0 \\ 0 \\ a \\ A \\ + \\ 0 \\ 0 \\ 3 \\ \end{array} $	10 8 2 0 10 10 10 9 1 1 0 5 itt - 10 10 8	0 2 8 10 + 0 0 1 9 10 10 € B + 0 0 2	10 9 2 0 10 10 10 9 1 1 0 5 itt 0 9 1 1 0 8	0 0 1 8 10 + 0 0 1 1 9 9 10 0 1 0 0 2
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0 15 22.5 37.5 45 SYNTHETIC MARIJUANA (K2-25) K2 conc. (ng/mL) 0 12.5 18.75 31.25 37.5	10 10 10 10 10 10 10 10 10 10	10 8 1 0 - 10 10 8 1 0 - 10 10 10 7 1 0	0 2 9 10 + 0 2 9 10 2 9 10 0 2 9 10 0 3 9 10	10 8 2 0 10 10 9 1 10 0 5 10 10 10 10 8 1 0	0 2 8 10 + 0 0 1 1 9 10 2 9 9 10	10 9 2 0 10 10 10 9 1 0 0 5 itt - 10 10 10 8 2 0	0 0 1 8 10
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0 15 22.5 37.5 45 SYNTHETIC MARIJUANA (K2-25) K2 conc. (ng/mL) 0 12.5 18.75 31.25	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 8 1 0 5 10 10 8 1 0 5 10 10 10 10 10 10 10 0 5 11 0 5 11 0 5 11 10 10 10 5 10 10 10 10 10 5 10 10 10 10 10 10 10 10 10 10	0 2 9 10 + 0 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10	10 8 2 0 10 10 9 1 1 0 5 10 10 10 10 8 8 1 0 0 5 10 10 10 10 10 10 10 10 10 10 10 10 10	0 2 8 10 9 8 + 0 0 1 1 9 10 9 9 10 2 9 9 10 2 9 9 10	10 9 2 0 10 10 9 1 1 0 0 5 10 10 10 10 8 8 2 0 0 5 10 10 10 10 10 10 10 10 10 10 10 10 10	0 0 1 8 10 + 0 0 1 1 9 9 10 0 1 1 9 9 10 0 0 2 8 8 10
25 37.5 62.5 75 SYNTHETIC MARIJUANA (K2-30) K2 conc. (ng/mL) 0 15 22.5 37.5 45 SYNTHETIC MARIJUANA (K2-25) K2 conc. (ng/mL) 0 12.5 18.75 31.25 37.5 6 MONOACETYLMORPHINE (6-MAM	10 10 10 10 10 10 10 10 10 10	10 8 1 0 - 10 10 8 1 0 - 10 10 10 7 1 0	0 2 9 10 + 0 2 9 10 2 9 10 0 2 9 10 0 3 9 10	10 8 2 0 10 10 9 1 10 10 9 1 0 10 10 10 8 1 0	0 2 8 10 + 0 0 1 1 9 10 2 9 9 10	10 9 2 0 10 10 10 9 1 0 5 10 10 10 10 8 2 0	0 0 1 8 10

0	10	10	0	10	0	10	0
5	10	10	0	10	0	10	0
7.5	10	9	1	9	1	9	1
12.5	10	1	9	1	9	1	9
15	10	0	10	0	10	0	10
(±)3,4-METHYLENEDIOXY-AMPHETA	MINE (MC	PA 500)					
MDA conc. (ng/mL)	n per	Site	θA	Site	эB	Site	эC
,	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10 10	9	1	9	1	9	1 9
625 750	10	1	10	0	10	0	10
ETHYL- B-D-GLUCURONIDE (ETG 30		0	10	0	10	0	10
Ethyl Glucuronide	n per	Sit	еA	Sit	e B	Sit	te C
conc. (ng/mL)	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	7	3	8	2	9	1
375	10	1	9	2	8	1	9
450	10	0	10	0	10	0	10
THYL- B-D-GLUCURONIDE (ETG 50	-	Ū	10	Ū	10	Ū	10
Ethyl Glucuronide	n per	Sit	еA	Sit	e B	Sit	te C
conc. (ng/mL)	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	8	2	8	2	9	1
625	10	1	9	2	8	2	8
750	10	0	10	0	10	0	10
ETHYL- B-D-GLUCURONIDE (ETG 1,	-	Ŧ				Ŧ	
Ethyl Glucuronide	n per	Sit	еA	Sit	e B	Sit	te C
conc. (ng/mL)	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
500	10	10	0	10	0	10	0
750	10	8	2	8	2	9	1
1250	10	1	9	2	8	2	8
1500	10	0	10	0	10	0	10
CLONAZEPAM (CLO 400)	10	0	10	0	10	0	10
Clonazepam	n per	Sit	еA	Sit	e B	Sit	te C
conc.(ng/mL)	Site	-	+	-	+	-	+
==::=:(::3;:::=)							0
0	10		0	10	0	10	
0	10	10	0	10	0	10	
200	10	10 10	0	10	0	10	0
200 300	10 10	10 10 9	0 1	10 8	0 2	10 9	0 1
200 300 500	10 10 10	10 10 9 1	0 1 9	10 8 2	0 2 8	10 9 1	0 1 9
200 300 500 600	10 10	10 10 9	0 1	10 8	0 2	10 9	0 1
200 300 500 600 CLONAZEPAM (CLO 150)	10 10 10 10	10 10 9 1 0	0 1 9 10	10 8 2 0	0 2 8 10	10 9 1 0	0 1 9 10
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam	10 10 10 10 n per	10 10 9 1 0 Site	0 1 9 10	10 8 2 0 Site	0 2 8 10	10 9 1 0 Site	0 1 9 10 e C
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL)	10 10 10 10 n per Site	10 10 9 1 0 Site	0 1 9 10 e A +	10 8 2 0 Site	0 2 8 10 e B +	10 9 1 0 Site	0 1 9 10 e C +
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0	10 10 10 10 10 N per Site 10	10 10 9 1 0 Site - 10	0 1 9 10 • A + 0	10 8 2 0 Site -	0 2 8 10 € B + 0	10 9 1 0 Site -	0 1 9 10 e C + 0
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75	10 10 10 10 10 N per Site 10 10	10 10 9 1 0 Site - 10 10	0 1 9 10 • A + 0 0	10 8 2 0 Site - 10 10	0 2 8 10 e B + 0 0	10 9 1 0 Site - 10	0 1 9 10 e C + 0 0
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112	10 10 10 10 10 10 10 10 10	10 10 9 1 0 Site - 10 10 9	0 1 9 10 × A + 0 0 1	10 8 2 0 Site - 10 10 8	0 2 8 10 9 8 + 0 0 2	10 9 1 0 Site - 10 10 9	0 1 9 10 e C + 0 0 1
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187	10 10 10 10 10 Site 10 10 10 10	10 10 9 1 0 Sitte - 10 10 9 9 1	0 1 9 10 2 A + 0 0 1 9	10 8 2 0 - 10 10 8 2	0 2 8 10 e B + 0 0 2 8	10 9 1 0 Sitte - 10 10 9 1	0 1 9 10 e C + 0 0 1 9
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225	10 10 10 10 10 Site 10 10 10 10 10	10 10 9 1 0 Site - 10 10 9	0 1 9 10 × A + 0 0 1	10 8 2 0 Site - 10 10 8	0 2 8 10 9 8 + 0 0 2	10 9 1 0 Site - 10 10 9	0 1 9 10 e C + 0 0 1
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225	10 10 10 10 10 Site 10 10 10 10 10	10 10 9 1 0 Sitte - 10 10 9 1 0	0 1 9 10 2 A + 0 0 1 9 9 10	10 8 2 0 Sitte - 10 10 8 2 0	0 2 8 10 8 + 0 0 2 8 8 10	10 9 1 0 Sitte - 10 10 9 1 0	0 1 9 10 e C + 0 0 1 9 10
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225 Lysergic ACID DIETHYLAMIDE (LS Lysergic Acid Diethylamide	10 10 10 10 10 10 10 10 10 10 10 D 20) n per	10 10 9 1 0 Sitte - 10 10 9 9 1	0 1 9 10 2 A + 0 0 1 9 9 10	10 8 2 0 - 10 10 8 2	0 2 8 10 8 + 0 0 2 8 8 10	10 9 1 0 Sitte - 10 10 9 1	0 1 9 10 e C + 0 0 1 9 10
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225 YSERGIC ACID DIETHYLAMIDE (LS	10 10 10 10 Site 10 10 10 10 10 10 50 20)	10 10 9 1 0 Sitte - 10 10 9 1 0	0 1 9 10 2 A + 0 0 1 9 9 10	10 8 2 0 Sitte - 10 10 8 2 0	0 2 8 10 8 + 0 0 2 8 8 10	10 9 1 0 Sitte - 10 10 9 1 0	0 1 9 10 e C + 0 0 1 9 10
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225 .YSERGIC ACID DIETHYLAMIDE (LS Lysergic Acid Diethylamide	10 10 10 10 10 10 10 10 10 10 10 D 20) n per	10 10 9 1 0 Sitte - 10 10 9 1 0 Sitte	0 1 9 10 • A + 0 0 1 9 10 • A	10 8 2 0 Sitte - 10 10 8 2 0	0 2 8 10 • B + 0 0 2 8 10 • B	10 9 1 0 - 10 10 9 9 1 0 Sitte	0 1 9 10 € C + 0 0 1 9 10 10 € C
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225 YSERGIC ACID DIETHYLAMIDE (LS Lysergic Acid Diethylamide conc. (ng/mL) 0 10	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 10 9 1 0 Sitte - 10 10 9 1 0 Sitte -	0 1 9 10 2 A + 0 0 1 9 10 9 10 2 A + + 0 0 1 1 9 10 10 10 10 10 10 10 10 10 10 10 10 10	10 8 2 0 - 10 10 8 2 0 Sitte -	0 2 8 10 2 8 + 0 0 2 8 10 2 8 10	10 9 1 0 - 10 10 9 9 1 0 Sitte -	0 1 9 10 • C + 0 0 1 9 10 • C +
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225 YSERGIC ACID DIETHYLAMIDE (LS Lysergic Acid Diethylamide conc. (ng/mL) 0 0	10 10 10 10 10 10 10 10 10 10	10 10 9 1 0 Sitte - 10 10 9 1 0 Sitte - 10	0 1 9 10 2 A + 0 0 1 9 10 10 9 10 2 A + 0 0 0 1 0 0 1 9 10 0 0 1 0 0 0 1 0 0 0 0	10 8 2 0 - 10 10 8 2 0 5 itte - 10	0 2 8 10 2 8 4 0 0 2 8 10 2 8 10 9 8 10	10 9 1 0 5itte - 10 10 9 1 0 5itte - 10	0 1 9 10 e C + 0 0 1 9 10 9 10 e C + 0
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225 YSERGIC ACID DIETHYLAMIDE (LS Lysergic Acid Diethylamide conc. (ng/mL) 0 10	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 10 9 1 0 Sitte - 10 10 9 1 0 0 Sitte - 10 0 10	0 1 9 10 2 4 + 0 0 1 9 10 10 9 10 2 4 + 0 0	10 8 2 0 - 10 10 8 2 0 Sitte - 10 10	0 2 8 10 + 0 2 8 10 2 8 10 2 8 10 0 0 0	10 9 1 0 - 10 10 9 1 0 Sitte - 10 10	0 1 9 10 e C + 0 0 10 9 10 e C + 0 0 0 + 0 0 0 0 0 0 0 0 0 0 0 0 0
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225 .YSERGIC ACID DIETHYLAMIDE (LS Lysergic Acid Diethylamide conc. (ng/mL) 0 10 15	10 10 10 10 10 10 10 10 10 10 10 10 10 1	10 10 9 1 0 Sitte - 10 10 9 1 0 0 Sitte - 10 0 9	0 1 9 10 A + 0 0 1 9 10 2 A + 0 0 1 9 10 2 4 - - - - - - - - - - - - -	10 8 2 0 - 10 10 8 2 0 Sitte - 10 10 9	0 2 8 10 + 0 2 8 10 2 8 10 2 8 10 2 1	10 9 1 0 5itte - 10 10 9 1 0 5itte - 10 0 9 9	0 1 9 10 e C + 0 0 1 9 10 e C + 0 0 1 9 10 10 10 10 10 10 10 10 10 10
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225 YSERGIC ACID DIETHYLAMIDE (LS Lysergic Acid Diethylamide conc. (ng/mL) 0 10 15 25 30	10 10 10 10 10 10 10 10 10 10	10 10 9 1 0 5 10 10 9 1 0 5 10 10 10 9 9 1	$ \begin{array}{c} 0 \\ 1 \\ 9 \\ 10 \\ 2 \\ 4 \\ - \\ 0 \\ 1 \\ 9 \\ 10 \\ 2 \\ 4 \\ - \\ 0 \\ 1 \\ 9 \\ 9 \\ 9 \\ 9 \\ 1 \\ 9 \\ 9 \\ 1 \\ 9 \\ 9 \\ 1 \\ 9 \\ 9 \\ 1 \\ 9 \\ 1 \\ 9 \\ 1 \\ 9 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1$	10 8 2 0 10 10 10 8 2 0 5 itte - 10 10 9 1	0 2 8 10 2 8 0 2 8 10 2 8 10 2 8 10 2 9	10 9 1 0 5 10 10 9 1 0 5 10 10 9 1 10 9 1	0 1 9 10 e C + 0 0 1 9 10 e C + 10 0 10 10 10 10 10 10 10 10
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225 YSERGIC ACID DIETHYLAMIDE (LS Lysergic Acid Diethylamide conc. (ng/mL) 0 10 15 25 30	10 10 10 10 10 10 10 10 10 10	10 10 9 1 0 5 10 10 9 1 0 5 10 10 10 9 9 1	0 1 9 10 2 4 + 0 0 1 9 10 2 4 + 0 0 1 9 10 2 4 + + 0 0 10 10 2 4 - - - - - - - - - - - - -	10 8 2 0 10 10 10 8 2 0 5 itte - 10 10 9 1	0 2 8 10 9 8 10 2 8 10 2 8 10 2 8 10 9 10 10 9	10 9 1 0 5 10 10 9 1 0 5 10 10 9 1 10 9 1	0 1 9 10 + 0 1 9 10 + 0 0 1 9 0 1 9 10 - - - - - - - - - - - - -
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225 .YSERGIC ACID DIETHYLAMIDE (LS Lysergic Acid Diethylamide conc. (ng/mL) 0 10 15 25 30 .YSERGIC ACID DIETHYLAMIDE (LS	10 10 10 10 10 10 10 10 10 10	10 10 9 1 0 Site - 10 10 9 1 0 Site 10 10 10 9 9 1 0	0 1 9 10 2 4 + 0 0 1 9 10 2 4 + 0 0 1 9 10 2 4 + + 0 0 10 10 2 4 - - - - - - - - - - - - -	10 8 2 0 Sitte - 10 10 8 2 0 Sitte - 10 9 1 0 - 10 9 1 0	0 2 8 10 9 8 10 2 8 10 2 8 10 2 8 10 9 10 10 9	10 9 1 0 5 5 5 5 5 10 10 10 10 9 9 1 0 0	0 1 9 10 + 0 1 9 10 + 0 0 1 9 0 1 9 10 - - - - - - - - - - - - -
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225 Lysergic Acid Diethylamide conc. (ng/mL) 0 10 15 25 30 Lysergic Acid DiethylAMIDE (LS Lysergic Acid Diethylamide conc. (ng/mL)	10 10 10 10 10 10 10 10 10 10	10 10 9 1 0 5itté 9 9 1 0 5itté 9 10 10 9 9 1 0 5itté 10 10 9 5 1 0 5 10 0 9 1 0 10 0 9 1 0 10 10 10 10 10 10 10 10 10 10 10 10	0 1 9 10 2 A + 0 0 1 9 10 2 A + 0 0 1 9 10 2 A + 0 0 1 9 10 2 A + 0 0 1 9 10 2 A - - - - - - - - - - - - -	10 8 3 10 10 10 8 2 0 0 5 10 10 10 9 1 10 0 5 10 10 0 5 10 10 10 5 10 10 10 10 10 10 10 10 10 10 10 10 10	0 2 8 10 9 8 + 0 0 2 8 10 2 8 10 2 8 10 2 8 10 2 8 10 2 8 10 2 8 10 2 8 10 10 10 10 10 10 10 10 10 10	10 9 1 0 5 10 10 9 9 1 0 5 5 10 10 10 9 1 0 5 5 11 0 9 5 1 0 5 5 11 0 10 10 0 9 10 0 10 10 10 10 10 10 10 10 10 10 10 1	0 1 9 10 9 C + 0 0 1 9 10 0 1 9 10 0 1 9 10 0 1 9 10 0 1 9 10 0 1 9 10 0 10 0 10 0 10 0 0 10 0 0 10 0 0 10 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225 LYSERGIC ACID DIETHYLAMIDE (LS Lysergic Acid Diethylamide conc. (ng/mL) 0 15 25 30 LYSERGIC ACID DIETHYLAMIDE (LS Lysergic Acid Diethylamide conc. (ng/mL) 0 0 10 15 25 30 LYSERGIC ACID DIETHYLAMIDE (LS 10 10 10 10 10 10 10 10 10 0 10 0 10 0 10 0 10 0 10 0 10 0 0 10 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	10 10 10 10 10 10 10 10 10 10	10 10 9 1 0 Sittef - - 10 10 9 1 0 Sittef - - - - - - - - - - - - -	0 1 9 10 2 A + 0 0 1 9 10 2 A + 0 0 1 9 10 2 A + 0 0 1 9 10 2 A + 0 0 0 1 9 10 2 A - - - - - - - - - - - - -	10 8 2 0 5 10 10 10 8 2 0 5 10 10 10 9 9 1 0 0 5 11 0 10 10 10 10 10 10 10 10 10 10 10 1	0 2 8 10 9 8 + 0 0 2 8 10 2 8 10 2 8 10 9 10 9 10 9 10 9 10 9 10 10 10 10 10 10 10 10 10 10	10 9 1 0 - 10 10 10 9 9 1 0 0 5 itte 9 1 0 0 5 5 itte - 10 0 9 1 0 0 9 1 0 0 9 1 1 0 1 0 1 0 1	0 1 9 10 e C + 0 0 1 9 10 e C + 0 0 1 9 10 e C + 0 0 1 9 10 e C + 10 0 0 10 e C + 10 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225 LYSERGIC ACID DIETHYLAMIDE (LS Lysergic Acid Diethylamide conc. (ng/mL) 0 15 25 30 LYSERGIC ACID DIETHYLAMIDE (LS Lysergic Acid Diethylamide conc. (ng/mL) 0 25	10 10 10 10 10 10 10 10 10 10	10 10 9 1 0 Sitte - 10 10 9 1 0 Sitte - 10 10 9 1 0 Sitte - - 10 10 9 1 0 - - - - - - - - - - - - -	0 1 9 10 2 2 4 + 0 0 1 9 10 2 4 + 0 0 1 9 10 2 4 + 0 0 1 9 10 2 4 + - - - - - - - - - - - - -	10 8 2 0 10 10 8 8 2 0 0 5 10 10 9 1 0 0 5 11 0 0 10 10 10 10	0 2 8 10 2 8 10 2 8 10 2 8 10 2 8 10 2 8 8 10 10 2 8 8 10 10 9 10 2 8 8 10 10 9 10 10 10 10 10 10 10 10 10 10 10 10 10	10 9 1 0 5 10 10 9 1 0 5 10 10 9 9 1 0 5 11 0 10 10 10 10 10	0 1 9 10 0 + 0 0 10 9 10 0 10 0 10 9 10 0 0 10 0 0 10 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225 Lysergic Acid Diethylamide conc. (ng/mL) 0 10 15 25 30 Lysergic Acid Diethylamide conc. (ng/mL) 0 25 37.5	10 10 10 10 10 10 10 10 10 10	10 10 9 1 0 5ittet 9 9 1 0 0 5ittet - 10 10 10 9 1 0 0 5ittet 9 10 10 9 9 10 10 9 9 10 0 9 11 0 9 9 11 0 9 9 11 0 9 11 0 9 11 0 10 9 11 10 10 10 9 10 10 10 10 10 10 10 10 10 10 10 10 10	0 1 9 10 2 4 + 0 0 1 9 10 2 4 + 0 0 1 9 10 2 4 + 0 0 1 9 10 2 4 + 0 0 0 1 9 10 2 4 - - - - - - - - - - - - -	10 8 2 0 - - 10 10 8 2 0 - 10 10 10 9 1 0 0 5 itte - - 10 10 9 9 10 0 9 9	0 2 8 10 2 8 10 2 8 10 2 8 10 2 8 10 2 8 10 0 1 9 10 10 1	10 9 1 0 5 10 10 9 1 0 5 10 10 10 9 1 0 0 5 11 0 0 9 1 0 10 10 9 9 1 0 0 9 1 10 9 9 1 10 9 9 1 10 9 9 1 10 10 10 10 10 10 10 10 10 10 10 10 1	0 1 9 10 + 0 10 + 0 0 10 + + 0 0 10 + + 0 0 10 + + 0 0 10 - - - - - - - - - - - - -
200 300 500 600 CLONAZEPAM (CLO 150) Clonazepam conc. (ng/mL) 0 75 112 187 225 LYSERGIC ACID DIETHYLAMIDE (LS Lysergic Acid Diethylamide conc. (ng/mL) 0 15 25 30 LYSERGIC ACID DIETHYLAMIDE (LS Lysergic Acid Diethylamide conc. (ng/mL) 0 25	10 10 10 10 10 10 10 10 10 10	10 10 9 1 0 Sitte - 10 10 9 1 0 Sitte - 10 10 9 1 0 Sitte - - 10 10 9 1 0 - - - - - - - - - - - - -	0 1 9 10 2 2 4 + 0 0 1 9 10 2 4 + 0 0 1 9 10 2 4 + 0 0 1 9 10 2 4 + - - - - - - - - - - - - -	10 8 2 0 10 10 8 8 2 0 0 5 10 10 9 1 0 0 5 11 0 0 10 10 10 10	0 2 8 10 2 8 10 2 8 10 2 8 10 2 8 10 2 8 8 10 10 2 8 8 10 10 9 10 2 8 8 10 10 9 10 10 10 10 10 10 10 10 10 10 10 10 10	10 9 1 0 5 10 10 9 1 0 5 10 10 9 9 1 0 5 11 0 10 10 10 10 10	0 1 9 10 • C + 0 0 10 • C + + 0 0 10 • C + + 0 0 10 • C • + 0 0 0 10 • • • • • • • • • • • • • • • • • • •

LYSERGIC ACID DIETHYLAMIDE (LSD 10)

	IC ACID DIETHYLAMIDE (LSD 1	0)									
L	_ysergic Acid Diethylamide		per	0,	Site	А		Site	вB		Site	еC
	conc. (ng/mL)		Site	-		+	-		+	-		+
	0		10	10)	0	10)	0	1	0	0
	5		10	10)	0	10)	0	1	0	0
	7.5		10	9		1	9		1	ç)	1
	12.5		10	1		9	1		9	1		9
	15		10	0		10	0		10	0)	10
METHYL	PHENIDATE (MPD 300)											
	Methylphenidate (Ritalin)	n	per	5	Site	А		Site	эB		Site	эC
	conc. (ng/mL)	:	Site	-		+	-		+	-		+
	0		10	10)	0	10)	0	1	0	0
	150		10	10)	0	10)	0	1	0	0
	225		10	9		1	8		2	ç		1
	375		10	1		9	2		8	1		9
	450		10	0		10	0		10	C)	10
METHYL	PHENIDATE (MPD 150)	-								-		
	Methylphenidate (Ritalin)		per		Site			Site	эB		Site	еC
	conc. (ng/mL)		Site	-	_	+	-		+	-		+
	0		10	10	_	0	10		0	1		0
	75		10	10)	0	10		0	1		0
	112.5		10	7		3	9		1	g		1
	187.5		10	1		9	2		8	2		8
	225		10	0		10	0		10	C)	10
METHYL	PHENIDATE (MPD 1,000)	-		-			-					-
	Methylphenidate (Ritalin)		per	5	Site		-	Site	Β	_	Site	эC
	conc. (ng/mL)		Site	-		+	-		+			+
	0		10	10		0	10		0	1		0
	500		10	10)	0	10		0	1		0
	750		10	9		1	9		1	ç		1
	1250		10	2		8	2		8	2		8
	1500		10	0		10	0		10	0)	10
ZOLPIDE	EM (ZOL 50)									_		
	Zolpidem		per	5	Site	A	;	Site	вB		Site	эC
	conc. (ng/mL)		Site	-		+	-		+	-		+
	0		10	10)	0	10		0	1		0
	25		10	9		1	10)	0	1	-	0
	75		10	0		10	1		9	C)	10
MEPHED	DRONE (MEP 500)	-								-		
	Mephedrone HCI		per		Site		-	Site	эB		Site	эC
	conc. (ng/mL)		site	-		+	-		+	-		+
	0	_	10	10		0	10		0	1		0
	250		10	10)	0	10)	0	1		0
	375	_	10	8		2	8		2	9		1
	625 750		10 10	2	_	8 10	1	_	9 10	2		8 10
MEDUER	DRONE (MEP 100)		10	0		10	0		10	, c	,	10
	Mephedrone HCI				Site			Sit/	эB	1	Sit/	эC
	conc. (ng/mL)		per site	<u>`</u>				Jill			Oild	
	0		10	10		+	10	,	+	1	0	+
			10	10	_	0	10		0	1		0
	50					-	8		2	9		1
	50 75		10	9		1			8	2		8
	75					1	2		0		<u> </u>	
			10	9				_	10	0	_	
3, 4 <u>-</u> MET	75 125		10 10 10	9 2 0		8 10	2			_	_	
	75 125 150 HYLENEDIOXYPYROVAL 3, 4-	ERONI	10 10 10 E (MI	9 2 0	000	8 10	2	e E	10	(_	10
	75 125 150 HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone		10 10 10 E (MI	9 2 0 0 0 0 0 7 0 7 0 7 0 7 0 7 1 Site	000 e A	8 10))	2	e E	10	()	10 C
	75 125 150 HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL)	n per	10 10 10 E (MI site	9 2 0 0 0 0 0 0 7 0 2 0 0 0 0 0 0 0 0 0 0	000 ∋ A	8 10)) +	2 0 Site	e E	10 5 +	-)	10 C +
	75 125 150 (HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL) 0	n per : 10	10 10 E (MI site	9 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	000 ∋ A	8 10)) + 0	2 0 Site - 10	e E	10 + 0	- 10)	10 C + 0
	75 125 150 HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL) 0 500	n per 10	10 10 E (MI site	9 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	000 ∋ A	8 10)) + 0 0	2 0 Site - 10 10	e E	10 + 0 0	- 10 10)	10 C + 0 0
	75 125 150 HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL) 0 500 750	n per : 10 10 10	10 10 E (MI site	9 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	000 ∋ A	8 10)) + 0 0 1	2 0 Site - 10 10 9	e B	10 + 0 0 1	- 10 10 8)	10 C + 0 2
	75 125 150 'HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL) 0 500 750 1250	n per : 10 10 10	10 10 E (MI site	9 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	000 A = A	8 10)) + 0 1 9	2 0 Site - 10 10 9 1		10 + 0 0 1 9	- 10 10 8 1)	10 C + 0 2 9
me	75 125 150 (HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL) 0 500 750 1250 1250	n per : 10 10 10 10 10	10 10 E (MI site	9 2 0 0 0 0 0 0 0 0 0 0 0 0 0	000 ⇒ A ((1	8 10)) + 0 0 1 9 9	2 0 Site - 10 10 9		10 + 0 0 1	- 10 10 8)	10 C + 0 2
me	75 125 150 HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL) 0 500 750 1250 1500 HYLENEDIOXYPYROVAL	n per : 10 10 10 10 10 10 10	10 10 E (MI site	9 2 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0	0000 ⇒ A (((((((((((((8 10)) + 0 0 1 9 9	2 0 Site 10 10 9 1 0		10 + 0 0 1 9 10	- 10 10 8 1 0) Site	10 C + 0 2 9 10
3, 4-MET	75 125 150 HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL) 0 500 750 1250 1500 HYLENEDIOXYPYROVAL 3, 4-	n per : 10 10 10 10 10 10 10 0 10 ERONI	10 10 E (MI site E (MI	9 2 0 0 0 0 0 0 0 0 0 0 0 0 0	0000 ⇒ A 0 0 0 0 0 0 0 0 0 0 0 0 0	8 10)) + 0 1 9 10	2 0 Site 10 10 9 1 0		10 + 0 1 9 10 B	- 10 10 8 1 0) Site	10 C + 0 2 9 10 e C
3, 4-MET	75 125 150 HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL) 0 500 750 1250 1500 HYLENEDIOXYPYROVAL	n per : 10 10 10 10 10 10 10	10 10 E (MI site E (MI	9 2 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0	0000 ⇒ A 0 0 0 0 0 0 0 0 0 0 0 0 0	8 10)) + 0 0 1 9 9	2 0 Site 10 10 9 1 0		10 + 0 0 1 9 10	- 10 10 8 1 0) Site	10 C + 0 2 9 10 e C
3, 4-MET	75 125 150 HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL) 0 500 750 1250 1250 1500 HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone	n per : 10 10 10 10 10 10 10 0 10 ERONI	10 10 E (MI site	9 2 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0	0000 ⇒ A ((00) ⇒ A	8 10)) + 0 1 9 10	2 0 Site 10 10 9 1 0		10 + 0 1 9 10 B	- 10 10 8 1 0) Site	10 C + 0 2 9 10 e C +
3, 4-MET	75 125 150 'HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL) 0 500 750 1250 1500 'HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL)	n per : 10 10 10 10 ERONI n per site	10 10 E (MI site E (MI E (MI	9 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0000 ⇒ A 0 0 0 0 0 0 0 0 0 0 0 0 0	8 10)) + 0 1 9 10 +	2 0 Sitt - 10 10 9 1 0 -		10 + 0 0 1 9 10 B +	- 10 10 8 1 0) Site	10 C + 0 0 2 9 10 e C + + 0 0 2 9 10 - - - - - - - - - - - - -
3, 4-MET	75 125 150 'HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL) 0 500 750 1250 1500 'HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL) 0	n per : 10 10 10 10 10 10 ERONI RONI n per site 10	10 10 E (MI site E (MI	9 2 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0	0000 ⇒ A 0 0 0 0 0 0 0 0 0 0 0 0 0	8 10)) + + 0 0 1 1 9 9 10 + +	2 0 Site - 10 10 9 1 0 Si - 10		10 + 0 0 1 9 10 B + 0	- 10 10 8 1 0 - -) Site Site	10 C + 0 0 2 9 9 10 0 0 0 0
3, 4-MET	75 125 150 HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL) 0 500 750 1250 1500 HYLENEDIOXYPYROVAL 3, 4- thylenedioxypyrovalerone conc. (ng/mL) 0 250	n per : 10 10 10 10 10 ERONI n per site 10 10 10 10 10 10 10 10 10 10	10 10 E (MI site	9 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0000 ⇒ A 0 0 0 0 0 0 0 0 0 0 0 0 0	8 10)) + 0 0 1 9 9 10 + 0 0	2 0 Site 10 10 9 1 0 5 - 10 10 10		10 + + 0 0 1 9 10 B + 0 0 0	- 10 10 8 1 0 - - - 10 10 - - - 10 10 - - - - - -	Site	10 C + 0 2 9 10

3, 4-METHYLENEDIOXYPYROVALERONE (MDPV 300)

3, 4-	n per	Sit	еA	Site B		Site C			
methylenedioxypyrovalerone conc. (ng/mL)	site	-	+	-	+	-	+		
0	10	10	0	10	0	10	0		
150	10	10	0	10	0	10	0		
225	10	8	2	9	1	9	1		
375	10	1	9	1	9	2	8		
450	10	0	10	0	10	0	10		

DIAZEPAM (DIA 300)

Diazepam conc. (ng/mL)	n per	n per Site A			еВ	Site C		
Diazepath conc. (ng/mL)	Site	-	+	-	+	•	+	
0	10	10	0	10	0	10	0	
150	10	10	0	10	0	10	0	
225	10	9	1	9	1	9	1	
375	10	1	9	1	9	1	9	
450	10	0	10	0	10	0	10	
7EPAM (DIA 200)								

DIAZEPAM (DIA 200)

	Diazepam conc. (ng/mL)	n per	Site	e A	Site	e B	Site C	
	Diazepani conc. (ng/mE)	Site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	100	10	10	0	10	0	10	0
	150	10	9	1	9	1	9	1
	250	10	1	9	1	9	1	9
	300	10	0	10	0	10	0	10
ZOPICLONE (ZOP 50)								
	Zopiclone n		Site A		Site B		Site C	

conc. (ng/mL) Site -+ + --+ 37.5 62.5

METHCATHINONE (MCAT 500)

Methcathinone	n per Site A		Sit	е В	Site C		
conc. (ng/mL)	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	9	1	8	2	9	1
625	10	2	8	2	8	2	8
750	10	0	10	0	10	0	10

7-AMINOCLONAZEPAM (7-ACL 300)

7- Aminoclonazepam	n per	Site A		Site B		Sit	te C
conc. (ng/mL)	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	8	2	9	1	9	1
375	10	2	8	2	8	3	7
450	10	0	10	0	10	0	10
7-AMINOCLONAZEPAM (7-ACL 2	:00)						

7- Aminoclonazepam n per Site A Site B Site C conc. (ng/mL) Site - + -+ -+ 10 0 2 8 0 10 7-AMINOCLONAZEPAM (7-ACL 100) 7- Aminoclonazepam n per Site Site A Site B Site C conc. (ng/mL) + -+ - + -

CARFENTANYL (CFYL 500)

Carfentanyl	n	Sit	e A	Sit	eВ	Site	еC
conc. (ng/mL)	per site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0

375	10	7		3	9	1	8	2
625	10	2		8	1	9	2	8
750	10	0		10	0	10	0	10
CARFENTANYL (CFYL 250)		Ū			I		I	
	n		Site /	Δ	Site	B	Site	C
Carfentanyl	per							
conc. (ng/mL)	site	-		+	-	+	-	+
0	10	10)	0	10	0	10	0
125	10	10		0	10	0	10	0
187.5	10	7	, 	3	9	1	8	2
			_		1	9	2	8
312.5	10	2		8		-		
375	10	0		10	0	10	0	10
CAFFEINE (CAF 1,000)						_		_
Caffeine	n		Site	A	Site	В	Site	С
conc. (ng/mL)	per	-		+	-	+	-	+
	site							
0	10	10)	0	10	0	10	0
500	10	10)	0	10	0	10	0
750	10	9		1	8	2	9	1
1250	10	2		8	2	8	2	8
	-					-		-
1500	10	0		10	0	10	0	10
CATHINE (CAT 150)								
(+)-Norpseudoephedrine HCl	n		Site	A	Site	В	Site	С
conc.(ng/mL)	per			+	_ T	+	_ T	+
	site				-		-	
0	10	10		0	10	0	10	0
75	10	10)	0	10	0	10	0
112.5	10	9		1	8	2	9	1
187.5	10	2		8	2	8	2	8
225	10	0		10	0	10	0	10
TROPICAMIDE (TRO 350)	.0	5	- 1		~	. 5	v	10
	n	I I	Site	Δ	Site	в	Site	C
Tropicamide conc. (ng/ml)	per		Sile	~	Sile	D	3110	C
hopicanide conc. (iig/iii)	site	-		+	-	+	-	+
0	10	10	+	0	10	0	10	0
175	10	10		0	10		10	0
262.5				2		0		2
437.5	10 10	8	+	2 8	8	2 8	8	2
525	10	2		8	2	8	2	10
TRAZODONE (TZD 200)	10	. 0		10	v	10	v	10
	n		Site /	Δ	Site	в	Site	C
Trazodone conc. (ng/ml)	per	- · ·	5.007		0.10		0.10	
	site	-		+	-	+	-	+
0	10	10		0	10	0	10	0
		10		0	10	0	10	0
100	10		,					
150	10	8		2	8	2	8	2
250	10	1		9	2	8	2	8
300	10	2		8	2	8	2	8
ALPRAZOLAM (ALP 100)								
	n		Site	A	Site	вB	Site	e C
Alprazolam conc. (ng/ml)	per	1 -	. [+		+	_ T	+
	site	1						
0	10	10	-	0	10	0	10	0
50	10	10	0	0	10	0	10	0
75	10	g	9	1	8	2	9	1
125	10	2	2	8	2	8	2	8
150	10	0		10	0	10	0	10
PREGABALIN (PGB 50,000)		. `	· .		5		~	
Pregabalin	n	1	Si	te A	9	ite B	Si	te C
conc. (ng/ml)	per Si	ite	-	+	-	+	-	+
0	10		- 10	+ 0	10	+	- 10	- +
		_						
25,000	10		10	0	10	0	10	0
37,500	10		8	2	8	2	8	2
62,500	10		2	8	2	8	2	8
75,000	10		0	10	0	10	0	10
150,000	10		0	10	0	10	0	10
PREGABALIN (PGB 500)								
Pregabalin	n	Ľ	Si	ite A	S	lite B	S	ite C
conc. (ng/ml)	per Si	ite	-	+	-	+	-	
0	10		10	0	10	0	10	1
250	10		10	0	10	0	10	(
375	10	1	9	1	8	2	8	
625	10		2	8	2	8	2	1
750	10		0	10	0	10	0	1
1500	10		0	10	0	10	0	1

741 EDL ON (741 400)

ZALEPLON (ZAL 100)		0.		0.		0.1	
ZAL conc. (ng/mL)	n per Site	Si	te A +	Si	te B +	Sit	e C +
0	10	10	0	10	0	10	0
50	10	10	0	10	0	10	0
75	10	10	0	10	0	10	0
125	10	2	8	10	9	1	9
150	10	0	10	0	10	0	1(
CANNABINOL (CNB 500)	10	0	10	0	10	0	
	n	Sit	te A	Sit	te B	Sit	e C
CNB conc. (ng/mL)	per Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	9	1	9	1	9	1
625	10	2	8	1	9	1	9
750	10	0	10	0	10	0	10
GABAPENTIN (GAB 2,000)		-		-		-	
	n	Si	te A	Sit	te B	Sit	e C
Gabapentin conc. (ng/mL)	per Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
1,000	10	10	0	10	0	10	0
1,500	10	9	1	9	1	8	2
2,500	10	2	8	2	8	2	8
3,000	10	0	10	0	10	0	10
CARISOPRODOL (CAR 2,000)	10	0	10	U	10	0	
	n	Sit	te A	Sit	te B	Sit	e C
Carisoprodol conc. (ng/mL)	per Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
1,000	10	10	0	10	0	10	0
1,500	10	8	2	9	1	9	1
2,500	10	2	8	2	8	2	8
3,000	10	0	10	0	10	0	10
CARISOPRODOL (CAR 1,000)	10	0	10	0	10	0	
	n	Si	te A	Sit	te B	Sit	e C
Carisoprodol conc. (ng/mL)	per Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
500	10	10	0	10	0	10	0
750	10	8	2	9	1	9	1
1,250	10	2	8	2	8	2	8
1,500	10	0	10	0	10	0	10
AB-PINACA (ABP 10)	10	Ũ		Ũ	10	Ū	
AB-PINACA	n per	Si	te A	Si	te B	Sit	e C
conc. (ng/mL)	Site	•	+	-	+	-	+
0	10	10	0	10	0	10	0
5	10	10	0	10	0	10	0
7.5	10	8	2	8	2	9	1
12.5	10	2	8	3	7	1	9
15	10	0	10	0	10	0	10
QUETIAPINE (QTP 1,000)	10	0	10	Ū	10	Ū	10
Quetiapine	n	Sit	e A	Sit	eВ	Site	ъ С
conc. (ng/mL)	per Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
500	10	10	0	10	0	10	0
750	10	9	1	9	1	9	1
1250	10	1	9	1	9	1	9
1500	10	0	10	0	10	0	10
FLUOXETINE (FLX 500)		C			_	<u>.</u>	~
Fluoxetine	n	Sit	e A	Sit	e B	Site	
conc. (ng/mL)	per Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	9	1	9	1	9	1
625	10	2	8	2	8	2	8
750	10	0	10	0	10	0	10
UR-144 (UR-144 25)		0	- 4	0.1	- D	0	
UR-144 5-Pentanoic acid	n	Sit	e A	Sit	e B	Site	эC
conc. (ng/mL)	per	-	+	-	+	-	+
	Site	4.0		40		40	
		10	0	10	0	10	0
0	10		Ċ.	4 -			
0 12.5	10	10	0	10	0	10	-
0 12.5 18.75	10 10	10 9	1	8	2	9	1
0 12.5	10	10					-

KRATOM (KRA 300)

KR/	ATOM (KRA 300)							
	Mitragynine	n	Site	eΑ	Sit	eВ	Sit	еC
	conc. (ng/mL)	per Site	-	+	•	+	•	+
	0	10	10	0	10	0	10	0
	150	10	10	0	10	0	10	0
	225	10	9	1	9	1	9	1
	375	10	1	9	1	9	2	8
	450	10	0	10	0	10	0	10
TIL	IDINE (TLD 50)							
	Nortilidine	n	Sit	eА	Sit	е В	Sit	еC
	conc. (ng/mL)	per Site	-	+	-	+	1	+
	0	10	10	0	10	0	10	0
	25	10	10	0	10	0	10	0
	37.5	10	8	2	9	1	9	1
	62.5	10	2	8	2	8	2	8
	75	10	0	10	0	10	0	10

ALPHA-PYRROLIDINOVALEROPHENONE (α-PVP 2,000)

	alpha-Pyrrolidinovalerophenone	n per	Sit	еA	Sit	еB	Sit	e C		
	conc. (ng/mL)	Site	-	+	-	+	-	+		
	0	10	10	0	10	0	10	0		
	1,000	10	10	0	10	0	10	0		
	1,500	10	8	2	8	2	9	1		
	2,500	10	2	8	3	7	1	9		
	3,000	10	0	10	0	10	0	10		
AL										

n	Sit	eА	Sit	e B	Sit	e C
per Site	-	+	-	+	-	+
10	10	0	10	0	10	0
10	10	0	10	0	10	0
10	8	2	9	1	9	1
10	2	8	3	7	1	9
10	0	10	0	10	0	10
	10 10 10 10 10 10	per Site - 10 10 10 10 10 8 10 2 10 0	per Site - + 10 10 0 10 10 0 10 8 2 10 2 8	per Site - + - 10 10 0 10 10 10 0 10 10 8 2 9 10 2 8 3 10 0 10 0	per Site - + - + 10 10 0 10 0 10 10 0 10 0 10 10 0 10 0 10 8 2 9 1 10 2 8 3 7 10 0 10 0 10	per Site - + - + - 10 10 0 10 0 10 10 10 0 10 0 10 10 10 0 10 0 10 10 8 2 9 1 9 10 2 8 3 7 1 10 0 10 0 10 0

ALPHA-PYRROLIDINOVALEROPHENONE (α-PVP 500)

	alpha-Pyrrolidinovalerophenone	n	Sit	eА	Sit	e B	Site	еC	l
	conc. (ng/mL)	per Site	-	+	-	+	-	+	l
	0	10	10	0	10	0	10	0	l
	250	10	10	0	10	0	10	0	l
	375	10	8	2	8	2	9	1	l
	625	10	2	8	2	8	1	9	l
	750	10	0	10	0	10	0	10	l
AL	PHA-PYRROLIDINOVAL FROPHE	NONE (a-F	PVP 30	0)					

HA-PYRROLIDINOVALEROPHENONE (α-PVF

alpha-Pyrrolidinovalerophenone	n per	Sit	e A	Sit	еB	Si	te C
conc. (ng/mL)	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	7	3	8	2	9	1
375	10	2	8	1	9	1	9
450	10	0	10	0	10	0	10

MESCALINE (MES 300)

Magaaling cong. (ng/ml.)	n per	Sit	eА	Site	эB	Site	еC
Mescaline conc. (ng/mL)	Site	1	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	9	1	9	1	9	1
375	10	2	8	1	9	1	9
450	10	0	10	0	10	0	10

MESCALINE (MES 100)

Maggaling gang (ng/ml.)	n per	Sit	e A	Site	eВ	Site	еC
Mescaline conc. (ng/mL)	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
50	10	10	0	10	0	10	0
75	10	9	1	9	1	9	1
125	10	2	8	1	9	1	9
150	10	0	10	0	10	0	10

PAPAVERINE (PAP 500)

Papaverine	n per	Site	eА	Site	eВ	Sit	эC
conc. (ng/ml)	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	8	2	9	1	9	1
625	10	2	8	2	8	2	8
750	10	0	10	0	10	0	10

Site A TAP n per Site conc. (ng/mL) -+ CITALOPRAM (CIT 500) Site A Desmethylcitalopram n per Site

Site B

-+ Site C

-+

TAPENTADOL (TAP 1,000)

Site B Site C conc. (ng/ml) + -+ -+ 10 0 10 10 0 10 2 8 2 2 8 3 0 10 0 10 0 F-KETAMINE (FKET 1,000) Site A Site C Site B FKET conc. (ng/ml) n per Site + -+ -+ -10 0 10 0 10 3 9 2 8 2 8 1 0 10 0 10 0 10 **RISPERIDONE (RPD 150)** Site A Site B Site C Risperidone conc. (ng/ml) n per Site + + --+ 112.5 187.5 0 10 SCOPOLAMINE (SCOP 500) Site C Site A Site B Scopolamine conc. (ng/ml) n per Site - + -+ -+ 10 0 9 1 0 10 0 10 0 N, N-DIMETHYLTRYPTAMINE (NND 1,000) N, N-Dimethyltryptamine Site A Site B Site C n per Site conc. (ng/ml) - + -+ -+ 10 0 10 0 10 1 8 2 9 2 8 2 8 1 0 10 0 10 0 10 **MIRTAZAPINE (MTZ 500)** Desmethylmirtazapine conc. Site A Site B Site C n per Site (ng/ml) + -+ -+ 0 10 0 10 OLANZAPINE (OZP 1,000) Site B Site C Site A Olanzapine conc. (ng/ml) n per Site + ---+ + 10 0 1 9

Analytical Sensitivity A drug-free urine pool was spiked with drugs at the listed concentrations. The results are summarized below.

0 10 0 10 0 10

Drug Concentration Cut-off Range		CE 00	AN 1,0	ЛР 000	AN 50			ИР 00	B/ 30	AR 00	B/ 20	\R 00	BZ 50	ZO 00	BZ 30	ZO 00
Cut-on Range	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	26	4	26	4	25	5	27	3	27	3	26	4	27	3	27	3
Cut-off	14	16	15	15	15	15	15	15	16	14	15	15	15	15	15	15

+25% Cut-off		3	27	3	27	3	27	4	26	4	26	_	_	27	4	26	3	27
+50% Cut-off +300% Cut-of	¢	0	30 30	0	30 30	0	30 30	0	30 30	0	30	_	_	30 30	0	30 30	0	30 30
+300 % Cut-01		0	50	0	30	0	50	0	30	0	50	, ,	5	50	0	30	0	30
Drug Concentrati	on	BZ			ZO		JP	В	UP	-	OC		СО	-		C		C
Cut-off Range	-	20			00		0	-	5	_	300		20	-		50	-	00
0% Cut-off	+	- 30	+	- 30	+	- 30	+	- 30	+	- 30	+		-	+	- 30	+	- 30	+
-50% Cut-off	-	30	0	30	0	30	0	30	0	30	_	_	0	0	30	0	30	0
-25% Cut-off		27	3	27	3	26	4	26	4	26	-	_	6	4	27	3	27	3
Cut-off		16	14	14	16	14	16	14	16	13	_	_	4	16	16	14	16	14
+25% Cut-off		3	27	3	27	3	27	3	27	3	27	7 :	3	27	4	26	4	26
+50% Cut-off		0	30	0	30	0	30	0	30	0	30	_)	30	0	30	0	30
+300% Cut-off		0	30	0	30	0	30	0	30	0	30) ()	30	0	30	0	30
		Tŀ	IC	Т	HC	TI	HC	M	ITD	N	/TD		ME	Т	М	ET	М	ET
Drug Concentrati Cut-off Range			50		50		25		00		200		1,00			00		00
		-	+	-	+	-	+	-	+	-	+	_	-	+	-	+	-	+
0% Cut-off		30	0	30	0	30	0	30	0	30	_	_	0	0	30	0	30	0
-50% Cut-off -25% Cut-off		30 27	0	30 26	0	30 27	0	30 27	0	30 25			0 7	0	30 27	0	30 27	0
Cut-off	-	15	15	14	4	15	15	14	16	15	_		4	3 16	15	15	16	3 14
+25% Cut-off	-	4	26	3	27	4	26	3	27	4	20	_	4 3	27	4	26	3	27
+50% Cut-off		0	30	0	30	0	30	0	30	0	3	_	0	30	0	30	0	30
+300% Cut-off		0	30	0	30	0	30	0	30	0	30) (0	30	0	30	0	30
						МС			DP/	1		-					1	
Drug Concentrati	on	MD		MD		NIC O			JP/ PI		DPI		PC			CP		РΧ
Cut-off Range	UII	1,0	00	50	00	30			00	2,	000		50		2	25	3	00
0		-	+	-	+	-	+	-	+	-	+	-		+	-	+	-	+
0% Cut-off		30	0	30	0	30	0	30	0	30	0	-	30	0	30	0	30	0
-50% Cut-off	_	30	0	30	0	30	0	30	0	30	0	_	30	0	30	0	30	0
-25% Cut-off Cut-off		26 15	4 15	25 14	5 16	25 15	5 15	26 15	4 15	27 15	3	-	26 15	4 15	25 15	5 15	26 14	4 16
+25% Cut-off	-+	5	25	4	26	3	27	3	27	4	26	_	3	27	3	27	3	27
+50% Cut-off		0	30	0	30	0	30	0	30	0	30	_	0	30	0	30	0	30
+300% Cut-off		0	30	0	30	0	30	0	30	0	30)	0	30	0	30	0	30
	—		1 -					. 1	1/5	-	145				· .	/FT		~
Drug Concentration		ML 00		ML 200		ИL)0	50	۸L ۵0	KE 1,0		KE 50			ET 800		<et 100</et 		QL 00
Cut-off Range	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	-	-	+
0% Cut-off		0	30	0	30	0	30	0	30	0	30	0	30	0	30	0 0	30	0
	30			•	00	0	30	0	30	0	30	0				•		
-50% Cut-off	30	0	30	_	30		_					0	30	_	30	0 0	30	
-25% Cut-off	30 27	0	27	3	27	3	26	4	27	3	27	3	26	4	27	0 7 3	27	3
-25% Cut-off Cut-off	30 27 15	0 3 15	27 15	3 15	27 15	3 15	26 14	16	16	14	15	3 15	26 15	4	27 5 15	0 0 7 3 5 15	27 5 15	3 15
-25% Cut-off Cut-off +25% Cut-off	30 27 15 4	0 3 15 26	27 15 4	3 15 26	27 15 4	3 15 26	26 14 3	16 27	16 3	14 27	15 4	3 15 26	26 15 4	4 15 26	27 5 15 5 3	0 0 7 3 5 15 6 27	27 5 15 7 4	3 15 26
-25% Cut-off Cut-off	30 27 15	0 3 15	27 15 4 0	3 15	27 15	3 15	26 14	16	16	14	15	3 15	26 15	4	27 5 15 5 3 0 0	0 0 7 3 5 15 6 27 0 30	27 5 15 7 4 0 0	3 15
-25% Cut-off Cut-off +25% Cut-off +50% Cut-off	30 27 15 4 0	0 3 15 26 30	27 15 4 0	3 15 26 30	27 15 4 0	3 15 26 30 30	26 14 3 0	16 27 30	16 3 0	14 27 30	15 4 0	3 15 26 30	26 15 4 0	4 15 26 30	27 5 15 5 3 0 0	0 0 7 3 5 15 6 27 0 30	27 5 15 7 4 0 0	3 15 26 30
-25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off	30 27 15 4 0 0	0 3 15 26 30 30 30	27 15 4 0 0	3 15 26 30 30 30	27 15 4 0 0 XY	3 15 26 30 30	26 14 3 0 0 0	16 27 30 30	16 3 0 0 0	14 27 30 30 E	15 4 0 0	3 15 26 30 30	26 15 4 0 0	4 15 26 30 30	27 5 15 5 3 0 0 0 0 F	0 0 7 3 5 15 6 27 0 30 0 30	27 5 15 7 4 0 0 0 0 F	3 15 26 30 30 YL
-25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off	30 27 15 4 0 0	0 3 15 26 30 30 30	27 15 4 0 0 0	3 15 26 30 30 30	27 15 4 0 0 0 XY	3 15 26 30 30	26 14 3 0 0 0 7 0	16 27 30 30	16 3 0 0 0 0 0 0 0	14 27 30 30 E	15 4 0 0 DDF 300	3 15 26 30 30	26 15 4 0	4 15 26 30 30 0P 0	27 5 15 5 3 0 0 0 0 F	0 0 7 3 5 15 6 27 0 30 0 30 YL 20	27 5 15 7 4 0 0 0 0 F	3 15 26 30 30 YL 0
-25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentrati Cut-off Range	30 27 15 4 0 0	0 3 15 26 30 30 30 -	27 15 4 0 0 (Y 00 +	3 15 26 30 30 30 30 -	27 15 4 0 0 0 XY 00 +	3 15 26 30 30 30 -	26 14 3 0 0 0 7 00 +	16 27 30 30 C 1 -	16 3 0 0 0 0 0 +	14 27 30 30 E	15 4 0 0 DDP 300 +	3 15 26 30 30	26 15 4 0 0 5 0 5	4 15 26 30 30 0P 0 +	27 5 15 5 3 0 0 0 0 F 2 -	0 0 7 3 5 15 6 27 0 30 0 30 7 1 20 +	27 5 15 7 4 0 0 0 0 F 1 -	3 15 26 30 30 YL 0 +
-25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentrati	30 27 15 4 0 0	0 3 15 26 30 30 30	27 15 4 0 0 0	3 15 26 30 30 30	27 15 4 0 0 0 XY	3 15 26 30 30	26 14 3 0 0 0 7 0	16 27 30 30	16 3 0 0 0 0 0 0 0	14 27 30 30 E	15 4 0 0 DDF 300 + 0 0	3 15 26 30 30	26 15 4 0 0	4 15 26 30 30 0P 0	27 5 15 5 3 0 0 0 0 F	0 0 7 3 5 15 6 27 0 30 0 30 YL 20	27 5 15 7 4 0 0 0 0 F	3 15 26 30 30 YL 0
-25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentrati Cut-off Range 0% Cut-off	30 27 15 4 0 0	0 3 15 26 30 30 30 10 - 30	27 15 4 0 0 (Y 00 + 0	3 15 26 30 30 30 30 - 30	27 15 4 0 0 XY 20 + 0	3 15 26 30 30 30 - 30	26 14 3 0 0 0 7 0 0 + 0	16 27 30 30 C 1 - 30	16 3 0 0 0 0 0 0 + 0	14 27 30 30 El 30	15 4 0 0 DDP 300 + 0 0 0	3 15 26 30 30 - - - - - - - - - - - - -	26 15 4 0 0 EDE 10 -	4 15 26 30 30 9P 0 + 0	27 5 15 5 3 0 0 0 0 F 2 - 30	0 0 7 3 5 15 6 27 0 30 0 30 YL 20 + 0	27 5 15 7 4 0 0 0 0 F 1 - 30	3 15 26 30 30 YL 0 + 0
-25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentrati Cut-off Range 0% Cut-off -50% Cut-off Cut-off	30 27 15 4 0 0	0 3 15 26 30 30 30 - 30 30 27 15	27 15 4 0 0 0 + 0 0 3 15	3 15 26 30 30 30 - 30 30 27 15	27 15 4 0 0 XY 00 + 0 0 3 15	3 15 26 30 30 20 - 30 30 27 15	26 14 3 0 0 0 T 00 + + 0 0 3 15	16 27 30 30 - 1 30 30 30 27 14	16 3 0 0 0 0 + 0 0 3 16	14 27 30 30 E 30 30 30 30 27 15	15 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 30 	26 15 4 0 0 5	4 15 26 30 30 0 + 0 4 15	27 i 15 i 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 7 3 5 15 6 27 0 30 0 30 YL 20 + 0 0 3 3 3 16	27 5 15 7 4 0 0 0 0 F 1 30 30 27 15	3 15 26 30 30 YL 0 + 0 3 15
-25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off 300% Cut-off Cut-off Range 0% Cut-off -25% Cut-off Cut-off +25% Cut-off	30 27 15 4 0 0	0 3 15 26 30 30 30 0) 1(- 30 30 27	27 15 4 0 0 (Y 00 + 0 3	3 15 26 30 30 30 - 30 30 27	27 15 4 0 0 XY 00 + 0 0 3 15 26	3 15 26 30 30 20 - 30 30 27	26 14 3 0 0 0 0 7 0 0 0 4 15 26 26	16 27 30 30 - 1 - 30 30 27	16 3 0 0 0 + 0 0 3	14 27 30 30 30 El 30 30 30 27	15 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 30 	26 15 4 0 0 5 10 - 50 80 80 86	4 15 26 30 30 30 + 0 4	27 5 15 5 3 0 0 0 0 F 2 - 30 30 27	0 0 7 3 5 15 5 15 6 30 9 30 9 30 9 30 9 30 9 30 9 30 9 30 9 3 16 26	27 5 15 7 4 0 0 0 0 F 1 - 30 30 27	3 15 26 30 30 YL 0 + 0 0 3 15 27
-25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Prug Concentrati Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +50% Cut-off	30 27 15 4 0 0	0 3 15 26 30 30 30 30 27 15 4 0	27 15 4 0 0 (Y 0 0 + 0 0 3 15 26 30	3 15 26 30 30 30 - 30 30 27 15 4 0	27 15 4 0 0 XY 00 + + 0 0 3 15 26 30	3 15 26 30 30 2 30 30 27 15 4 0	26 14 3 0 0 0 7 0 0 7 0 0 4 15 26 30	16 27 30 30 - - 30 30 30 27 14 4 0	16 3 0 0 0 0 0 0 0 0 16 26 30	14 27 30 30 30 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	15 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 	26 15 4 0 0 5 5 3 0	4 15 26 30 30 30 + 0 + 0 4 15 27 30	27 1 (1) 3 (1) 1 (1)	D 0 7 3 5 15 5 15 6 27 1 30 YL 20 + 0 0 3 16 26 30	27 5 15 7 4 0 0 0 0 F 1 - 30 30 27 15 3 0	3 15 26 30 30 YL 0 15 27 30
-25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off +300% Cut-off Cut-off Range 0% Cut-off -25% Cut-off Cut-off +25% Cut-off	30 27 15 4 0 0	0 3 15 26 30 30 30 - 30 30 27 15	27 15 4 0 0 0 + 0 0 3 15	3 15 26 30 30 30 - 30 30 27 15	27 15 4 0 0 XY 00 + 0 0 3 15 26	3 15 26 30 30 20 - 30 30 27 15	26 14 3 0 0 0 0 7 0 0 0 4 15 26 26	16 27 30 30 - 1 30 30 30 27 14	16 3 0 0 0 0 + 0 0 3 16	14 27 30 30 E 30 30 30 30 27 15	15 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 	26 15 4 0 0 5	4 15 26 30 30 0 + 0 4 15	27 i 15 i 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 7 3 5 15 5 15 6 30 9 30 9 30 9 30 9 30 9 30 9 30 9 30 9 3 16 26	27 5 15 7 4 0 0 0 0 F 1 30 30 27 15	3 15 26 30 30 YL 0 + 0 0 3 15 27
-25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off +300% Cut-off Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off	30 27 15 4 0 0	0 3 15 26 30 30 30 27 15 4 0 0	27 15 4 0 0 (Y 0 0 + 0 0 3 15 26 30	3 15 26 30 30 30 - 30 30 27 15 4 0 0	27 15 4 0 0 XY 00 + + 0 0 3 15 26 30	3 15 26 30 30 - 30 30 27 15 4 0 0	26 14 3 0 0 0 7 0 0 7 0 0 4 15 26 30	16 27 30 30 - - 30 30 30 27 14 4 0	16 3 0 0 0 0 0 0 0 0 0 0 0 0 0	14 27 30 30 30 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	15 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 	26 15 4 0 0 5 5 3 0 0 0	4 15 26 30 30 30 + 0 + 0 4 15 27 30	27 1 15 3 15 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	D 0 7 3 5 15 5 15 6 27 1 30 YL 20 + 0 0 3 16 26 30	27 i 15 4 0 0 0 0 1 - 300 300 277 15 3 0 0 0	3 15 26 30 30 YL 0 4 5 27 30
-25% Cut-off Cut-off +25% Cut-off +30% Cut-off +300% Cut-off Orug Concentrati Cut-off Range 0% Cut-off -25% Cut-off +25% Cut-off +30% Cut-off +30% Cut-off +300% Cut-off	30 27 15 4 0 0 0	0 3 15 26 30 30 30 27 15 4 0 0 27 2	27 15 4 0 0 (Y 0 + 0 0 3 15 26 30 30	3 15 26 30 30 30 30 27 15 4 0 2 6	27 15 4 0 0 + 0 0 3 15 26 30 30	3 15 26 30 30 20 - 30 30 27 15 4 0 0	26 14 3 0 0 0 T 0 0 + 0 0 3 15 26 30 30 30	16 27 30 30 30 - 30 30 27 14 4 0 0	16 3 0 0 0 0 0 0 0 0 0 0 16 26 30 30 30 G	14 27 30 30 El 30 30 27 15 4 0 0	15 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 30 30 30 30 30 51 30 51 30 10 30 10 10 10 10 10 10 10 10 10 1	26 15 4 0 0 5 5 3 0 0 0 5 5 5 3 6	4 15 26 30 30 30 	27 1 (1) 30 30 27 14 4 0 0 0	0 0 7 3 5 15 27 3 6 27 30 30 YL 20 + 0 0 16 26 30 30 30 30 30 30	27 i 15 4 0 0 0 0 15 30 27 15 3 0 0 L	3 15 26 30 30 30 YL 0 + 0 3 0 30 30 30 30
-25% Cut-off Cut-off +25% Cut-off +30% Cut-off +30% Cut-off Trug Concentrati Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off Concentration Cut-off Range	30 27 15 4 0 0 0	0 3 15 26 30 30 30 20 10 - 30 30 27 15 4 0 0 - +	27 15 4 0 0 0 + 0 0 3 15 26 30 30 30 -	3 15 26 30 30 30 30 30 30 27 15 4 0 27 15 4 0 2 6 +	27 15 4 0 0 + 0 0 3 15 26 30 30 30 	3 15 26 30 30 20 - 30 30 27 15 4 0 0 0 - - - - - - - - - - - - - - - -	26 14 3 0 0 0 + 0 0 3 0 30 30 DA 00 +	16 27 30 30 - 30 30 27 14 4 0 0 57 57 54 50 57 54 50 57 57 57 57 57 57 57 57 57 57 57 57 57	16 3 0 0 0 0 0 0 0 0 0 0 16 26 30 30 G 0 +	14 27 30 30 El 30 30 30 30 30 30 30 30 30 27 15 4 0 0 El 500 -	15 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 30 - - - - - - - - - - - - -	26 15 4 0 0 5 3 0 0 +	4 15 26 30 30 0 0 4 15 27 30 30 CLC 400 -	27 30 27 14 4 0 0 14 4 0 0 14 4 0 0 14 4 0 0 14 14 15 15 15 15 15 15 15 15 15 15	D 0 7 3 5 15 4 27 1 30 1 30 1 16 20 30 1 16 26 30 30 30 CLC0 150 - 1	27 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 YL 0 + 0 15 27 30 30 30 SD 20 +
-25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentrati Cut-off Range 0% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off	30 27 15 4 0 0 0	0 3 3 26 300 300 20 10 - 30 30 27 15 4 0 0 + 0 0 + 0	27 15 4 0 0 + 0 0 - 30 30 - 30	3 15 26 30 30 30 30 30 30 27 15 4 0 2 6 + 0 3	27 15 4 0 0 + 0 3 15 26 30 30 30 	3 15 26 30 30 - - 30 30 27 15 4 0 0 - - 30 30 27 15 4 0 0 - - 30 30 30 30 30 30 30 30 30 30 30 30 30	26 14 3 0 0 0 T 0 0 4 4 0 0 3 3 0 30 30 30 30 4 0 0 4 0 0 4 0 0 4 0 0 0 15 26 30 30 30 15 26 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	16 27 30 30 - 30 30 27 14 4 0 0 0 ET 30 - 30	16 3 0 0 0 0 0 0 0 0 0 16 26 30 30 30 4 0 + 0 16 16 16 16 16 16 16 16 16 16	14 27 30 30 30 27 15 4 0 0 ETC 500 - 30	15 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 1 5 1 1 5 1 1 5 1 1 5 1 1 5 1 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1	26 15 4 0 0 5 5 3 0 0 5 5 3 0 0 0 0 + 0 0 1 0 0 1 0 0 1 0 0 0 0 0 0	4 15 26 30 30 PP 0 4 15 27 30 30 CLC 400 - 30	27 30 30 27 14 4 0 0 + 0 30 27 14 4 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 7 3 3 5 15 27 6 27 30 7 30 30 7 30 30 7 30 0 7 30 0	27 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 YL 0 + 0 15 27 30 30 SD 20 + 0 0 0 15 0 15 27 30 30 0 0 0 0 0 0 0 0 0 0 0 0 0
-25% Cut-off Cut-off +25% Cut-off +30% Cut-off +300% Cut-off Drug Concentrati Cut-off Range 0% Cut-off -25% Cut-off +25% Cut-off +25% Cut-off +300% Cut-off -30% Cut-off Cut-off Range 0% Cut-off -50% Cut-off -50% Cut-off -50% Cut-off	30 27 15 4 0 0 0 0 0 0	0 3 3 26 30 30 30 27 15 4 0 0 2 0 + 0 0 0 + 0 0	27 15 4 0 0 (Y 0 - 30 30 30 - 30 30	3 15 26 300 300 300 300 300 300 27 15 4 0 2 6 + 0 0 0 0	27 15 4 0 0 + 0 0 3 15 26 30 30 30 	3 15 26 30 30 27 15 4 0 0 15 4 0 0 30 30 30 30 30 30 30 30	26 14 3 0 0 0 T 0 0 4 4 0 0 3 3 0 3 0 0 4 5 26 3 0 3 0 3 0 0 4 9 0 0 4 9 0 0 15 26 30 30 30 30 0 0 0 0 0 0 0 0 0 0 0 0 0	16 27 30 30 - 30 27 14 4 0 0 0 ET 300 30 30 30	16 3 0 0 0 0 0 0 16 26 30 30 30 	14 27 30 30 30 27 30 300 27 15 4 0 0 0 ETC 500 - 30 30 30 30 27 15 4 4 0 0 500 - 500 - 30 30 27 15 15 15 15 15 15 15 15 15 15	15 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 30 - - - - - - - - - - - - -	26 15 4 0 0 5 5 3 0 0 5 5 3 0 0 0 5 0 0 5 0 0 5 0 0 1 0 10 0 0 0 0	4 15 26 30 30 30 - - 30 - 30 - 30 - - - - - - - - - - - - -	27 30 30 27 14 4 0 0 14 4 0 0 14 4 0 0 14 4 0 0 14 15 15 15 15 15 15 15 15 15 15	0 0 0 7 3 5 15 5 15 27 30 1 30 30 16 26 30 30 0 1 16 30 150 20 - 4 30 0	27 5 15 7 4 0 0 0 0 0 0 11 - 30 30 27 15 3 0 0 L - - 30 30 0 0 - - - - - - - - - - - - -	3 15 26 30 30 YL 0 + 0 15 27 30 30 SD 20 + 0 0 0 0 0 0 0 0 0 0 0 0 0
-25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentrati Cut-off Range 0% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off	30 27 15 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 3 3 26 30 30 30 27 15 4 0 0 4 0 4	27 15 4 0 0 + 0 3 15 26 30 30 30 - 30 30 27	3 15 26 30 30 30 27 15 4 0 2 6 + 0 33	27 15 4 0 0 + 0 3 15 26 30 30 30 	3 15 26 30 30 27 15 4 0 0 15 4 0 0 30 27 15 4 0 0 30 27 15 4 0 26 30 27 15 4 0 30 27 15 4 0 30 27 15 4 0 26 26 26 26 27 15 4 0 26 26 27 15 4 0 26 26 27 15 26 26 27 27 27 26 27 27 26 27 27 26 27 27 26 27 27 26 27 27 26 27 26 26 27 27 26 26 27 26 26 27 26 26 27 26 26 27 26 26 27 26 26 27 26 26 26 26 26 26 26 26 27 26 26 26 26 26 27 26 26 26 26 26 26 26 26 26 26	26 14 3 0 0 0 T 00 + 0 3 30 30 30 DA 00 + 0 0 4	16 27 30 30 - 30 30 27 14 4 0 0 0 ET 30 - 30	16 3 0 0 0 0 0 0 16 26 30 30 30 4 0 16 30 30 4 5 5	14 27 30	15 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 30 5 1 30 5 1 30 5 1 1 5 1 1 1 5 1 1 5 1 1 5 1 1 5 1 1 5 1 1 1 5 1 5 1 1 5 1 1 5 1 1 5 1 1 5 1 1 5 1 1 5 1 1 5 1 1 1 5 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1	26 15 4 0 0 5 0 6 5 0 6 0 5 0 10 5 0 10 5 0 10 5 0 10 5 0 10 5 0 10 5 0 10 5 10 10 10 10 10 10 10 10 10 10	4 15 26 30 30 30 + 0 4 5 27 30 30 27 30 30 - 30 30 26	27 30 30 27 14 4 0 0 14 4 0 0 14 4 27 14 4 0 0 14 4 0 0 14 4 0 0 14 4 0 0 14 14 14 14 14 14 14 14 14 14	0 0 0 7 3 3 5 15 27 6 27 30 7 30 30 7 30 30 7 30 0 7 30 0	277 5 155 7 4 0 0 0 0 0 0 11 - 300 300 277 15 3 0 0 0 L - - 300 300 277 15 3 0 0 0 15 3 0 0 15 3 0 0 15 15 15 15 15 15 15 15 15 15	3 15 26 30 30 YL 0 + 0 3 15 27 30 30 SD 20 + 0 0 3 30 30 30 30 30 30 30 3
-25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentrati Cut-off Range 0% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off -25% Cut-off -25% Cut-off -25% Cut-off +25% Cut-off +25% Cut-off +25% Cut-off +25% Cut-off	30 27 15 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 3 3 2 6 3 0 3 0 3 0 2 7 15 4 0 0 4 15 2 7 2 7	27 15 4 0 0 (Y 0 0 + 0 0 - 30 30 - 30 30 27 16 4 - - - - - - - - - - - - -	3 3 15 26 30 30 30 30 27 15 4 0 0 2 6 4 0 3 215 4 0 0 2 6 + 0 3 2 114 1 26 1	27 15 4 0 0 + 0 0 3 15 26 30 30 - MAN 10 - + 0 0 0 0 3 5 15 26 30 30 - - - - - - - - - - - - -	3 15 26 30 30 27 15 4 0 0 15 4 0 0 15 30 30 27 15 30 30 27 15 30 30 27 15 30 30 27 15 30 30 30 27 15 30 30 30 30 30 30 30 30 30 30	26 14 3 0 0 0 T 0 0 4 15 26 30 30 30 DA 00 + + 0 0 0 4 15 27	16 27 30 30 - 30 27 14 4 0 0 0 ET 300 30 25	16 3 0 0 0 0 0 0 0 16 26 300 0 30 0 30 0 30 0 30 0 30 16 30 30 30 0 30 14 26	14 27 30	15 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 30 - - - - - - - - - - - - -	26 15 4 0 0 10 - 0 0 - 0 0 - 0 0 - 0 0 - 0 0 - 0 0 - 0 0 - - 0 0 - - - - - - - - - - - - -	4 15 26 30 0 + 0 0 4 15 27 30 30 CLC 400 - 30 30 26 14 5 27	27 5 15 5 30 0 0 7 300 27 14 4 0 0 7 14 4 0 0 7 14 4 0 0 7 14 4 0 0 7 14 4 0 0 0 0 0 0 0 0 0 0 0 0 0	D O O 7 3 35 15 35 15 27 30 1 30 30 16 20 + 0 33 16 26 30 130 10 300 10 300 20 - 1 16 300 0 300 10 20 - 1 1	277 5 15 7 4 0 0 0 0 7 4 15 30 30 277 15 3 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 YL 0 + 0 0 15 27 30 30 30 SD 20 + 0 16 27
-25% Cut-off Cut-off +25% Cut-off +30% Cut-off +30% Cut-off Cut-off Range 0% Cut-off -25% Cut-off +25% Cut-off +30% Cut-off +30% Cut-off -50% Cut-off -50% Cut-off -25% Cut-off -25% Cut-off -25% Cut-off -25% Cut-off +30% Cut-off +30% Cut-off +30% Cut-off +30% Cut-off +35% Cut-off Cut-off +35% Cut-off +35% Cut-off +35% Cut-off	30 27 15 4 0 0 0 0 0 0 0 5 0 7 30 30 26 15 3 0	0 33 15 26 30 30 27 15 4 0 0 4 15 27 30	27 15 4 0 0 + 0 3 15 26 30 30 - 30 30 - 30 30 - 16 4 27 16 4 27 16 4 27 16 30 30 30 30 - 30 30 - 30 30 - 30 - 30 - 30 - 30 - 30 - 30 - 30 - 30 - - - - - - - - - - - - -	3 15 26 30 30 - 30 27 15 4 0 2 6 + 0 3 2 6 + 0 3 2 6 + 0 3 2 6 + 0 3 2 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	27 15 4 0 0 15 26 30 30 	3 15 26 30 30 27 15 4 0 0 15 4 0 0 15 300 27 15 4 0 0 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 300 26 15 300 300 300 26 15 300 300 300 26 15 300 300 300 300 26 15 300 300 300 26 15 300 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 10 10 10 10 10 10 10 10 10	26 14 3 0 0 0 T 0 0 0 4 15 26 30 30 30 DA 00 4 15 27 30	16 27 30 30 - 30 30 27 14 4 0 0 0 ET 30 30 27 - 30 30 25 16 4 0	16 3 0 0 0 0 0 16 26 30 30 30 G0 1 0 1 10 1 11 1 26 30 30 30	14 27 30	15 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 30 	26 15 4 0 0 10 - 5 3 0 26 5 3 0 0 - 5 3 0 0 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - - - - - - - - - - - - -	4 15 26 30 30 - - - - - - - - - - - - -	27 15 30 0 0 30 27 14 0 0 0 0 14 0 0 0 14 0 0 14 0 0 14 0 0 125 30	D O O 7 3 3 5 15 27 30 30 30 YL 20 + 0 0 3 16 26 30 300 0 30 - + 4 300 0 26 14 1 5 20 30 3	277 5 15 7 4 0 0 0 0 7 4 15 30 277 15 3 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 YL 0 + 0 15 27 30 30 SD 20 + 0 0 33 15 27 30 30 30 30 30 30 30 30 30 30
-25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentrati Cut-off Range 0% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off -25% Cut-off -25% Cut-off -25% Cut-off +25% Cut-off +25% Cut-off +25% Cut-off +25% Cut-off	30 27 15 4 0 0 0 0 0 0 0 5 0 7 30 30 26 15 3 0	0 3 3 2 6 3 0 3 0 3 0 2 7 15 4 0 0 4 15 2 7 2 7	27 15 4 0 0 + 0 3 15 26 30 30 - 30 30 - 30 30 27 16 4 2 0 - 30 30 20 - 30 30 30 - 30 30 - - - - - - - - - - - - -	3 15 26 30 30 - 30 27 15 4 0 2 6 + 0 3 2 6 + 0 3 2 6 + 0 3 2 6 + 0 3 2 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	27 15 4 0 0 + 0 0 3 15 26 30 30 - MAN 10 - + 0 0 0 0 3 5 15 26 30 30 - - - - - - - - - - - - -	3 15 26 30 30 27 15 4 0 0 15 4 0 0 15 300 27 15 4 0 0 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 27 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 300 26 15 300 300 300 26 15 300 300 300 26 15 300 300 300 300 26 15 300 300 300 26 15 300 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 300 26 15 300 10 10 10 10 10 10 10 10 10	26 14 3 0 0 0 T 0 0 4 15 26 30 30 30 DA 00 + + 0 0 0 4 15 27	16 27 30 30 - 30 27 14 4 0 0 27 14 4 0 0 0 - 30 30 25 16 4	16 3 0 0 0 0 0 0 0 16 26 300 0 30 0 30 0 30 0 30 0 30 16 30 30 30 0 30 14 26	14 27 30	15 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 30 	26 15 4 0 0 10 - 5 3 0 26 5 3 0 0 - 5 3 0 0 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - - - - - - - - - - - - -	4 15 26 30 30 - - - - - - - - - - - - -	27 15 30 0 0 30 27 14 0 14 0 0 0 14 0 0 14 0 0 14 0 14 0 0 27 14 0 0 25 30	D O O 7 3 35 15 35 15 27 30 1 30 30 16 20 + 0 33 16 26 30 130 10 300 10 300 20 - 1 16 300 0 300 10 20 - 1 1	277 5 15 7 4 0 0 0 0 7 4 15 30 277 15 3 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 YL 0 + 0 - + 0 0 3 30 30 SD 20 + 0 3 30 - - - - - - - - - - - - -
-25% Cut-off Cut-off +25% Cut-off +30% Cut-off +30% Cut-off Cut-off Range 0% Cut-off -25% Cut-off +25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off -25% Cut-off -25% Cut-off -25% Cut-off -25% Cut-off -25% Cut-off +30% Cut-off +30% Cut-off +30% Cut-off +30% Cut-off +30% Cut-off	30 27 15 4 0 0 0 0 0 50 50 26 15 3 0 0	0 3 3 2 6 3 0 0 0 1 5 4 0 0 0 1 5 4 0 0 1 5 4 0 0 1 5 4 0 0 1 5 1	27 15 4 0 0 (Y 0 0 - 30 30 - 30 30 - 30 30 - 30 - 30 - 30 - 30 - 30 - 30 - 30 - - - - - - - - - - - - -	3 15 26 30 30 30 30 27 15 4 0 27 15 4 0 32 32 330 330	27 15 4 0 0 + 0 0 - + 0 0 - + 0 0 - + 0 0 - + - - - + - - - + - - - - - - - - - - - - -	3 15 26 30 30 27 15 4 0 0 15 4 0 0 300 27 15 30 30 27 15 30 30 27 15 30 30 27 15 30 30 27 15 30 30 27 15 30 30 30 27 15 30 30 27 15 30 30 27 15 30 30 27 15 30 30 27 15 30 30 27 15 30 30 27 15 30 30 27 15 30 30 27 15 30 30 27 15 30 30 27 15 30 30 27 15 30 30 27 15 30 30 30 26 15 15 30 30 26 15 30 30 30 26 15 30 30 26 15 30 30 30 26 15 30 30 26 15 30 30 26 15 30 30 26 15 30 30 26 15 30 30 26 15 30 30 26 15 30 30 26 30 30 26 15 30 30 26 15 30 30 26 15 30 30 26 15 30 30 00 00 00 15 30 00 00 00 00 15 15 15 15 15 15 15 15 15 15	26 14 3 0 0 + 0 0 3 15 26 0 0 30 30 30 4 15 27 30 30 30	16 27 30 30 - 30 30 27 14 4 0 0 - 30 30 27 14 4 0 0 - 30 30 27 14 4 0 0 - - - - - - - - - - - - -	16 3 0 0 0 0 0 16 26 30 30 30	14 27 30 30 30 30 30 30 30 30 30 30 27 15 4 0 0 0 30 30 26 15 13 2 0 3	15 4 0 <	3 15 26 30 30 - 3 - 3 - 3 - 3 - 3 - 3 - 3 - 3	26 15 4 0 0 10 - 0 0 - 0 0 - 0 0 - 0 0 - - 0 0 - - 0 0 0 - - - - - - - - - - - - -	4 15 27 30 4 15 27 30 30 CLC 400 - 30 30 26 14 5 27 30 30 20 400 - 5 27 30 30 20 40 20 40 20 40 20 40 20 40 20 20 40 20 20 20 20 20 20 20 20 20 2	27 30 30 27 14 4 0 0 27 14 4 0 0 27 14 4 0 0 27 14 4 0 0 27 14 4 0 0 27 14 4 0 0 0 0 0 0 0 0 0 0 0 0 0	D 0 0 7 3 3 5 15 27 30 30 7 30 0 30 16 26 30 20 14 1 50 26 4 14 12 0 30 0 30 30 26 14 14 20 0 30 30	277 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 YL 0 + 0 0 15 27 30 30 SD 20 16 27 30 30 15 20 16 27 30 30 30 15 27 30 30 30 30 30 30 30 30 30 30
-25% Cut-off Cut-off +25% Cut-off +30% Cut-off +30% Cut-off Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +300% Cut-off +300% Cut-off Concentration Cut-off Range 0% Cut-off -25% Cut-off -25% Cut-off -25% Cut-off +30% Cut-	30 27 15 4 0 0 0 0 0 50 50 26 15 3 0 0	0 3 3 15 26 30 30 0 15 4 0 0 - 30 30 27 15 4 0 0 - 15 4 0 0 - 30 27 15 - 30 30 27 15 - 30 30 27 15 - 30 30 27 - 30 30 27 - 30 30 27 - 30 30 27 - 30 30 27 - 30 30 27 - 30 30 27 - - 30 30 27 - - - - - - - - - - - - -	27 15 4 0 0 (Y 0 0 - 30 30 - 30 30 - 5D	3 15 26 30	27 15 4 0 0 + 0 0 - + 0 0 - + 0 0 - + 0 0 - - + 0 - - + - - - - - - - - - - - - -	3 15 26 30 30 - - 30 30 27 15 4 0 0 27 15 4 0 0 27 15 30 30 27 15 30 0 0 0 0 0 0 0 0 0 0 0 0 0	26 14 3 0 0 7 7 0 0 0 3 3 0 7 5 26 30 30 30 0 0 0 4 4 15 27 30 30 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	16 27 30 30 - 30 30 27 14 4 0 0 - 30 30 27 14 4 0 0 - - - - - - - - - - - - -	16 3 0 0 0 0 0 0 0 16 26 30 5 14 26 30 30 HC	14 27 30 30 30 30 30 30 30 30 30 30 27 15 4 0 0 0 30 30 26 15 13 2 0 3	15 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 - 3 - 3 - 3 - 3 - 3 - 3 - 3 - 3	26 15 4 0 0 10 - 00 26 5 3 0 0 - - 00 - - 00 - - - - - - - - - - - - -	4 15 26 300 27 30 400 - 30 30 26 14 5 27 30 30 20 - 15 27 400 - 15 27 400 - 15 27 400 - 15 27 400 - 15 27 15 15 15 15 15 15 15 15 15 15	27 11: 30 30 27 - 30 30 27 14 4 0 0 27 14 4 0 0 27 14 4 0 0 27 14 4 0 0 0 0 0 0 0 0 0 0 0 0 0	D 0 0 7 3 3 5 15 27 30 30 YL 20 + 0 0 30 16 26 300 30 CLC 150 - 4 330 6 26 2 14 1 20 30 0 3 0 3 0 3 0 3	27 300	3 15 26 30 30 YL 0 + 0 0 3 30 YL 0 0 30 YL 0 30 YL 0 30 YL 0 30 30 YL 0 30 30 YL 0 30 30 YL 0 30 30 30 YL 0 30 30 30 30 30 30 30 30 30
-25% Cut-off Cut-off +25% Cut-off +30% Cut-off +30% Cut-off Cut-off Range 0% Cut-off -25% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off -50% Cut-off -50% Cut-off -25% Cut-off -25% Cut-off -25% Cut-off -25% Cut-off +25% Cut-off +25% Cut-off +25% Cut-off +30% Cut-off +30% Cut-off +30% Cut-off +30% Cut-off +30% Cut-off +30% Cut-off	30 27 15 4 0 0 0 0 0 50 50 26 15 3 0 0	0 3 3 2 6 3 0 0 0 1 5 4 0 0 0 1 5 4 0 0 1 5 4 0 0 1 5 4 0 0 1 5 1	27 15 4 0 0 (Y 0 0 - 30 30 - 30 30 - 5D	3 15 26 30	27 15 4 0 0 + 0 0 - + 0 0 - + 0 0 - + 0 0 - + - - - + - - - + - - - - - - - - - - - - -	3 15 26 30 30 - - 30 30 27 15 4 0 0 27 15 4 0 0 27 15 30 30 27 15 30 0 0 0 0 0 0 0 0 0 0 0 0 0	26 14 3 0 0 + 0 0 3 15 26 0 0 30 30 30 4 15 27 30 30 30	16 27 30 30 - 30 30 27 14 4 0 0 - 30 30 27 14 4 0 0 - - - - - - - - - - - - -	16 3 0 0 0 0 0 16 26 30 30 30	14 27 30 30 30 30 30 27 4 0 30 27 4 0 30 27 30 30 30 27 30 30 30 30 30 30 30 30 30 30 26 0 30 30 0 3 0 3 0 3 0 3 0 3 0 3	15 4 0 0 0 0 0 0 0 0 0 0 0 0 0	3 15 26 30 30 - 3 - 3 - 3 - 3 - 3 - 3 - 3 - 3	26 15 4 0 0 10 - 0 0 - 0 0 - 0 0 - 0 0 - - 0 0 - - 0 0 0 - - - - - - - - - - - - -	4 15 26 300 27 30 400 - 30 30 26 14 5 27 30 30 20 - 15 27 400 - 15 27 400 - 15 27 400 - 15 27 400 - 15 27 15 15 15 15 15 15 15 15 15 15	27 11: 30 30 27 - 30 30 27 14 4 0 0 27 14 4 0 0 27 14 4 0 0 27 14 4 0 0 0 0 0 0 0 0 0 0 0 0 0	D 0 0 7 3 3 5 15 27 30 30 7 30 0 30 16 26 30 20 14 1 50 26 4 14 12 0 30 0 30 30 30	27 300	3 15 26 30 30 YL 0 + 0 0 15 27 30 30 SD 20 16 27 30 30 15 20 16 27 30 30 30 15 27 30 30 30 30 30 30 30 30 30 30

		-	+	-	+	-	+	-	_	+	-	+	-	+	-		+	-	+
0% Cut-off		30	0	30		30	-	30	_	0	30	0	30	0	30	_	0	30	0
-50% Cut-o -25% Cut-o		30	0	30	_	30		30	_	0 4	30 26	0	30 27	0	30		03	30 26	0
Cut-off		14	16	14	_	-	-	_		4 15	15	15	15	15	17		13	14	4 16
+25% Cut-c	ff	3	27	5	25	_	27	_	_	26	4	26	4	26	5	_	25	3	27
+50% Cut-c	ff	0	30	0	30	0 0	30	0		30	0	30	0	30	0		30	0	30
+300% Cut-	off	0	30	0	30	0	30	0		30	0	30	0	30	0		30	0	30
									T					1/0	-	70			
Drug Concentration		DPV 500		0PV 00		00	DI 20			HC	11	THC 30		K2 25		ZO 50		MC 50	
Cut-off Range	-	+	-	+	-	+	- 20	+	-	+	1.	+	-	25	+.	- 1	, +		+
0% Cut-off	30	_	30	0	30	0	30	0	30	0	30	_	30	_	3	0	0	30	0
-50% Cut-off	30		30	0	30	0	29	1	30	0	30		30		3		0	30	0
-25% Cut-off	25	5	26	4	27	3	27	3	26	4	26	6 4	25	5	2	7	3	28	2
Cut-off	15	-	14	16	15	15	15	15	15	15	14	16				7	13	17	13
+25% Cut-off	3	27	3	27	3	27	3	27	4	26		26	_	27		_	26	3	27
+50% Cut-off	0	30	-	30	-	30	1	29	0	30		30	-	30	_	_	30	0	30
+300% Cut-of	0	30	0	30	0	30	0	30	0	30	0	30	0	30) ()	30	0	30
Drug	7.	ACL	7.	ACL	7	ACL	C	FYL	Т	CAI	- 1	CA	т	т	20	Т	ALP	<i>a</i> .	PVP
Concentration		00		00		100		500		1,00		15		35			100		000
Cut-off Range	-	+	-	+	-	+	-	+	_	· -	+	-	+	-	+	1-	+	_	+
0% Cut-off	30	0	30	0	30	0	30	0			0	30	0	30	0	3			0
-50% Cut-off	30	0	30	0	30	0	30		_	0	0	30	0	30	0	3			
-25% Cut-off	26	4	27	3	27	3	25	-	_	6	4	27	3	27	3	2	-	_	
Cut-off	14	16	14	16	_		14	_	_	_	13	17	13	15	15	_	_	_	_
+25% Cut-off	5	25 30	3	27 30	-	26 30	6	24	_	-	24 30	4	26 30	3	27 30	3	_	-	27
+50% Cut-off +300% Cut-off	0	30	0	30		30	0	30	_	-	30 30	0	30 30	0	30	_	-		30 30
+50070 Out-on	0	50	U	50	0	50	0	50	<u>, , ,</u>		50	0	50	0	50		100	0	50
Drug	F	YL	FY	L	COT	T	ĊA	T	CA	T	CA	0	PI	TH	С	C	AR	C	AR
Concentration	3	00	10	C	300	_	000	1(00	3	00	1,0		20	_	2,0	000	1,(000
Cut-off Range	-	+	-	+	- +		+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0		_	30 (_	-	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0		_	30 0	_	_	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off Cut-off	27 17	3 13			25 5 15 1			26 14	4 16	27 14	3 16	27 14	3 16	26 14	4 16	28 15	2 15	27 16	3 14
+25% Cut-off	4	26		_	4 2		26	3	27	3	27	4	26		26	3	27	4	26
+50% Cut-off	0	30			03		30	0	30	0	30	0	30		30	0	30	0	30
+300% Cut-off	0	30	-		0 3		30	0	30	0	30	0	30	-	30	0	30	0	30
Drug		MPD		MPC		MPD		GВ		PGE		GAE		TZE			NB		AP
Concentration		150	_	300		,000	_	,000	_	500	_	2,00	_	200	_		00	-	00
Cut-off Range 0% Cut-off		0 0	⊦ -) 3		+ -) 3		- 30	+	3		-		-		+ 0	- 30	+	- 30	+
-50% Cut-off	_) 3	-			30	-	3	-	_			-	0	30	0	30	0
-25% Cut-off	_		1 2		3 2	_	25		2						-	27	3	29	1
Cut-off	_	-	5 1	_	4 1	-								_		14	16	15	15
+25% Cut-off	:		5 5	_	5 5	_	_	25	_	_			_	_	27	4	26	1	29
+50% Cut-off		_	0 0	_	0 0	_		30	_				_	_	30	0	30	0	30
+300% Cut-of	fl) 3	0 0	3	0 0	30	0 (30) () 3	0	0 3	80 (0 3	30	0	30	0	30
+50070 Out-01							-			_		T		<i>a</i> -	PVP	0	-PVI		IES
		P	TP	FI	хII	IR-1/	14 K	RA		יח		n-1			× 1.		300		
Drug	AB 10		2TP ,000	FL 50		IR-14 25		RA 800	TL 5		LSD 10		000	5	00		000	1	00
Drug	AB 10	1	,000		0	25	3	00		0	10	2,	000			_		_	
Drug Concentration Cut-off Range	AB 10	+ ·	,000	50 -)0 +	25	3	800 +	5 -	0 +	10 - +	2,	000	-	+	-	. 4		+
Drug Concentration Cut-off Range 0% Cut-off	AB 10 - 30	+ · 0 3	,000 + 0 0	50 - 30)0 + 0 3	25 30 (3 + - 0 30	800 + 0 0	5 - 30	0 + 0 3	10 - + 30 0	2, 	000 + 0	- 30	+ 0	-	· +) 30	+
Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off	AB 10 - 30 30	+ · 0 3 0 3	,000	50 - 30 30)0 + 0 3 0 3	25 30 (30 (3 + - 0 30 0 30	800 + 0 0 0 0	5 - 30 30	0 + 03	10 - + 30 0	2, 0 30 0 30	000 + 0 0	-	+ 0	- 3 3	· + 0 0) 30	+ 0 0 0 0
Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off	AB 10 - 30 30 25 15	+ · 0 3 0 3	,000 + 0 0 0 0 9 1	50 - 30 29	10 + 0 3 0 3 1 2	25 30 (30 (28 (3 30 30 2 2 2 8	800 + 0 0	5 30 30 29	0 + 03 12	10 - + 30 0 30 0 27 3	2, 30 30 30 30 30 30	0000 + 0 0 4	- 30 30	+ 0 0	3 3 3 2	- + 0 0 0 0 7 3) 30) 30) 30	+ 0 0 0 0 7 3
Drug Concentration Cut-off Range 0% Cut-off -25% Cut-off -25% Cut-off +25% Cut-off	AB 10 - 30 25 15 4	1 + · · · · · · · · · · · · · · · · · ·	,000 + 0 0 0 0 9 1 5 15 29	50 - 30 29 15 2	0 3 0 3 0 3 1 2 15 1 28	25 30 (30 (28 2 5 1 3 2	3 30 30 30 30 2 2 2 2 2 2 2 2 2 2 2 2 2	800 + 0 0 0 0 3 2 4 16 29	5 30 30 29 15 1	0 + 0 1 15 1 29	10 - + 30 0 27 3 14 10 3 2	2, 30 30 30 30 30 30 30 30 30 30 30 30 30	000 + 0 0 4 15 27	- 30 30 27 15 3	+ 0 3 15 27	3 3 2 1 1	- + 0 (0 7 (3 5 1 3 2) 30) 30 3 27 5 14 7 4	+ 0 0 7 3 4 16 26
Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +50% Cut-off	AB 10 - 30 30 25 15 4 2 0	+ · 0 3 0 3 5 2 15 1 26 1 30 0	,000 + 0 0 9 1 5 15 29 0 30	50 - 30 29 15 2 0	0 3 0 3 0 3 1 2 15 1 28 30	25 	3 3 30 3 30 2 28 5 14 7 1 0 0	800 + 0 0 0 0 3 2 4 16 29 30	5 30 30 29 15 1 0	0 + 0 3 1 2 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 3 0 3 3 3 3 3 3 3 3 3 3 3 3 3	10 - + 30 0 30 0 27 3 14 10 3 2 0 30	2, 30 30 30 30 30 30 30 30 30 30 30 30 30	000 + 0 4 15 27 30	- 30 30 27 15 3 0	+ 0 3 15 27 30	30 30 27 5 19 7 3 0 0	+ 0 (0 7 (3 5 1 3 2 0 3) 30) 30 3 27 5 14 7 4 0 0	+ 0 0 7 3 4 16 26 30
Drug Concentration Cut-off Range 0% Cut-off -25% Cut-off -25% Cut-off +25% Cut-off	AB 10 - 30 30 25 15 4 2 0	1 + · · · · · · · · · · · · · · · · · ·	,000 + 0 0 0 0 9 1 5 15 5 29 0 30	50 - 30 29 15 2 0	0 3 0 3 0 3 1 2 15 1 28 30	25 	3 30 30 30 30 2 2 2 2 2 2 2 2 2 2 2 2 2	800 + 0 0 0 0 3 2 4 16 29 30	5 30 30 29 15 1 0	0 + 0 3 1 2 3 0 3 0 3 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0	10 - + 30 0 27 3 14 10 3 2	2, 30 30 30 30 30 30 30 30 30 30 30 30 30	000 + 0 0 4 15 27	- 30 30 27 15 3	+ 0 3 15 27	30 30 27 5 19 7 3 0 0	+ 0 (0 7 (3 5 1 3 2 0 3) 30) 30 3 27 5 14 7 4	+ 0 0 7 3 4 16 26 30
Drug Concentration Cut-off Range 0% Cut-off -25% Cut-off +25% Cut-off +50% Cut-off +300% Cut-off	AB 10 30 30 25 15 4 2 0 30 0 30 0 30 25 15 15	+ - 0 3 0 3 5 2 15 1 26 1 30 (30 (,000 + 0 0 9 1 5 15 29 0 30 0 30	50 30 30 29 15 2 0 0	10 + 0 3 0 3 1 2 15 1 28 30 30	25 30 (30 (30 (30 (30 (31	3 - 30 - 30	800 + 0 0 0 0 3 2 4 16 29 30 30	5 30 30 29 15 1 0 0	0 + 0 3 1 2 1 2 9 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 3 0 3 3 3 3 3 3 3 3 3 3 3 3 3	10 - + 30 C 30 C 27 3 14 10 3 2 0 30 0 30 0 30	2, 30 30 26 26 15 7 3 0 0 0 0	0000 + 0 4 5 15 27 30 30	- 30 30 27 15 3 0 0	+ 0 3 15 27 30 30	- 30 22 5 15 7 3 0 0 0 0	0 0 0 0 0 0 7 3 5 1 3 2 0 3 0 3	 0 30 0 30 3 27 5 14 7 4 0 0 0 0	+ 0 0 7 3 4 16 26 30 30
Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off Cut-off +25% Cut-off +30% Cut-off +30% Cut-off Drug	AB 10 30 30 25 15 4 2 0 30 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0	1 + · 0 3 0 3 5 2 15 1 26 1 30 0 30 0	,000 + 0 0 9 1 5 15 5 15 29 0 30 0 30 COT	50 30 30 29 15 2 0 0	0 3 0 3 1 2 15 1 28 30 30 COT	25 30 0 30 0 28 2 5 1 3 2 0 3 0 3 0 3 CF	3 → - 0 30 0 30 2 28 5 14 7 1 0 0 0 0 0 0 	FY	5 30 30 29 15 1 0 0	0 + 0 3 1 29 30 30 2/	10 - + 30 0 27 3 14 10 3 2 0 30 0 30 0 30 AL	2, 30 30 30 30 30 30 30 30 30 30 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	000 + 0 4 5 15 27 30 30 8 0	- 30 30 27 15 3 0 0 0 TA	+ 0 3 15 27 30 30	- 31 31 22 5 11 3 7 3 0 0 0 0 0 0	- + 0 (0 7 (3 5 1) 3 (2) (3) (3) (3) (3) (3	 0 30 0 30 3 27 5 14 7 4 0 0 0 0 0 0	+ 0 0 7 3 4 16 26 30 30 30
Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off grug Concentration	AB 10 30 30 25 15 4 2 0 30 0 30 0 30 25 15 15	1 + · 0 3 0 3 5 2 15 1 26 1 30 0 30 0	,000 + 0 0 9 1 5 15 29 0 30 0 30	50 30 30 29 15 2 0 0	10 + 0 3 0 3 1 2 15 1 28 30 30	25 30 0 30 0 28 2 5 1 3 2 0 3 0 3 0 3 CF	3 - 30 - 30	800 + 0 0 0 0 3 2 4 16 29 30 30	5 30 30 29 15 1 0 0	0 + 0 3 1 29 30 30 2/	10 - + 30 C 30 C 27 3 14 10 3 2 0 30 0 30 0 30	2, 30 30 26 26 15 7 3 0 0 0 0	000 + 0 4 5 15 27 30 30 8 0	- 30 30 27 15 3 0 0	+ 0 3 15 27 30 30	- 31 31 22 5 11 3 7 3 0 0 0 0 0 0	0 0 0 0 0 0 7 3 5 1 3 2 0 3 0 3	 0 30 0 30 3 27 5 14 7 4 0 0 0 0 0 0	+ 0 0 7 3 4 16 26 30 30
Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off Drug Concentration Cut-off Range	AB 10 30 30 25 15 4 2 0 30 25 0 30 25 0 30 25 0 30 25 0 30 25 0 30 25 0 30 25 0 30 30 25 5 0 30 30 25 5 0 30 30 30 30 30 30 30 30 30 30 30 30 3	1 + - 0 3 0 3 5 2 15 1 26 1 30 (30 (T)	,000 + 0 0 9 1 5 15 5 15 29 0 30 0 30 COT	50 - 30 30 29 15 2 0 0 0	0 3 0 3 1 2 15 1 28 30 30 COT	25 30 0 30 0 28 2 5 1 3 2 0 3 0 3 0 3 CF	3 → - 0 30 0 30 2 28 5 14 7 1 0 0 0 0 0 0 	FY	5 30 30 29 15 1 0 0	0 + 0 3 1 29 30 30 2/	10 - + 30 0 27 3 14 10 3 2 0 30 0 30 0 30 AL	2, 30 30 30 30 30 30 30 30 30 30 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	000 + 0 4 5 15 27 30 30 8 0	- 30 30 27 15 3 0 0 0 TA	+ 0 3 15 27 30 30	- 31 31 22 5 11 3 7 3 0 0 0 0 0 0	- + 0 (0 7 (3 5 1) 3 (2) (3) (3) (3) (3) (3	 0 30 0 30 3 27 5 14 7 4 0 0 0 0 0 0	+ 0 0 7 3 4 16 26 30 30 30
Drug Concentration Cut-off Range 0% Cut-off -25% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off	AB 10 30 25 15 4 25 0 30 0 500 - 30	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	,000 + 0 0 9 1 5 15 29 0 30 0 30 0 30 0 30 0 30 - - + 0 0 0 0 0 0 0 0 0 0 0 0 0 0	50 - 30 30 29 15 2 0 0 0 -	0 3 + 0 3 1 2 15 1 28 30 30 COT 10 + 0 0 0 3 0 3 0 3 0 3 0 3 0 3 0 3	25 	3 + - 3 30 3 30 2 28 5 14 7 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	600 + 0 0 0 0 0 0 3 2 4 16 29 30 30 30 FY 20 - 30	50 - 30 30 29 15 1 0 0 - - - - - - - - - - - - - - - - -	0 + 0 3 0 3 1 2 9 30 30 2 / 1 1 2 9 30 30 - 30	10 - ++ 80 C 80 C 27 3 14 10 3 2 0 30 0 30 AL 00 + 0	2, 30 30 30 30 30 30 0 0 0 0 0 0 0 0 0 0	+ 0 1 0 1 1 0 1 1 5 27 30 30 30 30 + 0 0 +	- 30 27 15 3 0 0 0 TA 1,00 - 30	+ 0 3 15 27 30 30 30 9 0 0 + 0		+ 0 (0 0 (0 7 3 5 1 3 2 0 3 0 3 CIT 00 + 0) 30) 30 3 27 5 12 7 4 0 0 0 0 0 0 FH 1,1 - 30	+ 0 0 7 3 4 16 26 30 30 30 ET 000 + 0
Drug Concentration Cut-off Range -50% Cut-off -25% Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Concentration Cut-off Range 0% Cut-off -50% Cut-off	AB 10 30 30 25 15 4 2 5 0 30 500 - 30 30	1 1 +	,000 + 0 0 9 1 5 15 29 0 30 0 30 0 30 0 30 0 30 0 - + 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	500 300 299 155 2 0 0 0 0 0 0 0 0 300 300 300 300 300 3	0 1 0 3 1 2 15 1 28 30 300 30 COTT 10 + 0 0 0 10 0	25 30 (28 2 5 1 3 2 5 1 3 2 5 1 3 2 2 5 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 3 0 3 3 0 3 3 0 3 3 0 3 3 0 3 3 3 3 3 3 3 3 3 3 3 3 3	3 + - 3 30 3 30 2 28 5 14 7 1 0 0 0 0 − + 0 0 0	600 + 0 0 0 0 3 2 4 16 29 30 30 - 30 30 30	50 - 30 30 29 15 1 0 1 0 - 1 0 - 1 0 - - - - - - - - - - - - -	0 + 0 0 1 29 30 30 30 - 30 30 30	10 - + 80 C 80 C 27 3 14 10 3 2 14 10 3 2 0 30 0 30 - - - - - - + 0 0 0 0 - - - - - - - - - - - - -	2, 30 30 30 26 15 7 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0000 + 0 1 1 0 1 1 5 1 5 27 30 30 30 30 0 0 + 0 0	- 30 27 15 3 0 0 0 TA 1,00 - 30 30	+ 0 3 15 27 30 30 30 + 0 0	- 30 2 11 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	 + 0 0 0 7 3 2 3 3 3 3 3 	+ -) 3()	+ 0 0 0 0 0 1 3 0 0 0 0 0 0 0 0 0 0 0 0 0
Drug Concentration Cut-off Range -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off	AB 10 30 30 25 15 4 2 0 30 30 500 - 500 - 500 - 30 30 26	1 1 +	,000 + 0 0 0 0 9 1 5 15 29 0 30 0 30 0 30 0 30 - + 0 0 0 0 0 7 3	50 30 29 15 2 0 0 0 - 30 - 30 29 15 2 0 0 0 - 30 29 15 2 0 0 0 2 - - - - - - - - - - - - -	0	25 	3 + - 0 300 300 2 28 5 14 7 1 0 0 0 0 5 - + 0 5 - - - - - - - - - - - - -	600 + 0 0 0 0 0 0 0 0 0 0 0 0 0 0	50 - 30 30 29 15 1 0 - L 0 + 0 3 - - - - - - - - - - - - -	0 + 0 3 1 29 30 30 30 - 30 30 27	10 - + 30 0 30 0 27 3 4 10 3 2 0 30 0 30 0 30 AL 00 4 0 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 0 0 3 0 0 3 0 0 3 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0	2, 30 26 126 15 7 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0000 + 0 1 1 1 1 1 2 7 30 30 30 30 0 0 + 0 0 3	- 30 27 15 3 0 0 0 1,00 - 30 30 27	+ 0 3 15 27 30 30 30 + 0 0 3		+ 0 0 0 0 0 0 0 0 0 0 0 0 0	+ -) 30) 30) 30) 30) 30) 30) 10) 10]	+ 0 0 0 1 1 6 2 6 3 0 3 0 5 5 5 5 5 5 5 5 5 5 5 5 5
Drug Concentration Cut-off Range 0% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off Drug Concentration Cut-off Range 0% Cut-off -50% Cut-off Cut-off	AB 10 30 30 25 15 4 2 0 30 0 30 500 500 - 30 30 26 14	1 + 0 30 35 20 35 215 115 126 130 (0) 300 (1) + + 0 30 0 33 4 21 16	,000 + 0 0 0 0 9 1 5 15 29 0 300 0 300 - + 0 0 0 0 0 0 0 0 0 0 0 0 0 0	500 - 300 299 155 2 0 0 0 - 300 - - 300 - - 300 - - - - - - - - - - - - -	0 + 0 3 1 2 30 30 30 30 COT 10 + 0 0 30 0 30 0 30 0 7 30 10	25 	3 + - 0 300 300 2 28 5 14 7 1 0 0 0 0 5 16 - - - - - - - - - - - - -	300 + 0 0 0 0 0 0 0 0 0 0 0 0 0 10 10 10 10 10 10	50 - 30 30 29 15 1 0 - L 0 - - - - - - - - - - - - -	0 + 0 3 0 3 1 2 2 9 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 2 7 15	10 - + 30 0 30 0 27 3 30 0 30	2, 300 300 300 300 00 00 30 27 15	000 + 0 1 1 27 30 30 30 30 + 0 0 1 5	- 30 30 27 15 3 0 0 0 7 15 30 30 27 15	+ 0 3 15 27 30 30 30 9 0 0 4 0 0 3 15	- 30 2 11 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	+ 4 0 0 0 0 7 3 5 1 3 2 0 3 0 3 0 0 + 0 0 3 15	+ -) 300) 30) 30) 30 3 27 5 12 7 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	+ 0 0 0 0 1 1 6 2 6 3 0 3 0 0 0 1 5 1
Drug Concentration Cut-off Range -50% Cut-off -25% Cut-off +25% Cut-off +300% Cut-off +300% Cut-off -25% Cut-off -50% Cut-off -25% Cut-off -25% Cut-off +25% Cut-off	AB 10 30 30 25 4 25 4 2 0 30 500 500 - 500 - 500 - 14 3 3 2 6 14 3 2 2 3 2 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3	1 + 0 30 35 20 35 215 115 130 (0) 300 (1)	,000 + 0 0 0 0 9 1 5 15 29 0 30 0 30 0 30 0 30 - + 0 0 0 0 0 7 3	50 - 30 29 15 2 0 0 0 - 30 29 15 2 0 0 0 - 30 29 15 2 0 0 0 - - 30 - - - - - - - - - - - - -	00 + 0 3 0 3 1 2 15 1 28 30 30 30 COT 10 + 0 0 0 0 7 3 5 15 26	25 	3 + - 0 300 300 2 28 5 14 7 1 0 0 0 0 5 - + 0 5 - - - - - - - - - - - - -	800 + 0 0 0 0 0 0 3 2 4 16 29 30 30 30 30 - - - 30 30 27 15 3	50 - 30 30 29 15 1 0 - L 0 + 0 3 - - - - - - - - - - - - -	0 + 0 3 1 29 30 30 30 - 30 30 27	10 - + 30 0 30 0 27 3 4 10 3 2 0 30 0 30 0 30 AL 00 4 0 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 0 0 3 0 0 3 0 0 3 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0	2, 30 26 126 15 7 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0000 + 0 1 1 1 1 1 2 7 30 30 30 30 0 0 + 0 0 3	- 30 30 27 15 3 0 0 0 0 7 15 30 30 27 15 4	+ 0 3 15 27 30 30 30 + 0 0 3		+ 0 0 0 0 0 0 0 0 0 0 0 0 0	+ -) 300) 30) 30) 30 3 27 5 12 7 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	+ 0 0 0 1 1 6 2 6 3 0 3 0 5 5 5 5 5 5 5 5 5 5 5 5 5

+300% Cut-off 0 30 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0

Drug Concentration Cut-off Range		PD 50	SC 50			ND)00	M 50		OZ 1,0			ES DO
	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	27	3	26	4	27	3	27	3	27	3	27	3
Cut-off	15	15	14	16	15	15	15	15	14	16	14	16
+25% Cut-off	4	26	3	27	4	26	4	26	4	26	4	26
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30

Analytical Specificity The following table lists the concentrations of compounds (ng/mL) that are detected as positive in urine by the Multi-Drug Rapid Test at 5 minutes.

Analytes	conc. (ng/mL)	-	conc. (ng/mL)
	ACETAMINOPH	EN (ACE 5,000)	
Acetaminophen	5,000		
	AMPHETAMINE		
D,L-Amphetamine sulfate	300	Phentermine	1,000
L-Amphetamine	25,000	Maprotiline	50,000
(±) 3,4-Methylenedioxy	500	Methoxyphenamine	6,000
amphetamine		D-Amphetamine	1,000
	AMPHETAMIN		
D,L-Amphetamine sulfate	150	Phentermine	500
L-Amphetamine	12,500	Maprotiline	25,000
(±) 3,4-Methylenedioxy	250	Methoxyphenamine	3,000
amphetamine		D-Amphetamine	500
	AMPHETAMIN		
D,L-Amphetamine sulfate	75	Phentermine	300
L-Amphetamine	10,000	Maprotiline	15,000
(±) 3,4-Methylenedioxy	150	Methoxyphenamine	2,000
amphetamine		D-Amphetamine	300
	BARBITURAT		
Amobarbital	5,000	Alphenol	600
5,5-Diphenylhydantoin	8,000	Aprobarbital	500
Allobarbital	600	Butabarbital	200
Barbital	8,000	Butalbital	8,000
Talbutal	200	Butethal	500
Cyclopentobarbital	30,000	Phenobarbital	300
Pentobarbital	8,000	Secobarbital	300
	BARBITURATI	S (BAR 200)	
Amobarbital	3,000	Alphenol	400
5,5-Diphenylhydantoin	5,000	Aprobarbital	300
Allobarbital	400	Butabarbital	150
Barbital	5,000	Butalbital	5,000
Talbutal	150	Butethal	300
Cyclopentobarbital	20,000	Phenobarbital	200
Pentobarbital	5,000	Secobarbital	200
	BENZODIAZEPII	NES (BZO 500)	
Alprazolam	200	Bromazepam	1,500
a-hydroxyalprazolam	2,500	Chlordiazepoxide	1,500
Clobazam	300	Nitrazepam	300
Clonazepam	800	Norchlordiazepoxide	200
Clorazepatedipotassium	800	Nordiazepam	1,500
Delorazepam	1,500	Oxazepam	500
Desalkylflurazepam	300	Temazepam	300
Flunitrazepam	300	Diazepam	500
(±) Lorazepam	5.000	Estazolam	10,000
RS-Lorazepamglucuronide	300	Triazolam	5.000
Midazolam	10,000		0,000
	BENZODIAZEPI	NES (BZO 300)	1
Alprazolam	100	Bromazepam	900
a-hydroxyalprazolam	1,500	Chlordiazepoxide	900
Clobazam	200	Nitrazepam	200
Clonazepam	500	Norchlordiazepoxide	100
Clorazepatedipotassium	500	Nordiazepam	900
Delorazepam	900	Oxazepam	300
Desalkylflurazepam	200	Temazepam	100
Flunitrazepam	200	Diazepam	300
	200	LIUZOPAIII	500

RS-Lorazepamglucuronide	200	Triazolam	3,000
Midazolam	6,000		-,
	ENZODIAZEPIN		
Alprazolam	70	Bromazepam	600
a-hydroxyalprazolam	1,000	Chlordiazepoxide	600
Clobazam	120	Nitrazepam	120
Clonazepam	300	Norchlordiazepoxide	70
Clorazepatedipotassium	300	Nordiazepam	600
Delorazepam	600 120	Oxazepam	200 70
Desalkylflurazepam	120	Temazepam Diazepam	200
Flunitrazepam (±) Lorazepam	2,000	Estazolam	4,000
RS-Lorazepamglucuronide	120	Triazolam	2.000
Midazolam	4.000	Thazolam	2,000
	ENZODIAZEPIN	ES (BZO 100)	
Alprazolam	40	Bromazepam	300
a-hydroxyalprazolam	500	Chlordiazepoxide	300
Clobazam	60	Nitrazepam	60
Clonazepam	150	Norchlordiazepoxide	40
Clorazepatedipotassium	150	Nordiazepam	300
Delorazepam	300	Oxazepam	100
Desalkylflurazepam	60	Temazepam	40
Flunitrazepam	60	Diazepam	100
(±) Lorazepam	1,000	Estazolam	2,000
RS-Lorazepamglucuronide	60	Triazolam	1,000
Midazolam	2,000		
	BUPRENORPHI		
Buprenorphine	10	Norbuprenorphine	50
Buprenorphine 3-D-Glucuronide	50	Norbuprenorphine	100
	DUDDENODDU	3-D-Glucuronide	
Buprenorphine	BUPRENORPHI		25
Buprenorphine 3-D-Glucuronide	5 25	Norbuprenorphine Norbuprenorphine	25 50
Baprenorphine 3-D-Glacaronide	25	3-D-Glucuronide	50
	COCAINE (C		
Benzoylecgonine	300	Cocaethylene	20,000
Cocaine HCI	200	Ecgonine	30,000
	COCAINE (C		
Benzoylecgonine		Cocaethylene	13,500
Cocaine HCI	135	Ecgonine	20,000
	COCAINE (C	OC 150)	
Benzoylecgonine	150	Cocaethylene	1,0000
Cocaine HCI		Ecgonine	15,000
	COCAINE (C		
Benzoylecgonine	100	Cocaethylene	7,000
Cocaine HCI	80	Ecgonine	10,000
- · · ·	MARIJUANA (
	200,000	∆ ⁸ -THC	100,000
11-nor-△ ⁸ -THC-9 COOH	200	∆ ⁹ -THC	100,000
11-nor-∆ ⁹ -THC-9 COOH	300	(7110.000)	
O a sea a bia a l	MARIJUANA (50.000
	140,000	⊿ ⁸ -THC ⊿ ⁹ -THC	50,000
11-nor-∆ ⁸ -THC-9 COOH 11-nor-∆ ⁹ -THC-9 COOH	120 120	A -THC	50,000
11-1101-2 - THC-9 COOH	MARIJUANA ((THC 150)	
Cannabinol	100,000		50,000
11-nor-∆ ⁸ -THC-9 COOH	100,000	∆ ⁸ -THC ∆ ⁹ -THC	50,000
11-nor-∆9-THC-9 COOH	150	A -1110	50,000
	MARIJUANA	(THC 50)	
Cannabinol	35,000	∆ ⁸ -THC	17,000
11-nor-∆ ⁸ -THC-9 COOH	30	△ ⁹ -THC	17,000
11-nor-∆9-THC-9 COOH	50		
	MARIJUANA	(THC 30)	•
Cannabinol	20,000	∆ ⁸ -THC	10,000
11-nor-△ ⁸ -THC-9 COOH	20	∆ ⁹ -THC	10,000
11-nor-∆9-THC-9 COOH	30		
	MARIJUANA		
		∆ ⁸ -THC	8,500
Cannabinol	17,500		
11-nor-∆ ⁸ -THC-9 COOH	15	⊿ ⁹ -THC	8,500
	15 25	∆ ⁹ -THC	8,500
11-nor-∆ ⁸ -THC-9 COOH 11-nor-∆9-THC-9 COOH	15 25 MARIJUANA	∆ ⁹ -ТНС (ТНС 20)	
11-nor-∆ ⁸ -THC-9 COOH 11-nor-∆9-THC-9 COOH Cannabinol	15 25 MARIJUANA 14,000	∆ ⁹ -THC (THC 20) ∆ ⁸ -THC	6,800
11-nor-∆ ⁸ -THC-9 COOH 11-nor-∆9-THC-9 COOH Cannabinol 11-nor-∆ ⁸ -THC-9 COOH	15 25 MARIJUANA 14,000 12	∆ ⁹ -ТНС (ТНС 20)	
11-nor-∆ ⁸ -THC-9 COOH 11-nor-∆9-THC-9 COOH Cannabinol	15 25 MARIJUANA 14,000	Δ ⁹ -THC (THC 20) Δ ⁸ -THC Δ ⁹ -THC	6,800

Methadone	300	Doxylamine	100,000
	METHADONE		
Methadone	200	Doxylamine	65,000
	THAMPHETAMI	(±)-3,4-Methylenedioxy-	1600
p-Hydroxymethamphetamine D-Methamphetamine	25,000 1,000	(±)-3,4-methylenedioxy-	1600
L-Methamphetamine	20,000	Mephentermine	50,000
	ETHAMPHETAN		50,000
p-Hydroxymethamphetamine	12,500	(±)-3,4-Methylenedioxy-	800
D-Methamphetamine	500	methamphetamine	
L-Methamphetamine	10,000	Mephentermine	25,000
	ETHAMPHETAN		
o-Hydroxymethamphetamine	7,500	(±)-3,4-Methylenedioxy-	500
D-Methamphetamine	300	methamphetamine	15.000
L-Methamphetamine		Mephentermine AMINE (MDMA 1, 000) Ecstas	15,000
(±) 3,4-Methylenedioxy-		3,4-Methylenedioxyethyl-	
methamphetamine HCI	1,000	amphetamine	600
(±) 3,4-Methylenedioxyampheta	6,000		
mine HCI			
	XYMETHAMPHE	TAMINE (MDMA 500) Ecstasy	·
(±) 3,4-Methylenedioxy-	500	3,4-Methylenedioxyethyl-	300
methamphetamine HCI (±) 3,4-Methylenedioxyampheta	1	amphetamine	+
mine HCI	3,000		
	XYMETHAMPHE	TAMINE (MDMA 300) Ecstasy	
(±) 3,4-Methylenedioxy-	300	3,4-Methylenedioxyethyl-	180
methamphetamine HCI	500	amphetamine	100
(±) 3,4-Methylenedioxyampheta	1,800		
mine HCI	MORPHINE (MO	2B/OBI 200)	
Codeine	200	Norcodeine	6,000
Levorphanol	1,500	Normorphone	50,000
Morphine-3-β-D-Glucuronide	800	Oxycodone	30,000
Ethylmorphine	6,000	Oxymorphone	50,000
Hydrocodone	50,000	Procaine	15,000
Hydromorphone	3,000	Thebaine	6,000
6-Monoacethylmorphine	300	Morphine	300
	MORPHINE (M	,	
Codeine	160	Norcodeine	4,000
Levorphanol	1,000	Normorphone	40,000
Morphine-3-β-D-Glucuronide Ethylmorphine	600 4,000	Oxycodone	20,000 40,000
Hydrocodone	40,000	Oxymorphone Procaine	40,000
Hydromorphone	2,000	Thebaine	4,000
6-Monoacethylmorphine	200	Morphine	200
	MORPHINE (M		
Codeine	80	Norcodeine	2,000
Levorphanol	500	Normorphone	20,000
Morphine-3-β-D-Glucuronide	300	Oxycodone	10,000
Ethylmorphine	2,000	Oxymorphone	20,000
Hydrocodone	20,000	Procaine	5,000
Hydromorphone	1,000	Thebaine	2,000
6-Monoacethylmorphine	200 METHAQUALON	Morphine	100
Methaqualone	300		
	IORPHINE/OPIA	TE (OPI 2,000)	
Codeine	2,000	Morphine	2,000
	3,000	Norcodeine	25,000
			50,000
Hydrocodone	50,000	Normorphone	
Hydrocodone Hydromorphone	50,000 15,000	Oxycodone	25,000
Hydrocodone Hydromorphone Levorphanol	50,000 15,000 25,000	Oxycodone Oxymorphone	25,000 25,000
Hydrocodone Hydromorphone Levorphanol S-Monoacetylmorphine	50,000 15,000 25,000 3,000	Oxycodone Oxymorphone Procaine	25,000 25,000 50,000
Hydrocodone Hydromorphone Levorphanol δ-Monoacetylmorphine Morphine 3-β-D-glucuronide	50,000 15,000 25,000 3,000 2,000	Oxycodone Oxymorphone Procaine Thebaine	25,000 25,000
Hydrocodone Hydromorphone _evorphanol 6-Monoacetylmorphine Morphine 3-β-D-glucuronide Ν	50,000 15,000 25,000 3,000 2,000 IORPHINE/OPIA	Oxycodone Oxymorphone Procaine Thebaine TE (OPI 1,000)	25,000 25,000 50,000 25,000
Hydrocodone Hydromorphone _evorphanol 3-Monoacetylmorphine Morphine 3-β-D-glucuronide N Codeine	50,000 15,000 25,000 3,000 2,000 IORPHINE/OPIA 1,000	Oxycodone Oxymorphone Procaine Thebaine TE (OPI 1,000) Morphine	25,000 25,000 50,000 25,000 1,000
Hydrocodone Hydromorphone Levorphanol 5-Monoacetylmorphine Morphine 3-β-D-glucuronide N Codeine Ethylmorphine	50,000 15,000 25,000 3,000 2,000 IORPHINE/OPIA 1,000 1,500	Oxycodone Oxymorphone Procaine Thebaine TE (OPI 1,000)	25,000 25,000 50,000 25,000
Hydrocodone Hydromorphone Levorphanol 5-Monoacetylmorphine Morphine 3-β-D-glucuronide Morphine Ethylmorphine Hydrocodone	50,000 15,000 25,000 3,000 2,000 IORPHINE/OPIA 1,000	Oxycodone Oxymorphone Procaine Thebaine TE (OPI 1,000) Morphine Norcodeine	25,000 25,000 50,000 25,000 1,000 12,500
Hydrocodone Hydromorphone Levorphanol δ-Monoacetylmorphine Morphine 3-β-D-glucuronide Codeine Ethylmorphine Hydrocodone Hydrocodone	50,000 15,000 25,000 2,000 2,000 IORPHINE/OPIA' 1,000 1,500 25,000	Oxycodone Oxymorphone Procaine Thebaine TE (OPI 1,000) Morphine Norcodeine Normorphone	25,000 25,000 50,000 25,000 1,000 12,500 25,000
Codeine Ethylmorphine Hydrocodone Hydromorphone evorphanol 5-Monoacetylmorphine	50,000 15,000 25,000 2,000 ORPHINE/OPIA 1,000 1,500 25,000 7,500 12,500 1,500	Oxycodone Oxymorphone Procaine Thebaine TE (OPI 1,000) Morphine Norcodeine Normorphone Oxycodone Oxymorphone Procaine	25,000 25,000 50,000 25,000 12,500 25,000 12,500 12,500 12,500 25,000
Hydrocodone Hydrocodone Levorphanol 6-Monoacetylmorphine Morphine 3-β-D-glucuronide Codeine Ethylmorphine Hydrocodone Hydrocodone Levorphanol	50,000 15,000 25,000 2,000 2,000 IORPHINE/OPIA 1,000 1,500 25,000 12,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500	Oxycodone Oxymorphone Procaine Thebaine TE (OPI 1,000) Morphine Norcodeine Normorphone Oxycodone Oxymorphone Procaine Thebaine	25,000 25,000 50,000 25,000 1,000 12,500 25,000 12,500 12,500
Hydrocodone Hydromorphone Levorphanol S-Monoacety/morphine Morphine 3-β-D-glucuronide M Codeine Ethylmorphine Hydrocodone Hydromorphone Levorphanol 3-Monoacety/morphine	50,000 15,000 25,000 2,000 ORPHINE/OPIA 1,000 1,500 25,000 7,500 12,500 1,500	Oxycodone Oxymorphone Procaine Thebaine TE (OPI 1,000) Morphine Norcodeine Normorphone Oxycodone Oxymorphone Procaine Thebaine	25,000 25,000 50,000 25,000 12,500 25,000 12,500 12,500 12,500 25,000

Phencyclidine	50	4-Hydroxyphencyclidine	25,000
	PHENCYCLIDIN		,
Phencyclidine	25	4-Hydroxyphencyclidine	12,500
	PROPOXYPHEN		
D-Propoxyphene		D-Norpropoxyphene SSANTS (TCA 1,000)	300
Nortriptyline	1,000	Imipramine	400
Nordoxepine	500	Clomipramine	50,000
Trimipramine	3,000	Doxepine	2,000
Amitriptyline	1,500	Maprotiline	2,000
Promazine	3,000	Promethazine	50,000
Desipramine	200	Perphenazine	50,000
Cyclobenzaprine		Dithiaden SSANTS (TCA 500)	10,000
Nortriptyline	500	Imipramine	200
Nordoxepine	250	Clomipramine	25,000
Trimipramine	1,500	Doxepine	1,000
Amitriptyline	750	Maprotiline	1,000
Promazine	1,500	Promethazine	25,000
Desipramine	100	Perphenazine	25,000
Cyclobenzaprine	1,000	Dithiaden	5,000
		SSANTS (TCA 300)	100
Nortriptyline Nordoxepine	300 150	Imipramine Clomipramine	120 15,000
Trimipramine	900	Doxepine	15,000 600
Amitriptyline	450	Maprotiline	600
Promazine	900	Promethazine	15,000
Desipramine	60	Perphenazine	15,000
Cyclobenzaprine	600	Dithiaden	3,000
-	TRAMADOL (
n-Desmethyl-cis-tramadol	200	o-Desmethyl-cis-tramadol	10,000
Cis-tramadol Procyclidine	100 100,000	Phencyclidine d,I-O-Desmethyl venlafaxine	100,000 50,000
Flocyclidine	TRAMADOL (50,000
n-Desmethyl-cis-tramadol	400	o-Desmethyl-cis-tramadol	20,000
Cis-tramadol	200	Phencyclidine	200,000
Procyclidine	200,000	d,I-O-Desmethyl venlafaxine	100,000
	TRAMADOL (
n-Desmethyl-cis-tramadol	600	o-Desmethyl-cis-tramadol	30,000
Cis-tramadol	300	Phencyclidine	300,000
Procyclidine	300,000	d,I-O-Desmethyl venlafaxine	150,000
n-Desmethyl-cis-tramadol	TRAMADOL (1000	o-Desmethyl-cis-tramadol	50,000
Cis-tramadol	500	Phencyclidine	500,000
Procyclidine	500,000	d,I-O-Desmethyl venlafaxine	250,000
2	KETAMINE (K		
Ketamine	1,000	Benzphetamine	25,000
Dextromethorphan	2,000	(+) Chlorpheniramine	25,000
Methoxyphenamine	25,000	Clonidine	100,000
d-Norpropoxyphene	25,000	EDDP 4. Hydroxyphongycliding	50,000
Promazine Promethazine	25,000 25,000	4-Hydroxyphencyclidine Levorphanol	50,000 50,000
Pentazocine	25,000	MDE	50,000
Phencyclidine	25,000	Meperidine	25,000
Tetrahydrozoline	500	d-Methamphetamine	50,000
. Stanya ozonno			50,000
Mephentermine	25,000	I-Methamphetamine	
	25,000 100,000	3,4-Methylendioxymethamphet	
Mephentermine (1R, 2S) - (-)-Ephedrine	100,000	3,4-Methylendioxymethamphet amine (MDMA)	100,000
Mephentermine (1R, 2S) - (-)-Ephedrine	100,000 25,000	3,4-Methylendioxymethamphet amine (MDMA) Thioridazine	
Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide	100,000 25,000 KETAMINE (I	3,4-Methylendioxymethamphet amine (MDMA) Thioridazine KET 500)	100,000 50,000
Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine	100,000 25,000 KETAMINE (I 500	3,4-Methylendioxymethamphet amine (MDMA) Thioridazine KET 500) Benzphetamine	100,000 50,000 12,500
Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan	100,000 25,000 KETAMINE (1 500 1,000	3,4-Methylendioxymethamphet amine (MDMA) Thioridazine KET 500)	100,000 50,000 12,500 12,500
Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine	100,000 25,000 KETAMINE (I 500	3,4-Methylendioxymethamphet amine (MDMA) Thioridazine KET 500) Benzphetamine (+) Chlorpheniramine	100,000 50,000 12,500
Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine	100,000 25,000 KETAMINE (I 500 12,500 12,500 12,500	3,4-Methylendioxymethamphet amine (MDMA) Thioridazine KET 500) Benzphetamine (+) Chlorpheniramine Clonidine	100,000 50,000 12,500 12,500 50,000 25,000 25,000
Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine	100,000 25,000 KETAMINE (1 500 12,500 12,500 12,500 12,500	3,4-Methylendioxymethamphet amine (MDMA) Thioridazine KET 500) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol	100,000 50,000 12,500 12,500 50,000 25,000 25,000 25,000
Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine	100,000 25,000 KETAMINE (1 500 12,500 12,500 12,500 12,500 12,500 12,500	3,4-Methylendioxymethamphet amine (MDMA) Thioridazine KET 500 Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE	100,000 50,000 12,500 50,000 25,000 25,000 25,000 25,000
Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promethazine Promethazine Pentazocine Phencyclidine	100,000 25,000 KETAMINE (1 500 1,000 12,500 12,500 12,500 12,500 12,500 12,500 12,500	3,4-Methylendioxymethamphet amine (MDMA) Thioridazine KET 500) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine	100,000 50,000 12,500 50,000 25,000 25,000 25,000 25,000 25,000 12,500
Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine Phencyclidine Tetrahydrozoline	100,000 KETAMINE (500 1,000 12,500 12,500 12,500 12,500 12,500 12,500 12,500 250	3,4-Methylendioxymethamphet amine (MDMA) Thioridazine KET 500) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE MDE Meperidine d-Methamphetamine	100,000 12,500 12,500 50,000 25,000 25,000 25,000 12,500 12,500 25,000
Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine Phencyclidine Tetrahydrozoline Mephentermine	100,000 KETAMINE (500 1,000 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500	3,4-Methylendioxymethamphet amine (MDMA) Thioridazine KET 500) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine d-Methamphetamine -Methamphetamine	100,000 50,000 12,500 50,000 25,000 25,000 25,000 12,500 25,000 25,000 25,000 25,000
Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine	100,000 25,000 KETAMINE (1 500 1,000 12,500 12,500 12,500 12,500 12,500 12,500 250 12,500 50,000	3,4-Methylendioxymethamphet amine (MDMA) Thioridazine KET 500) Benzphetamine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE Meperidine d-Methamphetamine 1-Methamphetamine 3,4-Methylendioxymethamphet amine (MDMA)	100,000 50,000 12,500 50,000 25,000 25,000 25,000 25,000 12,500 12,500 25,000 50,000
Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promethazine Promethazine Pentazocine Phencyclidine Tetrahydrozoline Mephentermine (1R, 2S) - (-)-Ephedrine	100,000 KETAMINE (500 1,000 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500 12,500	3,4-Methylendioxymethamphet amine (MDMA) Thioridazine KET 500) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE MDE Meperidine d-Methamphetamine -Methamphetamine 3,4-Methylendioxymethamphet amine (MDMA) Thioridazine	100,000 50,000 12,500 50,000 25,000 25,000 25,000 12,500 25,000 25,000 25,000 25,000
Mephentermine (1R, 2S) - (-)-Ephedrine Disopyramide Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Phenoyclidine Tetrahydrozoline Mephentermine	100,000 25,000 KETAMINE (1 500 1,000 12,500 12,500 12,500 12,500 12,500 12,500 250 12,500 50,000	3,4-Methylendioxymethamphet amine (MDMA) Thioridazine KET 500) Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE MDE Meperidine d-Methamphetamine -Methamphetamine 3,4-Methylendioxymethamphet amine (MDMA) Thioridazine	100,000 50,000 12,500 50,000 25,000 25,000 25,000 25,000 12,500 12,500 25,000 50,000

Dextromethorphan	600	(+) Chlorpheniramine	6,250
Methoxyphenamine	6,250	Clonidine	30,000
d-Norpropoxyphene Promazine	6,250 6,250	EDDP 4-Hydroxyphencyclidine	15,000 15,000
Promethazine	6,250	Levorphanol	15,000
Pentazocine	6,250	MDE	15,000
Phencyclidine	6,250	Meperidine	6,250
Tetrahydrozoline	150	d-Methamphetamine	15,000
Mephentermine	6,250	I-Methamphetamine	15,000
(1R, 2S) - (-)-Ephedrine	30,000	3,4-Methylendioxymethamphe tamine (MDMA)	∋- 30,000
Disopyramide	6,250	Thioridazine	15,000
		IE (KET 100)	
Ketamine	100	Benzphetamine	2,000
Dextromethorphan	200	(+) Chlorpheniramine	2,000
Methoxyphenamine	2,000	Clonidine EDDP	10,000
d-Norpropoxyphene Promazine	2,000		5,000 5,000
Promazine	2,000	4-Hydroxyphencyclidine Levorphanol	5,000
Pentazocine	2,000	MDE	5,000
Phencyclidine	2,000	Meperidine	2,000
Tetrahydrozoline	50	d-Methamphetamine	5,000
Mephentermine	2,000	I-Methamphetamine	5,000
(1R, 2S) - (-)-Ephedrine	10,000	Thioridazine	5,000
Disopyramide	2,000	3,4-Methylendioxymethamphe	
		tamine (MDMA)	
	OXYCODO	NE (OXY 300)	
Oxycodone	300	Hydromorphone	150,000
Oxymorphone	900	Naloxone	75,000
Levorphanol	15,000	Naltrexone	75,000
Hydrocodone	75,000		
		NE (OXY 100)	
Oxycodone	100	Hydromorphone	50,000
Oxymorphone Levorphanol	300	Naloxone Naltrexone	25,000 25,000
Hydrocodone	50,000 25,000	Nattiexone	25,000
riydrocodone		E (COT 300)	
(-)-Cotinine	300	(-)-Nicotine	7,500
		E (COT 200)	1,000
(-)-Cotinine	200	(-)-Nicotine	5,000
	Cotinine	e (COT 100)	
(-)-Cotinine	100	(-)-Nicotine	2,500
	Cotinine	e (COT 500)	
(-)-Cotinine	500	(-)-Nicotine	12,500
		e (COT 50)	
(-)-Cotinine	50	(-)-Nicotine	1,250
		e (COT 10)	050
(-)-Cotinine		(-)-Nicotine DIPHENYLPYRROLIDINE (EDDI	250 B 200)
2-Ethylidene-1,5-dimethyl-3,3			300
		DIPHENYLPYRROLIDINE (EDDI	
2-Ethylidene-1,5-dimethyl-3,3			100
		(L (FYL 300)	100
Fentanyl	100	Buspirone	80,000
Norfentanyl	10	Sufentanyl	50,000
Fenfluramine	25,000	Alfentanyl	300,000
	FENTAN	/L (FYL 200)	
Alfentanyl	>600,000	Buspirone	30,000
Fenfluramine	100,000	Fentanyl	200
Norfentanyl	40	Sufentanyl	100,000
		/L (FYL 100)	
Alfentanyl	600,000	Buspirone	15,000
Fenfluramine	50,000	Fentanyl	100
Norfentanyl	20 FENTAN	Sufentanyl YL (FYL 20)	50,000
Alfentanyl	600.000	Buspirone	15,000
Fenfluramine	50,000	Fentanyl	100
Norfentanyl	20	Sufentanyl	50,000
paliperidone	1,250	Risperidone	5,000
		YL (FYL 10)	
Alfentanyl	300,000	Buspirone	8,000
Fenfluramine	25,000	Fentanyl	50
Norfentanyl	10	Sufentanyl	25,000
paliperidone	500	Risperidone	2,500
	SYNTHETIC MA	ARIJUANA (K2-50)	
-		: /	

	- I		
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl	50 400	JWH-073 4-butanoic acid	50 500
IWH-073 4-Hydroxybuty	500	JWH-018 5-Hydroxypentyl	500
	SYNTHETIC MAR	LIUANA (K2-30)	
WH-018 5-Pentanoic acid	30	JWH-073 4-butanoic acid	30
WH-018 4-Hydroxypentyl	250	JWH-018 5-Hydroxypentyl	300
WH-073 4-Hydroxybuty	300		
	YNTHETIC MAR	IJUANA (K2-25)	
WH-018 5-Pentanoic acid	25	JWH-073 4-butanoic acid	25
WH-018 4-Hydroxypentyl	200	JWH-018 5-Hydroxypentyl	250
WH-073 4-Hydroxybuty	250		
6-	Monoacetylmorp	ohine (6-MAM 10)	
-Monoacethylmorphine	10	Morphine	100,000
	HYLENEDIOXY/	AMPHETAMINE (MDA 500)	
 ±) 3,4-Methylenedioxy 	500	Methoxyphenamine	6,000
Imphetamine	200	D-Amphetamine	2,000
),L-Amphetamine sulfate	300	Phentermine	1,000
-Amphetamine	25,000	Maprotiline	50,000
	500	RONIDE (ETG 300)	50.000
thyl- β -D-Glucuronide		Propyl β-D-glucuronide Morphine 6β-glucuronide	50,000
Morphine 3β-glucuronide	100,000	Ethanol	100,000
Blucuronic Acid	60,000 >100,000	Ethanol	>100,000
		RONIDE (ETG 500)	
thyl- β -D-Glucuronide	500	Propyl β-D-glucuronide	50,000
Arphine 3β-glucuronide	100,000	Morphine 68-glucuronide	100,000
Slucuronic Acid	100,000	Ethanol	>100,000
Aethanol	>100,000		
		ONIDE (ETG 1,000)	1
Ethyl- β -D-Glucuronide	1,000	Propyl β-D-glucuronide	100.000
Morphine 3β-glucuronide	>100,000	Morphine 6β-glucuronide	>100,000
Blucuronic Acid	>100,000	Ethanol	>100,000
Iethanol	>100,000		
	CLONAZEPA	M (CLO 400)	
Clonazepam	400	Flunitrazepam	300
Alprazolam	200	(±) Lorazepam	1,250
a-hydroxyalprazolam	2,000	RS-Lorazepamglucuronide	250
Bromazepam	1,000	Midazolam	5,000
Chlordiazepoxide	1,000	Nitrazepam	200
Clobazam	250	Norchlordiazepoxide	200
Clorazepatedipotassium	600	Nordiazepam	1,000
Delorazepam	1,000	Oxazepam	350
Desalkylflurazepam	250	Temazepam	150
Diazepam	300	Triazolam	5,000
stazolam	1,250		
	CLONAZEPA		
Clonazepam	150	Flunitrazepam	120
Alprazolam	75	(±) Lorazepam	500
-hydroxyalprazolam	750	RS-Lorazepamglucuronide	100
Bromazepam	400	Midazolam	2,000
Chlordiazepoxide	400	Nitrazepam	75
Clobazam	100	Norchlordiazepoxide	75
Clorazepatedipotassium	250	Nordiazepam	400
Delorazepam	400	Oxazepam	130
Desalkylflurazepam	100	Temazepam	60 2,000
Diazepam	120 500	Triazolam	2,000
Estazolam			
	RGIC ACID DIET		
ysergic Acid Diethylamide	10		
ysergic Acid Diethylamide LYSE	10 RGIC ACID DIET	HYLAMIDE (LSD 10) HYLAMIDE (LSD 20)	
ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide	10 RGIC ACID DIET 20	HYLAMIDE (LSD 20)	
ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide LYSE	10 RGIC ACID DIET 20 RGIC ACID DIET		
ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide	10 RGIC ACID DIET 20 RGIC ACID DIET 50	HYLAMIDE (LSD 20) HYLAMIDE (LSD 50)	
ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide	10 RGIC ACID DIET 20 RGIC ACID DIET	HYLAMIDE (LSD 20) HYLAMIDE (LSD 50)	1,000
ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide // /////////////////////////////////	10 RGIC ACID DIET 20 RGIC ACID DIET 50 METHYLPHENID	HYLAMIDE (LSD 20) HYLAMIDE (LSD 50) ATE (MPD 300) Ritalinic Acid	 1,000
ysergic Acid Diethylamide LYSE .ysergic Acid Diethylamide LYSE .ysergic Acid Diethylamide //ethylphenidate (Ritalin)	10 RGIC ACID DIET 20 RGIC ACID DIET 50 METHYLPHENID 300	HYLAMIDE (LSD 20) HYLAMIDE (LSD 50) ATE (MPD 300) Ritalinic Acid ATE (MPD 150)	
ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide dethylphenidate (Ritalin)	10 RGIC ACID DIET 20 RGIC ACID DIET 50 METHYLPHENID 300 METHYLPHENID	HYLAMIDE (LSD 20) HYLAMIDE (LSD 50) ATE (MPD 300) Ritalinic Acid ATE (MPD 150) Ritalinic Acid	1,000 500
ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide dethylphenidate (Ritalin) Methylphenidate (Ritalin)	10 RGIC ACID DIET 20 RGIC ACID DIET 50 METHYLPHENID 300 METHYLPHENID 150	HYLAMIDE (LSD 20) HYLAMIDE (LSD 50) ATE (MPD 300) Ritalinic Acid ATE (MPD 150) Ritalinic Acid	
ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide Acthylphenidate (Ritalin) Methylphenidate (Ritalin)	10 RGIC ACID DIET 20 RGIC ACID DIET 50 ΜΕΤΗΥLΡΗΕΝΙΟ 150 ΙΕΤΗΥLΡΗΕΝΙΟΑ	HYLAMIDE (LSD 20) HYLAMIDE (LSD 50) ATE (MPD 300) Ritalinic Acid ATE (MPD 150) Ritalinic Acid TE (MPD 1,000) Ritalinic Aicd	500
ysergic Acid Diethylamide LYSE Jesergic Acid Diethylamide LYSE Jesergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin)	10 RGIC ACID DIET 20 RGIC ACID DIET 50 METHYLPHENID 300 METHYLPHENID 150 ETHYLPHENIDA 350	HYLAMIDE (LSD 20) HYLAMIDE (LSD 50) ATE (MPD 300) Ritalinic Acid ATE (MPD 150) Ritalinic Acid TE (MPD 1,000) Ritalinic Aicd	500
ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin) Nethylphenidate (Ritalin)	10 RGIC ACID DIET 20 RGIC ACID DIET 50 METHYLPHENID 150 16THYLPHENIDA 350 ZOLPIDEM	HYLAMIDE (LSD 20) HYLAMIDE (LSD 50) ATE (MPD 300) Ritalinic Acid ATE (MPD 150) Ritalinic Acid ITE (MPD 1,000) Ritalinic Aicd (ZOL 50)	500
ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin) Nethylphenidate (Ritalin)	10 RGIC ACID DIET 20 RGIC ACID DIET 50 METHYLPHENID 150 IETHYLPHENIDA 350 ZOLPIDEM 50	HYLAMIDE (LSD 20) HYLAMIDE (LSD 50) ATE (MPD 300) Ritalinic Acid ATE (MPD 150) Ritalinic Acid ITE (MPD 1,000) Ritalinic Aicd (ZOL 50)	500 1,000 1 7,500
ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide LYSE ysergic Acid Diethylamide Acthylphenidate (Ritalin) Methylphenidate (Ritalin)	10 RGIC ACID DIET 20 RGIC ACID DIET 50 METHYLPHENID 150 IETHYLPHENIDA 350 ZOLPIDEM 50 MEPHEDRON	HYLAMIDE (LSD 20) HYLAMIDE (LSD 50) ATE (MPD 300) Ritalinic Acid ATE (MPD 150) Ritalinic Acid ITE (MPD 1,000) Ritalinic Aicd (ZOL 50) E (MEP 500)	500 1,000

		NE (MEP 100)	4500
Mephedrone HCI S(-)-Methcathinone HCI	100 500	R(+)-Methcathinone HCl 3-Fluoromethcathinone HCl	1500 1500
4-Fluoromethcathinone HCl	300	Methoxyphenamine	100.000
		ROVALERONE (MDPV 1,000)	100,000
3, 4- methylenedioxy-	1,000		
oyrovalerone	-		
	YLENEDIOXYPY	(ROVALERONE (MDPV 500)	
3, 4- methylenedioxy- oyrovalerone	500		
	YLENEDIOXYPY	(ROVALERONE (MDPV 300)	
3, 4- methylenedioxy-			
byrovalerone	300		
		M (DIA 300)	
Diazepam	300	Midazolam	6,000
Clobazam	200	Nitrazepam	200
Clonazepam Clorazepate dipotassium	500 500	Norchlordiazepoxide Nordiazepam	900
Alprazolam	100	Flunitrazepam	200
a-hydroxyalprazolam	1,500	(±) Lorazepam	3,000
Bromazepam	900	RS-Lorazepam glucuronide	200
Chlordiazepoxide	900	Triazolam	3,000
Estazolam	6,000	Temazepam	100
Delorazepam	900	Oxazepam	300
Desalkylflurazepam		M (DIA 200)	1
Diazepam	200	Midazolam	4,000
Clobazam	120	Nitrazepam	4,000
Clonazepam	300	Norchlordiazepoxide	70
Clorazepate dipotassium	300	Nordiazepam	600
Alprazolam	70	Flunitrazepam	120
a-hydroxyalprazolam	1,000	(±) Lorazepam	2,000
Bromazepam	600	RS-Lorazepam glucuronide	120
Chlordiazepoxide	600	Triazolam	2,000
Estazolam Delorazepam	4,000 600	Temazepam Oxazepam	70 200
Desalkylflurazepam	120	Oxazepani	200
Jesaikyillulazepaili		NE (ZOP 50)	
Zopiclone-x-oxide	50	Zopiclone	50
		ONE (MCAT 500)	
S(-)-Methcathinone HCI	500	R(+)-Methcathinone HCI	1,500
Nethoxyphenamine	100,000	3-Fluoromethcathinone HCl	1,500
		ZEPAM (7-ACL 300)	-
a-hydroxyalprazolam	6,000	Flunitrazepam	3,000
Bromazepam	6,000	RS-Lorazepam glucuronide	2,700
Chlordiazepoxide Clobazam	6,000 9,000	Norchlordiazepoxide Nordiazepam	4,500 15,000
Clonazepam	2,400	Temazepam	9,000
Delorazepam	6,000	7-Aminoclonazepam	300
Desalkylflurazepam	6,000		1
	-AMINOCLONAZ	ZEPAM (7-ACL 200)	
a-hydroxyalprazolam	4,000	Flunitrazepam	2,000
a-hydroxyalprazolam Bromazepam	4,000 4,000	Flunitrazepam RS-Lorazepam glucuronide	1,800
a-hydroxyalprazolam Bromazepam Chlordiazepoxide	4,000 4,000 4,000	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide	1,800 3,000
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam	4,000 4,000 4,000 6,000	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam	1,800 3,000 10,000
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam	4,000 4,000 4,000 6,000 1,600	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam	1,800 3,000 10,000 6,000
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam	4,000 4,000 6,000 1,600 4,000	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam	1,800 3,000 10,000
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam	4,000 4,000 6,000 1,600 4,000 4,000	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam	1,800 3,000 10,000 6,000 200
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam 7	4,000 4,000 6,000 1,600 4,000 4,000	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam 7-Aminoclonazepam	1,800 3,000 10,000 6,000
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clobazepam Delorazepam Delorazepam Desalkylflurazepam 7 a-hydroxyalprazolam Bromazepam	4,000 4,000 6,000 1,600 4,000 4,000 7- AMINOCLONA 2,000 2,000	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam 7-Aminoclonazepam ZEPAM(7-ACL100) Flunitrazepam RS-Lorazepam glucuronide	1,800 3,000 10,000 6,000 200 1,000 900
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clobazepam Delorazepam Desalkylflurazepam 7 a-hydroxyalprazolam Bromazepam Chlordiazepoxide	4,000 4,000 6,000 1,600 4,000 4,000 7-MINOCLONA 2,000 2,000 2,000	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Temazepam 7-Aminoclonazepam ZEPAM(7-ACL100) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide	1,800 3,000 10,000 6,000 200 1,000 900 1,500
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam Pdroxyalprazolam Bromazepam Chlordiazepoxide Clobazam	4,000 4,000 4,000 6,000 1,600 4,000 7-AMINOCLONA 2,000 2,000 2,000 3,000	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Temazepam 7-Aminoclonazepam ZEPAM(7-ACL100) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam	1,800 3,000 10,000 6,000 200 1,000 900 1,500 5,000
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam A-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam	4,000 4,000 4,000 6,000 1,600 4,000 	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Temazepam 7-Aminoclonazepam ZEPAM(7-ACL100) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Norchlazepam Temazepam	1,800 3,000 10,000 6,000 200 1,000 900 1,500 5,000 3,000
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clobazepam Delorazepam Desalkylflurazepam 7 a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clobazam Delorazepam	4,000 4,000 4,000 6,000 1,600 4,000 7- MINOCLONA 2,000 2,000 2,000 3,000 800 2,000	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Temazepam 7-Aminoclonazepam ZEPAM(7-ACL100) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam	1,800 3,000 10,000 6,000 200 1,000 900 1,500 5,000
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clobazepam Delorazepam Desalkylflurazepam 7 a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clobazam Delorazepam	4,000 4,000 4,000 6,000 1,600 4,000 7-AMINOCLONA 2,000 2,000 2,000 3,000 800 2,000 2,000 2,000	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Temazepam 7-Aminoclonazepam ZEPAM(7-ACL100) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam 7-Aminoclonazepam	1,800 3,000 10,000 6,000 200 1,000 900 1,500 5,000 3,000
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam A-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Delorazepam Delorazepam	4,000 4,000 4,000 1,600 1,600 4,000 7-AMINOCLONA 2,000 2,000 2,000 3,000 800 2,000 2,000 2,000 CARFENTAN	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Temazepam 7-Aminoclonazepam ZEPAM(7-ACL100) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Norchlordiazepam Temazepam 7-Aminoclonazepam	1,800 3,000 10,000 6,000 200 1,000 900 1,500 5,000 3,000 100
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Delorazepam Desalkylflurazepam Carfentanyl	4,000 4,000 4,000 6,000 1,600 4,000 -AMINOCLONA 2,000 2,000 2,000 2,000 3,000 800 2,000 2,000 CARFENTAN 500	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Temazepam 7-Aminoclonazepam ZEPAM(7-ACL100) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Norchlordiazepam Temazepam 7-Aminoclonazepam YL (CFYL 500) Fentanyl	1,800 3,000 10,000 6,000 200 900 1,500 5,000 3,000 100 100
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Desalkylflurazepam Pa-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Desalkylflurazepam Desalkylflurazepam Desalkylflurazepam Desalkylflurazepam Desalkylflurazepam	4,000 4,000 4,000 6,000 1,600 4,000 7-MINOCLONA 2,000 2,000 2,000 2,000 2,000 2,000 2,000 CARFENTAN 500 50,000	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Temazepam 7-Aminoclonazepam ZEPAM(7-ACL100) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam 7-Aminoclonazepam YL (CFYL 500) Fentanyl Ramifentanil	1,800 3,000 10,000 6,000 200 200 1,500 5,000 3,000 100 100 100 10,000
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam Desalkylflurazepam Desalkylflurazepam Desalkylflurazepam Desalkylflurazepam	4,000 4,000 4,000 1,600 1,600 4,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Temazepam 7-Aminoclonazepam ZEPAM(7-ACL100) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Norchlordiazepam Temazepam 7-Aminoclonazepam YL (CFYL 500) Fentanyl	1,800 3,000 10,000 6,000 200 1,000 900 1,500 5,000 3,000 100
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Desalkylflurazepam Pesalkylflurazepam Chlordiazepoxide Clobazam Clobazepam Desalkylflurazepam Desalkylflurazepam Carfentanyl Sufentanil ±)cis-3-Menthylfentanyl	4,000 4,000 4,000 1,600 1,600 4,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Temazepam T-Anrinoclonazepam ZEPAM(7-ACL100) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam 7-Aminoclonazepam Itemazepam Pentanyl Ramifentanil Butyl fentanyl	1,800 3,000 10,000 6,000 200 900 1,500 5,000 3,000 100 100 100
a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Delorazepam Desalkylflurazepam Carfentanyl	4,000 4,000 4,000 6,000 1,600 4,000 7-AMINOCLONA: 2,000 2,000 2,000 2,000 2,000 CARFENTAN 500 50,000 20,000 CARFENTAN	Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam 7-Aminoclonazepam ZEPAM(7-ACL100) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Norchlordiazepam Temazepam 7-Aminoclonazepam VIL (CFYL 500) Fentanyl Ramifentanil Butyl fentanyl NUL (CFYL 250)	1,800 3,000 10,000 6,000 200 1,000 1,500 5,000 3,000 100 100 100 150

Caffeine	1,000		
odifolito	CATHINE (C	AT 150)	
(+)-Norpseudoephedrine HCI	150	(+)3,4-Methylenedioxyampheta	100
(Cathine)		mine (MDA)	
d/I-Amphetamine	100	p-Hydroxyamphetamine	100
Tryptamine	12,500 TROPICAMIDE	Methoxyphenamine	12,500
Tropicamide	350	(TRO 350)	
Tropicarilide			
Benzodiazepines	300	Flunitrazepam	200
a-hydroxyalprazolam	1,500	(±) Lorazepam	3,000
Bromazepam	900	RS-Lorazepamglucuronide	200
Chlordiazepoxide	900	Midazolam	6,000
Clobazam	200	Nitrazepam	200
Clonazepam	500	Norchlordiazepoxide	100
Clorazepatedipotassium	500	Nordiazepam	900
Delorazepam	900	Oxazepam	300
Desalkylflurazepam	200	Temazepam	100
Diazepam	300	Triazolam	3,000
Estazolam	6000	Alprazolam	100
Presshalin	PREGABALIN (PGB 50,000)	1
Pregabalin	50,000 PREGABALIN	(PCB 500)	I
Progabalia	500		1
Pregabalin	ZALEPLON (741 100)	1
Zaleplon	100		
zaiepion	CANNABINOL	(CNB 500)	
cannabinol	500	49 -THC	10,000
11-nor-∆9 -THC-9 COOH	300		10,000
	GABAPENTIN ((GAB 2.000)	
Gabapentin	2,000		
	TRAZODONE	(TZD 200)	
Trazodone	200		
	CARISOPRODOL	(CAR 2,000)	
Carisoprodol	2,000		
	CARISOPRODOL	_ (CAR 1,000)	
Carisoprodol	1,000		
	AB-PINACA		
AB-PINACA	10	AB-PINACA 5-Pentanoic	10
AB-PINACA 5-hydroxypentyl	10	AB-FUBINACA	10
AB-PINACA 4-hydroxypentyl	10,000	UR-144 5-Pentanoic	5,000
UR-144 5-hydroxypentyl	10,000	UR-144 4-hydroxypentyl	10,000
APINACA 5-hydroxypentyl	10,000	ADB-PINACA Pentanoic Acid	10
	30	5-fluoro AB-PINACA	30
N-(5-hydroxypentyl) 5-fluoro AB-PINACA	25	N-(4-hydroxypentyl)	
S-IIUOIO AB-FINACA	UR-144	(25)	
UR-144 5-Pentanoic acid	25	UR-144 4-hydroxypentyl	10,000
UR-144 5-hydroxypentyl	5000	XLR-11 4-hydroxypentyl	2,000
5-fluoro		ADB-PINAC	
AB-Pinaca N-(4-hydroxypentyl)	10,000	N-(4-hydroxypentyl)	>10,000
AB-PINACA 4-hydroxypentyl	>10.000	(injuroxyponiyi)	
	QUETIAPINE(QTP 1,000)	
Quetiapine	1000	Norquetiapine	10,000
	FLUOXETINE		
Fluoxetine	500		
	KRATOM (K		
Mitragynine	300	7-hydroxymitragynine	>50,000
	TILIDINE (1		
Nortilidine	50	Tilidine	100
		tone (α-PVP 2000)	
Alpha-Pyrrolidinovalerophenone			
		OPHENONE (α-PVP 1000)	1
Alpha-Pyrrolidinovalerophenon			
		ROPHENONE (α-PVP 500)	1
Alpha-Pyrrolidinovalerophenon			1
		PHENONE (α-PVP 300)	1
Alpha-Pyrrolidinovalerophenone	Mescaline (MES	: 100)	1
Mescaline	100		
Westallie	Mescaline (MES	300)	1
	mescallie (IVES		
Mescaline	300		
Mescaline	300 Papaverine (PA	2 500)	
	Papaverine (PA		1.000.000
Mescaline Papaverine Methortrexate		> 500) Diflunisal Methedrone	1,000,000 500,000

Pragablin	500,000	Phenelzine	8,000
Quinine	4,000		
1	apentadol (T	AP 1,000)	
3-((1R,2R)-3-(dimethylamino)-1- ethyl-2-methylpropyl)phenol	1,000		
	Citalopra	am (CIT 500)	
Desmethylcitalopram	500		
	F-Ketamine	e (FKET 1,000)	
2-(2-fluorphenyl)-2-methylamino- cyclohexanone	1,000		
	Risperido	ne (RPD 150)	
Risperidone	150		
	Scopolami	ne (SCOP 500)	
Scopolamine	500	atropine	3,000
N, N	-Dimethyltry	ptamine (NND 1,000)	
N, N-Dimethyltryptamine	1,000		
	Mirtazapine (MTZ 500)	
Desmethylmirtazapine	500	Mirtazapine	500
	Dlanzapine(C	ZP 1,000)	
Olanzapine	1,000		

Effect of Urinary Specific Gravity

Fifteen (15) urine samples of normal, high, and low specific gravity ranges (1.005-1.045) were spiked with drugs at 50% below and 50% above cut-off levels respectively. The Multi-Drug Rapid Test was tested in duplicate using fifteen drug-free urine and spiked urine samples. The results demonstrate that varying ranges of urinary specific gravity do not affect the test results.

Effect of Urinary pH

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with drugs at 50% below and 50% above cut-off levels. The spiked, pH-adjusted urine was tested with the Multi-Drug Rapid Test. The results demonstrate that varving ranges of pH do not interfere with the performance of the test.

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free urine or drug positive urine containing above related calibrator substances. The following compounds show no cross-reactivity when tested with the Multi-Drug Rapid Test at a concentration of 100 µg/mL.

Non Cross-Reacting Compounds					
Acetophenetidin	Cortisone	Zomepirac	d-Pseudoephedrine		
N-Acetylprocainamide	Creatinine	Ketoprofen	Quinidine		
Acetylsalicylic acid	Deoxycorticosterone	Labetalol	Quinine		
Aminopyrine	Dextromethorphan	Loperamide	Salicylic acid		
Amoxicillin	Diclofenac	Meprobamate	Serotonin		
Ampicillin	Diflunisal	Isoxsuprine	Sulfamethazine		
I-Ascorbic acid	Digoxin	d,I-Propanolol	Sulindac		
Apomorphine	Diphenhydramine	Nalidixic acid	Tetracycline		
Aspartame	Ethyl-p-aminobenzoate	Naproxen	Tetrahydrocortisone,		
Atropine	β-Estradiol	Niacinamide	3-acetate		
Benzilic acid	Estrone-3-sulfate	Nifedipine	Tetrahydrocortisone		
Benzoic acid	Erythromycin	Norethindrone	Tetrahydrozoline		
Bilirubin	Fenoprofen	Noscapine	Thiamine		
d,I-Brompheniramine	Furosemide	d,I-Octopamine	Thioridazine		
	Gentisic acid	Oxalic acid	d,I-Tyrosine		
Cannabidiol	Hemoglobin	Oxolinic acid	Tolbutamide		
Chloral hydrate	Hydralazine	Oxymetazoline	Triamterene		
Chloramphenicol	Hydrochlorothiazide	Papaverine	Trifluoperazine		
Chlorothiazide	Hydrocortisone	Penicillin-G	Trimethoprim		
d,I-Chlorpheniramine	o-Hydroxyhippuric acid	Perphenazine	d,I-Tryptophan		
Chlorpromazine	3-Hydroxytyramine	Phenelzine	Uric acid		
Cholesterol	d,I-Isoproterenol	Prednisone	Verapamil		
Clonidine					

[ALCOHOL PERFORMANCE CHARACTERISTICS]

The detection limit on the Urine Alcohol Rapid Test is from 0.02% to 0.30% for approximate relative blood alcohol level. The cutoff level of the Urine Alcohol Rapid Test can vary based on local regulations and laws. Test results can be compared to reference levels with color chart on the foil package.

[ALCOHOL ASSAY SPECIFICITY]

The Urine Alcohol Rapid Test will react with methyl, ethyl and allyl alcohols.

[ALCOHOL INTERFERING SUBSTANCES]

The following substances may interfere with the Urine Alcohol Rapid Test when using samples other than urine. The named substances do not normally appear in sufficient quantity in urine to interfere with the test.

- A. Agents which enhance color development
- Peroxidases Strong oxidizers
- B. Agents which inhibit color development
- · Reducing agents: Ascorbic acid, Tannic acid, Pyrogallol, Mercaptans and tosylates, Oxalic acid, Uric Acid Bilirubin
 - L-dopa
 - Methampyrone
- L-methyldopa [BIBLIOGRAPHY]
- 1. Hawks RL, CN Chiang, Urine Testing for Drugs of Abuse, National Institute for Drug Abuse

(NIDA), Research Monograph 73, 1986.

- 2 Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 1986; 1735. 3. Stewart DJ, Inaba T, Lucassen M, Kalow W. Clin. Pharmacol. Ther. April 1979; 25 ed: 464, 264-8.
- Ambre J. J. Anal. Toxicol. 1985: 9:241. 4
 - Winger, Gail, A Handbook of Drug and Alcohol Abuse, Third Edition, Oxford Press, 1992, 5 page 146.
 - Robert DeCresce. Drug Testing in the workplace, 1989 page 114. 6
- 7 Glass, IB. The International Handbook of Addiction Behavior, Routledge Publishing, New York, NY, 1991: 216
- 8 B. Cody, J.T., "Specimen Adulteration in drug urinalysis. Forensic Sci. Rev., 1990, 2:63. C. Tsai, S.C. et.al., J. Anal. Toxicol. 1998; 22 (6): 474 9
- 10. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 6th Ed. Biomedical Publ., Foster City, CA 2002.
- 11. Hardman JG, Limbird LE. Goodman and Gilman's: The Pharmacological Basis for Therapeutics. 10th Edition. McGraw Hill Medical Publishing, 2001; 208-209
- 12. Cumming, E. (22 April 2010). "Mephedrone: Chemistry lessons". London: The Daily Telegraph. Retrieved 2010-09-14.
- 13. "Drugs crackdown hailed a success". BBC News. 8 March 2010. Retrieved2010-03-31.
- Kihara, Rhiannon; Day, Edward (May 2014). "Transient psychotic episodes following recreational use of NRG-3". Progress in Neurology and Psychiatry 18 (3): 14-18. doi:10.1002/pnp.331. Retrieved 22 March2015.
- 15. Schifano, F.; Albanese, A.; Fergus, S.; Stair, J. L.; Deluca, P.; Corazza, O.; Davey, Z.; Corkery, J.; Siemann, H.; Scherbaum, N.; Farre', M.; Torrens, M.; Demetrovics, Z.; Ghodse, A. H.; Psychonaut Web, M.; Rednet Research, G. (2010). "Mephedrone (4-methylmethcathinone: 'meow meow'); chemical, pharmacological and clinical issues".Psychopharmacology 214 (3):593-602. doi:10.1007/s00213-010-2070-x.ISSN 0033-3158. PMID 21072502.
- 16. "Assessment of Zopiclone" (PDF).World Health Organization. Essential Medicines and Health Products World Health Organization. p.9 (Section 5. Pharmacokinetics). Retrieved5 December 2015.
- 17. Kratzsch C. Tenberken O. Peters FT et al. Screening, library-assisted identification, and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem, and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. J. Mass Spec. 39: 856-872, 2004.
- 18. Gustavsen I, Al-Sammurraie M, Mørland J, Bramness JG. Impairment related to blood drug concentrations of zopiclone and zolpidem compared with alcohol in apprehended drivers. Accid. Anal. Prev. 41: 462-466, 2009.
- 19. R. Baselt, Disposition of Toxic Drugs and Chemicals i Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1677-1679.
- 20. Calkins RF. Aktan GB. Hussain KL (1995), "Methcathinone: the next illicit stimulant epidemic?". Journal of Psychoactive Drugs. 27 (3): 277-85. doi:10.1080/ 02791072.1995.10472472. PMID 8594170.
- 21. Methcathinone, https://en.wikipedia.org/wiki/Methcathinone.
- 22. Bersani, F. S.; Corazza, O.; Simonato, P.; Mylokosta, A.; Levari, E.; Lovaste, R.; Schifano, F. (2013). "Drops of madness? Recreational misuse of tropicamide collyrium; early warning alerts from Russia and Italy".General Hospital Psychiatry 35 (5):571-3.Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 2nd Ed. Biomedical Publ., Davis, CA. 1982; 488
- 23. Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders". In Sydor A, Brown RY. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.).NewYork:McGraw-Hill Medical. p. 375. ISBN 9780071481274.
- 24. American Psychiatric Association (2013). "Substance-Related and Addictive Disorders". American Psychiatric Publishing. pp. 1-2. Retrieved 10 July 2015.
- 25. Juliano LM, Griffiths RR (2004). "A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features". Psychopharmacology (Berl.) 176 (1):1-29. doi:10.1007/s00213-004-2000-x. PMID 15448977. Archived from the original on 29 January 2012.
- 26. Arnaud MJ. Pharmacokinetics and metabolism of natural methylxanthines in animal and man. Handb Exp Pharmacol 2011; 200:33-91.
- 27. Jeukendrup AE, Randell R-Fat burners: nutrition supplements that increase fat metabolism. Obes Rev 2011: 193:1-24.
- 28. Cumming, E. (22 April 2010). "Mephedrone: Chemistry lessons". London: The Daily Telegraph. Retrieved 2010-09-14.
- 29. "Drugs crackdown hailed a success". BBC News. 8 March 2010. Retrieved2010-03-31.
- 30. Kihara, Rhiannon; Day, Edward (May 2014). "Transient psychotic episodes following recreational use of NRG-3". Progress in Neurology and Psychiatry 18 (3): 14-18. doi:10.1002/pnp.331. Retrieved 22 March2015.
- 31. Schifano, F.; Albanese, A.; Fergus, S.; Stair, J. L.; Deluca, P.; Corazza, O.; Davey, Z.; Corkery, J.; Siemann, H.; Scherbaum, N.; Farre', M.; Torrens, M.; Demetrovics, Z.; Ghodse, A. H.; Psychonaut Web, M.; Rednet Research, G. (2010). "Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues".Psychopharmacology 214 (3):593-602. doi:10.1007/s00213-010-2070-x.ISSN 0033-3158, PMID 21072502,
- 32. Work Group on Panic Disorder (January 2009). APA Practice Guideline for the Treatment of Patients With Panic Disorder (2nd ed.).
- 33. "FDA approved labeling for Xanax revision 08/23/2011" (PDF). Federal Drug Administration. 2011-08-23. p. 4. Retrieved 2011-09-14.
 - "Xanax XR (Alprazolam) Clinical Pharmacology Prescription Drugs and Medications". RxList. First DataBank. July 2008.

- Frampton, JE (September 2014). "Pregabalin: a review of its use in adults with generalized anxiety disorder." CNS Drugs 28 (9): 835–54.
- 35. "Pregabalin". The American Society of Health-System Pharmacists. Retrieved Oct 23,2015.
- 36. 3. D.R. Guay. Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? Am. J. Geriatr. Pharmacother, 3: 274–287 (2005).
- 37. 4. "Summary of product characteristics" (PDF). European Medicines Agency. 6 March 2013. Retrieved 6 May 2013.
- 5. "Detection times of Pregabalin in urine after illicit use: when should a positive specimen be considered a new intake?" Ther Drug Monit. 2013 Feb;35(1):137-40.
- Karniol IG, Shirakawa I, Takahashi RN, Knobel E, Musty RE (1975). "Effects of delta9-tetrahydrocannabinol and cannabinol in man". Pharmacology. 13 (6): 502–12.
- Andre, Christelle M.; Hausman, Jean-Francois; Guerriero, Gea (2016-20-4), "Cannabis sativa: The Plant of the Thousand and One Molecules". Frontiers in Plant Science. 7: 19
 McCalum ND, Yagen B, Levy S, Mechoulam R (May 1975). "Cannabino1: a rapidly formed
- metabolite of delta-1- and delta-6-tetrahydrocannabinol". Experientia. 31 (5): 520–1
- Mahadevan A, Siegel C, Martin BR, Abood ME, Beletskaya I, Razdan RK (October 2000). "Novel cannabinol probes for CB1 and CB2 cannabinoid receptors". Journal of Medicinal Chemistry. 43 (20): 3778–85.
- 43. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998).
- "Gabapentin". The American Society of Health-System Pharmacists. Archived from the original on 8 September 2017. Retrieved 23 Oct 2015.
- Wijemanne, S; Jankovic, J (June 2015). "Restless legs syndrome: clinical presentation diagnosis and treatment". Sleep medicine. 16 (6): 678–90.
- "Suicidal Behavior and Ideation and Antiepileptic Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 1 August 2009.
- "Neurontin packaging insert" U.S. Food and Drug Administration (FDA). 1 May 2009. Archived from the original on 14 December 2010. Retrieved 16 July 2010.
- Agarwal P, Griffith Å, Costantino HR, Vaish N (2010). "Gabapentin enacarbil clinical efficacy in restless legs syndrome". Neuropsychiatr Dis Treat. 6: 151–8.
- Calandre EP, Rico-Villademoros F, Slim M (2016). "Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use". Expert Rev Neurother. 16 (11): 1263–1277.
- Calandre EP, Rico-Villademoros F, Slim M (2016). "Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use". Expert Rev Neurother. 16 (11): 1263–1277.
- Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P (2010)."A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin". Clin Pharmacokinet. 49(10): 661–9.
- Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM (2008). "Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin". J Clin Pharmacol. 48 (12): 1378–88.
- Schatzberg, AF; Nemeroff, CB, eds. (2009). Textbook of Psychopharmacology (4th ed.). Washington, D.C.: American Psychiatric Publishing. ISBN 978-1-58562-309-9.
- Amalia Scotto di Telia, Ciro di Nunzio, Pietrantonio Ric(1986). Determination of Trazodone and Its Metabolite, m-CPP, in Serum and Urine by HPLC,233-235.
- 55. Jauch R, Kopitar Z, Prox A, Zimmer A; Kopitar; Prox; Zimmer (1976). "[Pharmacokinetics and metabolism of trazodone in man

		Index of	Symbols		
	Consult Instructions For Use	Σ	Tests per kit	EC REP	Authorized Representative
IVD	For <i>in vitro</i> diagnostic use only		Use by	$\widehat{\mathbf{Z}}$	Do not reuse
2°C	Store between 2-30°C	LOT	Lot Number	REF	Catalog #
\otimes	Do not use if package is damaged		Manufacturer		



#550, Vinhai Street Hangzhou Economic & Technological Development Area Hangzhou, 310018 P.R. China Web: www.alltests.com.cn Email: info@alltests.com.cn

Hangzhou AllTest Biotech Co.,Ltd.



Number: 145177406 Revision date: 2022-09-16